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CHAPTERl 
GENERAL INTRODUCTION 
HISTORICAL PERSPECTIVE OF SUDDEN CARDIAC DEATH 
The term sudden cardiac death pertains to an unexpected death from cardiac causes within 
a short time period and has been described throughout history. 1 
The ancient Egyptians inscribed on the tomb of a nobleman some 4500 years ago that he 
had died suddenly and without apparent cause. 
Another early case of sudden death was Phidippides, the young Greek messenger, who 
collapsed and died after he ran 26.2 miles from Marathon to Athens to deliver the news of 
the Greek victory over the Persians in 460 BC. 
It has been hypothesised that Hippocrates in his writings provided the first medical 
description (approximately 400 BC) of sudden cardiac death: "Those who are subject to 
frequent and severe fainting attacks without obvious cause die suddenly".12 
Sudden (cardiac) death was originally ascribed to supernatural causes. In the bible Ananias 
and his wife Sapphira were punished for their deceit by sudden death "WhenAnanias heard 
this, he fell down and died. And great fear seized all who heard what had happened. About three 
hours later his wife came in, not knowing what had happened. Peter asked her, "Tell me, is this 
the price you and Ananias got for the land?" "Yes," she said, "that is the price." Peter said to her, 
"How could you agree to test the Spirit of the Lord? Look! 1he feet of the men who buried your 
husband are at the door, and they will carry you out also. " At that moment she fell down at his 
feet and died. 1hen the young men came in and, .finding her dead, carried her out and buried her 
beside her husband. (ACTS 4:32-5:II). 
Even when medical science advanced to a stage where autopsies became available many 
sudden cardiac deaths remained unexplained. 
Only recently, it has been hypothesized that Napoleon might have died due cardiac 
arrhythmias induced by drugs the Emperor was using at that time.3 
DEFINITION OF SUDDEN CARDIAC DEATH 
Efforts to understand sudden cardiac death and its underlying mechanism, treatment, and, 
ultimately, prevention have been complicated by the multiplicity of definitions used to 
characterize it.4 Recently the European Society of Cardiology Task force on Sudden Cardiac 
Death has suggested the use of the Meyer burg Castellanos definition as follows: 5 "natural 
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death due to cardiac causes, heralded by abrupt loss of consciousness within one hour of 
the onset of acute symptoms; preexisting heart disease may have been known to be present, 
but the time and the mode of death are unexpected." A difficult issue is the classification 
of deaths that occur unwitnessed, for instance when a patient is found dead in bed. Most 
authors have classified such events as sudden cardiac deaths. The clinical presentation of 
sudden cardiac death is frequently used as a surrogate implying that a specific mechanism 
is involved. 5 Ventricular tachy-arrhythmia is the final fatal mechanism in approximately 
85% of all sudden cardiac deaths. Brady-arrhythmias and pulse-less electrical activity occur 
less frequently and generally in hearts with more advanced disease. 
MAGNITUDE OF THE PROBLEM 
Sudden cardiac death remains a major public health problem. Cardiovascular disease is the 
leading cause of death in the western world. 6 7 Sudden cardiac death accounts for almost 
half of these cardiovascular deaths, constituting the largest component of coronary heart 
disease mortality. Approximately 30% of the cases of sudden cardiac death have cardiac 
arrest as the first and only manifestation of cardiovascular disease. 7 8 The commonly used 
estimate of300,000 sudden cardiac deaths in the United States has not been based on any 
epidemiological studies, but has rather been derived from the estimation that there were 
600,000 cardiovascular deaths annually, of which 50% were sudden.9 
Because the majority of patients who suffer sudden cardiac death have coronary artery 
disease, the epidemiology of sudden cardiac death to a great extent parallels that of coronary 
heart disease.1° For many years, clinicians have considered risk factors for coronary heart 
disease as similar to those for sudden cardiac death.11 The risk factors for sudden cardiac 
death include, in line with cardiovascular risk factors: age, sex, hypertension, left ventricular 
function, elevated serum cholesterol, diabetes mellitus, body mass index, conduction 
disturbances, smoking, alcohol abuse and a family history of sudden cardiac death.10 12 
Sudden cardiac death is among the most common causes of death in the developed world. 13 
It is estimated that more than 3 million people die yearly from sudden cardiac death. It is 
estimated that cardiac arrest has a survival rate ofless than 5 %. 
Although there has been a reduction in total cardiac mortality the percentage of deaths that 
are sudden has increased from 38% to 47%. This increase is primarily due to an increase 
in out of hospital cardiac arrest. The magnitude can be understood by noting that sudden 
cardiac death accounts for more deaths annually than AIDS, breast cancer, lung cancer and 
stroke together.13 
The incidence rate of sudden cardiac death varies between 0.5-2 per 1000 persons annually, 
depending on definitions used and populations studied.5 14-16 A generally assumed risk of 
0.1-0.2% per year in the population of 18 years and older, is an average figure across that 
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age spectrum. The most marked increase occurs in the age group of 40-65 years of age, 
predominantly in association with coronary artery disease.11 
ETIOLOGY OF SUDDEN CARDIAC DEATH 
Ventricular arrhythmias are present in 80-85% of the cases.13 17 18 Most commonly sudden 
cardiac death is caused by the onset of a rapid monomorphic ventricular tachycardia that 
degenerates into ventricular fibrillation. Less frequently it is initiated by polymorphic 
ventricular tachycardias and ventricular fibrillation directly. In only a few cases ST segment 
changes suggestive of ischemia precede the initiation of the terminal event. Polymorphic 
ventricular arrhythmias are the most common initiating event. Sudden cardiac death 
associated with brady-arrhythmias usually represents end stage heart failure. 
A major, if not the major, unanswered question in sudden cardiac death is, what is the 
immediate precipitating event that causes the arrhythmia, leading to sudden cardiac death in 
an otherwise stable patient? 19 Most of the stable risk factors (e.g. hypertension, heart failure) 
lack sufficient sensitivity, specificity and predictive value to permit using a specific intervention 
in a particular patient before the actual event. This probably relates, at least in part to the 
transient nature of many risk factors, such as myocardial ischemia; abnormality in electrolytes, 
such as low potassium; and the transient effects of toxins, such as drugs or alcohol.10 
Evidence is accumulating that the occurrence of an abrupt ventricular arrhythmia is a multi-
factorial, time dependent process involving a changing complex interplay of myocardial scar, 
ischemia, adrenergic factors, electrical heterogeneity, time, and possibly genetic factors, all 
superimposed on a vulnerable myocardial substrate that is acquired as a result of occlusive 
and progressive coronary artery disease. 
To simplifY our understanding the factors involved in sudden cardiac death are sometimes 
categorized into 3 groups: substrate, modulator and trigger.17 
Substrate is commonly used for factors that damage the normal structure of the myocardium, 
the more stable risk factors. Major factors in this group are myocardial infarction (leaving 
scarred myocardial tissue), heart failure (leading to remodeling of myocardium) and genetic 
predisposition. These factors have in common that they are permanent, thus creating a 
surrounding (substrate) in which ventricular fibrillation can more readily occur.10 17 20 In 
recent years, genetic studies began to reveal how mutations in ion channel genes predispose 
patients to certain cardiac arrhythmias.21 
Modulators are those risk factors that temporarily increase the risk of sudden cardiac death, 
such as plaque rupture, acute ischemia, autonomic nerve influences, electrolyte disturbances 
or drugs. 
The trigger is the event, the critically timed premature stimulus (e.g. ventricular extrasystole), 
which initiates the ventricular fibrillation. 
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Ischemic Heart Disease 
Coronary artery disease with or without myocardial infarction is by far the most common 
underlying substrate for sudden cardiac death in the Western world, being responsible for 
65 to 70% of all cases.11 10 13 15 22 
The modulator thought to be responsible for converting chronic coronary artery disease 
into acute cardiac events is termed plaque rupture. 23 24 Plaque rupture is probably the 
most common lesion underlying acute coronary syndromes. 25 1he frequency of unstable 
plaques and coronary thrombosis in sudden cardiac death is extremely variable and the 
reported percentages of active coronary lesions observed at autopsy in sudden cardiac death 
victims ranges from less than 20% to more than 80%.26 lt is estimated that sudden cardiac 
death accounts for at least 36% to 50% of all mortality after myocardial infarction and new 
ischemia may be an important modulator. 27 28 
Any type of atherosclerosis related myocardial injury, such as ischemia, an old or new 
myocardial infarction, inflammation and or fibrosis, potentially increases the patient's 
vulnerability to arrhythmia and sudden cardiac death. 23 241he greatest risk of sudden cardiac 
death seems to be in the first 6 to 12 months after the myocardial infarction 29 , especially 
in high-risk patients. Recent studies, however, showed that the risk remains increased with 
time after a myocardial infarction in patients using beta blocking therapy.28 
Atherogenesis CONVENTIONAL CORONARY Conditioned Risk 
RIKS FACTORS; PLAQUE FORMATION 
Quiescent State CHANGES IN PLAQUE ANATOMY Transitional State 
INFLAMMATION 
Active State PLAQUE DISRUPTION; Onset ofACS 
THROMBOTIC CASCADE 
Triggering SELECTIVE PREDISPOSITION; Arhythmogenesis 
ELECTROPHYSIOLOGY 
Cascade from conventional risk factors to arrhytmogenesis in sudden cardiac death due to coronary heart disease. 
The cascade indentifies four levels of evolution of risk, beginning with lesion initiation at development, progressing 
to onset of an active state, to onset of acute coronary syndromes (ACS), and finally the specific expression of 
life-threatening cardiac arrhythmias. Multiple factors enter at each level, including specific risk based on genetic 
profiles of individual patients. 
A possible cascade for the development of coronary artery disease and acute coronary 
events is shown here. It cites four levels of evolution, beginning with atherogenesis, driven 
by conventional coronary risk factors, which leads to the presence of coronary artery disease 
that is the conditioning factor for future events.9 
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Heart failure 
The incidence and prevalence of heart failure, an important substrate of sudden cardiac 
death, has continued to increase with the ageing population.19 30 Despite remarkable 
improvements in therapy, the prognosis of patients with heart failure remains poor. 
Arrhythmic death is a common mode of death in heart failure, occurring in approximately 
half of the cases. 8 It has been estimated that patients with heart failure have 6 to 9 times the 
rate of sudden cardiac death of the general population.19 Sudden cardiac death most likely 
results from a cascade of events that create an electrically unstable heart, that most often 
is manifested by a ventricular tachy-arrhythmia.19 What is certain about sudden cardiac 
death in the setting of heart failure is, that there are a number of structural and functional 
changes in the heart and a genetic predisposition that may contribute to an increased risk 
of dying suddenly. Sudden death in patients with heart failure is a complex phenotypic 
expression of a systemic disease that most often results from the unfortunate confluence 
of a number of factors. These include: a hospitable substrate, the results of remodeling 
membrane properties of the heart, altered neurohumoral signaling, myocardial ischemia 
and a genetic predisposition to electrical instability. 20 
The risk of sudden cardiac death varies over time, reflecting temporal heterogeneity of both 
the myocardial substrate and triggers. 19 
Autonomic nervous system 
Enhanced activity of the sympathetic nervous system is a modulator associated with 
the occurrence of sudden cardiac death. Autonomic function is often linked to sudden 
cardiac death but the exact mechanism is subject to debate as there are many points 
of interaction. Autonomic tone could play a role in initiating the transient ischemia. 
The interaction between autonomic tone and thrombosis might play an important 
link in the pathogenesis of sudden cardiac death.31 A mechanism that also received 
attention recently is the nerve sprouting hypothesis.32 The nerve sprouting hypothesis 
of sudden cardiac death suggests that myocardial infarction results in nerve injury 33 , 
followed by nerve sprouting and regional myocardial hyperinnervation. It is known 
that sympathetic stimulation is important in the generation of sudden cardiac death. 
Sympathetic nerve sprouting may be an important determinant of sudden cardiac death 
in chronic ischemia. 33 
The sympathetic imbalance has also been implicated in the prolongation of the 
QT interval. 
Research has indicated that reduced parasympathetic nervous system activity increases the 
likelihood of ventricular fibrillation. 34 
Deranged cardiac autonomic activity is associated with an increased burden of cardiovascular 
mortality, including arrhythmias and sudden cardiac death.35 
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Genetic factors 
There are inherited diseases leading to genetically determined cardiac arrhythmias and 
sudden cardiac death. In the last decade, genetic studies began to reveal how mutations 
in ion channels cause arrhythmias in patients and increase the likelihood of ventricular 
fibrillation and sudden cardiac death.21 36 
The identification of the genes responsible for the long QT syndrome led to the 
discovery that they all encode ion channels. All the encoded ion channels are involved 
in the control of repolarization and this fostered the concept that LQTS may represent 
an unique model for the study of genotype-phenotype correlation in hereditary 
arrhythmogenic disorders. 37 Mutations identified in these genes produce either gain or 
loss of function, resulting in an excess inward sodium current or in reduced potassium 
outward current.37 The ionic alterations lengthen the action potential and explain the 
prolonged QT interval characteristic of the Long QT Syndrome (LQTS), which can 
be either congenital or acquired. 
A brief overview of the normal electrophysiology of the heart is necessary to better 
understand the mechanism underlying the Long QT Syndrome. 
Normal electrophysiology 
The normal regular beating of the heart is accompanied by cyclic changes in the 
membrane potential of cardiac cells.38 The electrical activity of each cardiac cell is made 
possible by electrochemical currents, carried by ion channels and exchangers, which give 
rise to the action potential.39 As with many other excitable cells the resting potential 
of cardiac cells is largely determined by the concentration gradient for potassium ions 
across the cell membrane whereas the rapid potential change during pulse initiation 
depends on the concentration gradient for sodium ions. The rapid depolarization is 
caused by a large inward current of sodium ions (Phase 0). Repolarization consists of 
three phases: the rapid repolarization phase is carried by a transient surge of outward 
current of potassium ions (Phase 1). This is followed by a plateau phase (Phase 2), which 
duration is determined by a delicate balance between inward and outward currents 
through competing ion channels and exchangers (mainly calcium and sodium). Phase 3 
of the repolarization process is caused mainly by inactivation of inward calcium currents 
and increasing potassium outward currents. Outward potassium currents carry the 
repolarization plateau. The delayed rectifier current is the most important repolarizing 
current and has at least 3 distinct components: Ikur (ultra rapidly activating delayed 
rectifier current), Ikr (rapidly activating delayed rectifier current) and Iks (slowly activating 
delayed rectifier current).40 
. 
+45mV 
-85mV 
Depolarisation 
QRS 
QT Interval 
Aepolarisalion 
The cardiac action potential: (a) action potential showing the phases of cardiac depolarisation and repolarisation with 
ion current directions during activation of the different ion channels; (b) ECG. lea= calcium current; IK =potassium 
current; IK1 = inwardly rectifying potassium current; INa = depolarising sodium current; Ito = transient outward 
potassium current; IKr =rapidly activating delayed rectifier potassium current; IKs = slowly activating delayed rectifier 
potassium current; IKu = ultra rapidly activating delayed rectifier potassium current. (Reprinted with permission) 
Congenital Long QT Syndrome 
The long QJ syndrome is an inherited arrhythmogenic disease characterized by 
susceptibility to life threatening arrhythmias, often but not always occurring in the setting 
of high adrenergic activity e.g. physical or emotional stress.41 
Two phenotypic variants have been initially identified: the more common autosomal 
dominant Romano Ward syndrome and the autosomal recessive Jervell and Lange Nielsen 
syndrome, in which the cardiac phenotype is associated with neurosensory deafness. 38 41 42 
Prolonged ventricular repolarization (i.e. prolonged QJ interval) is the electrocardiographic 
marker of LQTS. The QJ interval of the ECG reflects the duration of the action potential 
that is determined by the delicate balance between inward and outward currents. 39 
Syncope and fainting are the typical manifestations ofLQTS and are often precipitated by 
vigorous exercise, stress or strong emotions. 
There is a great diversity in genes that control the expression of potassium channels. 39 The 
ultra-rapidly activating Ikur is mediated by KCNA.5 
Four HERG (human ether a go-go gene) alpha subunits assemble to form Ikr (rapidly 
activating delayed rectifier current) and four subunits assemble with beta subunits to 
form Iks (slowly activating delayed rectifier current). Mutations of these subunits lead to 
dysfunctional channels, reduced Ikr and Iks current and a clinical syndrome of prolonged 
QT interval. The evidence that there are least 6 genes, for which at least 5 encode for 
channel proteins responsible for LQJS, implies that the classification into two phenotypes 
was insufficient to completely describe the disease. 41 Subsequently more findings have 
led to the conclusion that LQTS is not only a channelopathy but may also be caused 
by mutation of intracellular proteins. Therefore genetic heterogeneity and multiplicity of 
mechanisms are distinguishing features of LQJS. Furthermore besides the remarkable 
number of mutations reported so far it is also evident that the clinical manifestations may 
span from completely asymptomatic individuals to fully penetrant and symptomatic forms, 
even among patients harboring the same mutations.41 This phenomenon is defined as 
variable penetrance, and it represents an important feature ofLQTS. 
Acquired Long QT Syndrome 
Reduction in the major outward current, mediated by the rapid component of the delayed 
rectifier potassium channels (Ikr), results in the prolongation of the QJ interval. The most 
frequent cause of reduction of the potassium outward current at present is the administration 
of many clinically useful drugs. 39 
Drugs reduce this current, mainly by their effect on the alpha subunits of human ether 
a go- go related gene of the Ikr channel. In the past decade one of the most frequent causes 
of withdrawal or restriction of the use of drugs has been the prolongation of the QT interval 
associated with Torsade de Pointes, which can be fatal. 43 Current evidence suggests that 5 to 
10% of persons in whom Torsade de Pointes develops on exposure to QJ interval prolonging 
drugs may harbour mutations associated with the Long QJ syndrome and can therefore be 
viewed as having sub-clinical forms of the congenital syndrome.43 44 
Despite progress in clinical profiling and interventions sudden cardiac death remains a 
major clinical and public health problem. There remain important unresolved issues that are 
a challenge for future progress. Among these are a better understanding of the magnitude of 
the problem and methods of profiling risk for individuals, the etiology and mechanisms of 
sudden cardiac death in individuals with and without previously identified structural heart 
disease and strategies for prevention of sudden cardiac death.45 
As has been illustrated in these introductory notes many causes of sudden cardiac death are 
known, yet seldom is one single cause sufficient to provoke a life threatening arrhythmia. 
Sudden cardiac death is a multifactorial process and we are most likely dealing with a 
probabilistic event in which each of the risk factors identifies only a small fraction of the 
multifactorial process. 46 
SCOPE AND OUTLINE OF THIS THESIS 
This thesis comprises a number of epidemiological studies aimed at gaining more insight 
into the problem of sudden cardiac death in a general population, and the role of drugs in the 
occurrence of sudden cardiac death. We have focused on drugs associated with an increased 
risk of sudden cardiac death, drugs as a cause of QJc prolongation and QJc prolongation as 
a risk factor for sudden cardiac death. 
Most studies presented in this thesis used data from the Integrated Primary Care Information 
(IPCI) project in the Netherlands.47 1he IPCI project is a general practice research database, 
containing the complete medical records on approximately 500,000 patients. The electronic 
records contain coded and anonymous data on patient demographics, symptoms (in free 
text), diagnoses (using the International Classification for Primary Care and free text) from 
GPs and specialists, referrals, laboratory findings, hospitalizations, and drug prescriptions, 
including their indications and dosage regimen. To maximize completeness of the data, 
general practitioners participating in the IPCI project are not allowed to maintain a system 
of paper-based records besides the electronic medical records. 
The two studies evaluating the QJc interval were performed in the Rotterdam study, a large 
prospective population-based cohort study among 7983 inhabitants ofOmmoord, a suburb 
of Rotterdam, who were 55 years of age or older. 48 This study provides an excellent setting 
for observational studies. 
In Chapter 2 of this thesis, the incidence of sudden cardiac death in a general population 
was assessed. Chapter 3 focuses on the value of the QTc interval in predicting the risk of 
sudden cardiac death in a general population of older adults, using the data from 
the Rotterdam study. In Chapter 4 the association between the current use of drugs, 
reported to be associated with Torsade de Pointes, and the duration of the QJc interval 
was explored. 
Chapter 5 and 6 describe the results of a case control study examining antipsychotic drugs 
and non-cardiac QJc prolonging drugs as risk factor for sudden cardiac death. In Chapter 
7 the effect of current use ofbrochodilator medication and the risk of sudden cardiac death 
is discussed. Finally in the general discussion presented in Chapter 8 we discuss the main 
findings of this thesis in the context of current scientific knowledge and suggestions for future 
research are provided. 
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CHAPTER2 
INCIDENCE OF SUDDEN CARDIAC 
DEATH 
ABSTRACT 
Objective: Sudden cardiac death (SCD) is a major clinical and public health issue. We 
conducted a cohort study within the Integrated Primary Care Information database (IPCI) 
in the Netherlands to determine the incidence of sudden cardiac death in the general 
population. 
Methods and results: The study population consisted of a dynamic cohort of all subjects of 
18 years and older without a diagnosis of cancer, registered with the General Practitioner 
(GP) during the period between 1995-2001. SCD was defined as death within one hour 
after the onset of the terminal event or an unwitnessed death, if the subject was seen alive 
and well sometime during the preceding 24 hours. The cause was attributed to cardiac 
disorders unless other causes were apparent. The study population comprised 249,126 
subjects with a mean follow-up of2.54 years. During follow up we identified 4892 deaths, 
of which 582 cases were classified as probable SCD. The overall incidence of SCD in this 
population was 0.92 cases per 1000 person-years (py) (95% CI: 0.85-0.99), was 2.3 fold 
higher in men than in women and increased with age: from 0.1/1000 py (95% Cl: 0.07-
0.13) for the people aged under 50 up to 7.9/1000 py (95% CI: 6.8-9.2) for subjects above 
80 years of age. The incidence of SCD peaked in October: 1.36/1000 py (95% Cl: 1.07-
1.69) and was lowest in August 0.6/ 1000 py (95% CI: 0.45-0.87). 
Conclusions: The incidence of SCD in the general Dutch population was almost 1 per 
1000 person- years per year during the period January 1, 1995 to April1, 2001. Most of 
the cases occurred at home. 
INTRODUCTION 
Cardiovascular disease still remains the most common cause of natural death in developed 
countries, despite a substantial reduction in age-adjusted rates of death from cardiovascular 
causes over the past decades. Of all cardiac deaths approximately 50% is estimated to 
be of sudden nature.1 2 Sudden cardiac death is defined as natural death due to cardiac 
causes, heralded by abrupt loss of consciousness within one hour after the onset of acute 
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symptoms. Although pre-existing heart disease may be present, the time and mode of death 
are unexpected by definition.3 The time interval between the onset of symptoms and death 
initially was 24 hours, but has subsequently been reduced to 1 hour. 3 4 A difficult issue in 
the assessment of sudden death is the classification of deaths, which occur unwitnessed, 
for instance if somebody is found dead in bed. Most authors have preferred to classify such 
events as sudden cardiac death, even though the delay between onset of symptoms and 
death is unknown. 5-9 Due to the variation in required time delay definitions, inclusion or 
exclusion of unwitnessed deaths and the type of population, the reported incidence rates 
vary largely.5 6 10-12 In this study we aimed to estimate the incidence of sudden cardiac 
death in the general population, since up until now there are no incidence studies that 
were conducted in a well-defined general population by using the current definitions and 
guidelines of sudden death.3 
METHODS 
Setting 
The Integrated Primary Care Information (IPCI) database is a longitudinal 
observational database, which contains information from computer-based records 
of general practitioners (GPs) in the Netherlands. Details of the database have been 
described elsewhere.13 14 The database contains the full medical electronic records 
of approximately 500,000 patients. The electronic records contain information on 
patient demographics, symptoms (in free text) , diagnoses (using the International 
Classification for Primary Care), drug prescriptions plus their ICPC coded indication, 
and hospitalisations.15 Summaries of the hospital discharge letters or information from 
specialists are entered in a free text format and copies can be provided upon request. 
To maximise completeness of the data, GPs who participate in the IPCI project are 
not allowed to use paper-based records. The system complies with European Union 
guidelines on the use of medical data for medical research and has been proven valid 
for epidemiological research.14 
Study p opulation 
The study population consisted of a dynamic population of subjects 18 years and 
older who had a valid history of at least 1 year in the IPCI database. Subjects with 
a diagnosis of cancer were excluded, because in these patients the cause of death is 
often difficult to assess even in case of acute deaths. The study period started on 
January 1, 1995 and ended on April 1, 2001. Subjects were followed until death, 
transferral out of practice, last data draw- down or end of the study period, whichever 
came first. 
Case definition 
All subjects who died during the study period were identified by an automated database search. 
Cases were classified "probable" sudden cardiac death if the medical record indicated that death 
occurred within one hour after the onset of cardiovascular symptoms or if the following wording 
was found: "sudden cardiac death", "acute cardiac death", "mors subita", "sudden death", "died 
suddenly", "died unexpectedly" or if this was an unexpected death of someone seen in "good 
health" or in a stable medical condition less than 24 hours previously. Our definition included 
unwitnessed deaths. The cause of death was supposed to be of cardiac origin unless the patient's 
(medical) history suggested otherwise (e.g. pneumonia, cerebrovascular accident etc). 
All cases of death were assessed manually and validated independendy by two physicians as 
probable or no sudden cardiac death. In case of discrepancy (n=13) a third physician arbitrated. 
Statistical analysis 
The incidence of sudden cardiac death was determined by dividing the total number of 
cases of (probable) sudden cardiac death by the total number of person-years accumulated 
by the study population. 
Incidence estimates were calculated per age category (5 years categories), calendar year, 
calendar month and gender. 95% confidence intervals were calculated based on a Poisson 
distribution. Differences in age were tested by means of the Mann Whitney test. The 
number of cases of sudden cardiac death per week day was assessed and 95% confidence 
intervals were calculated based on the normal distribution.16 To extrapolate our data to the 
Dutch population we standardised our incidence estimates of sudden cardiac death direcdy 
to the data from the Central Bureau for Statistics (CBS, www.cbs.nl). 
RESULTS 
The source population consisted of 431,942 subjects of whom 253,500 were 18 years of age or 
older and had a valid history of at least 365 days in the IPCI database. After exclusion of patients 
with a diagnosis of cancer the study population comprised 249,126 subjects. The median age 
of the study population was 40 years (Inter-Qyartile Range, IQR 29- 55) and 49.1% were 
males. Males were younger than females (median age of39, I QR 29-53 versus 41, IQR 29-57). 
Within this population 4892 deaths were identified, 582 of which were classified as probable 
sudden cardiac death. The mean age of the cases was 72±13 years and the majority (59.3%) 
were male.The mean age of male cases was significandy lower than that of female cases ( 69± 13 
years versus 76±11 years, p<0.01). Of the 582 cases 228 (39.2%) were unwitnessed deaths.The 
unwitnessed cases were significandy older than the witnessed cases (75±12 years versus 70± 14 
years p<0.01). Sudden unwitnessed cardiac deaths occured more frequendyin females (48.9%) 
than in males (32.5%, p<0.01).1he unwitnessed cases were significandy older than the witnessed 
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cases (median age 75 years [IQR: 66-81] vs. 70 years [IQR: 61-78], P<.Ol) . Of the witnessed 
cases (n=354), the majority (75.9%) occurred at home, 14.1o/o occurred in a public place or 
during sport, 5.4o/o on the way to the hospital or upon arrival at the hospital, and in 4.6o/o the 
site where sudden cardiac death occurred was not specified (TABm). 
The overall incidence of sudden cardiac death in this population was 0.92 / 1000 person 
years (95o/o CI: 0.85-0.99) ( TABLE2). 
TABLE 1 : SITE OF OCCURRENCE OF WITNESSED CASES OF SUDDEN CARDIAC DEATH (n=354) 
Location Cases 
Home 269 (75.9%) 
Public places 
Street 
Hotel/Camping 
Sport 
Work 
Church 
Car 
Library 
Railway station 
Market 
Shop 
GP office 
Cafe 
Ambulance 
UAH• 
Not Specified 
a Upon arrival at the hospital. 
50 (14.1%) 
16 
9 
8 
5(1.4%) 
14 (4.0%) 
16 (4.6%) 
TABLE 2 : INCIDENCE OF SUDDEN CARDIAC DEATH BY CALENDAR YEAR 
Calendar year Person years (PY) Cases Incidence 
offollow-up per1oooPY 
1996 53223.54 53 
1997 93949.92 101 1.08 
1998 125417.9 123 0.98 
1999 173102.9 158 0.91 
2000 166290.1 131 0.79 
Overall" 634314.3 582 0.92 
95%CI 
0.75-1.29 
0.88-1.3 
0.82-1.17 
0.77-1.06 
0.66-0.93 
0.84-0.99 
• Sum of cases and person time during the period 1996-2000 does not add up to overall since the sparse data from 1995 and 
2001 are not included in th.is table 
The incidence of sudden cardiac death increased with age: from 0.01/ 1000 person years 
(95% CI: 0.07-0.13) for subjects aged between 18 to 50 years to 7.9/1000 person years (95% 
CI: 6.79-9.17) for subjects aged above 80 years ( FIGURE 1). 
FIGURE 1 : INCIDENCE OF SUDDEN CARDIAC DEATH BY AGE AND GENDER 
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The unadjusted incidence of sudden cardiac death in men was significantly higher: 1.1/ 
1000 person years (95% CI: 0.99-1.23) than in women 0.73/1000 person years (95% CI: 
0.65-0.83). Mter age-standardisation of the female population age to the male population 
the incidence in women was 0.48 per 1000 person years, leading to a rate ratio of 2.3 for 
sudden cardiac death in men versus women. The incidence of sudden cardiac death was 
highest in October (1.36, 95% CI: 1.07-1.69) and lowest in August (0.63, 95% CI: 0.45-
0.87 p=0.001 peak low ratio: 1.58) (FIGURE 2). 
FIGURE 2 : INCIDENCE OF SUDDEN CARDIAC DEATH BY CALENDAR MONTH 
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In our study most cases of sudden cardiac death occurred on Mondays (16%) and Tuesdays 
(15.8%), but the differences were not statistically significant. In men the incidence was 
highest on Mondays independent of age ( 0.59, 95% CI: 0.38-0.87 in men 65 years or 
younger and 8.14, 95% CI:5.92-10.93 in men elder than 65). In women 65 years of age 
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or younger the highest incidence occurred on Tuesdays (0.18, 95% CI:0.035-0.25) and in 
elderly women (above 65) the highest incidence occurred on Wednesdays (5.02, 95% CI: 
3.61-6.81) (FIGURE3). 
FIGURE 3 : PERCENTAGE OF SUDDEN CARDIAC DEATH CASES PER WEEKDAY 
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Applying the age specific incidence rates to the Dutch population resulted in incidence 
rates of 1.07/1000 person years in 1996, 1.15 in 1997,0.98 in 1998, 0.95 in 1999, and 
0.8/ 1000 person years in 2000. 
DISCUSSION 
Sudden cardiac death is the most common lethal manifestation of heart disease. This study 
showed that the incidence of sudden cardiac death in Dutch population is around 1/1000py, 
the incidence increases with age and varies by gender, calendar month and weekdays. 
Our incidence estimate is in line with the incidence in the US, which is estimated to be 1 
to 2 per 1000 inhabitants per yearY 17 The incidence found in other studies varies from 
0.19 to 1.9 per 1000 inhabitants, depending on the variations in definition used, differences 
in study population and area of research.2 6 10 17 In the British Regional Heart Study, the 
incidence was relatively high at 1. 9 per 1000py since this population comprised only middle 
aged men, but on the other hand it did not include unwitnessed deaths.6 In a previous 
hospital based Dutch study the incidence was estimated at 0.97 per 1000 inhabitants per 
year (aged 20 to 75).10 However this study defined sudden cardiac death as an unexpected, 
non-traumatic loss of vital signs without preceding complaints or within 24 hours after the 
onset of complaints, unwitnessed deaths were included. A study in healthy workers in Japan 
showed an incidence of0.19 per 1000 person-years (cases defined as death occurring within 
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24 hours of the onset of symptoms or signs without any difficulties in daily working). 11 
The percentage of unwitnessed deaths in our study was similar to other studies. Women 
suffer more often unwitnessed sudden cardiac death, possibly due to the fact that elderly 
women more often live alone. 3 10 The higher incidence in males is consistent with other 
studies.9 lS-20 
Seasonal variation of sudden cardiac death has been the subject of previous studies.21 22 
The peak incidence occurs usually in winter (December and January) with a pronounced 
reduction in the summer period (from June through September). Our study confirmed that 
the incidence was lowest in August whereas the incidence peaked in October. 
The weekly variation of sudden cardiac death in our western society seems to be related to 
work stress and most cases occur on Mondays and Tuesdays.21 23 In Japan the seasonal peak 
occurred in April, when the business year starts, and the weekly peak on Sundays, which has 
been attributed to binge drinking. 11 In our study 16o/o of the cases occurred on Mondays 
and 15.8o/o and Tuesdays. The incidence in men was highest on Mondays, independent of 
age. In women the highest incidence occurred on Tuesdays in women 65 years or younger 
and on Wednesdays in women older than 65(FIGURE 3). 
Our study has one potential limitation i.e. potential misclassification. Such misclassification 
might be false positive or false negative. Underestimation of deaths is unlikely as death is 
mostly registered by the general practitioner in the Netherlands due to the pivotal role of 
the GP in the Dutch health care system. Some false positive misclassification however 
may result from the potential inclusion of unwitnessed death of non-cardiac origin. Some 
of these cases might for instance result from a massive stroke.The percentage unwitnessed 
death was 3 9 .2o/o in our study, which is in line with earlier findings. 12 24 1he circumstances 
surrounding these deaths remain unclear and other causes of death cannot always be 
excluded. The incidence of unwitnessed death in women is relatively high, possibly due to 
the fact that elderly women more often live alone.In conclusion we found that incidence of 
sudden cardiac death was approximately 1 in 1000 person-years, of which the large majority 
occurred at home. 
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CHAPTER 3 
PROLONGED OTc INTERVAL AND RISK 
OF SUDDEN CARDIAC DEATH IN A 
POPULATION OF OLDER ADULTS 
ABSTRACT 
Background: In developed countries, sudden cardiac death is one of the major causes of 
cardiovascular mortality. Prolongation of the QJc interval has been associated with ventricular 
arrhythmias but in most population-based studies no consistent association was found 
between QTc prolongation and total or cardiovascular mortality. Only very few of these 
studies specifically addressed sudden cardiac death. We investigated whether prolongation of 
the QTc interval is a risk factor for sudden cardiac death in the general population. 
Methods and results: This study was conducted as part of the Rotterdam Study, a 
prospective population-based cohort study which comprises 3105 men and 4878 women 
aged 55 years and older. The QTc interval on the ECG was by determined during the 
baseline visit (1990-1993) and the first follow-up examination (1993-1995). During an 
average follow-up period of 6. 7 years (SD 2.3 years) 125 subjects died from sudden cardiac 
death. The association between prolonged QTc interval and sudden cardiac death was 
estimated using Cox's proportional hazards analysis. 
An abnormally prolonged QTc interval(> 450 ms in men, > 470 ms in women) was 
associated with threefold increased risk of sudden cardiac death (RR 3.2, 95% CI: 1.7-
5.9), after adjustment for age, sex, body mass index, hypertension, cholesterol/hdl ratio, 
diabetes mellitus, myocardial infarction and heart failure. In subjects with an age below 
the median of 68 years, the corresponding relative risk was 7.6 (2.0-29.0) .1he attributable 
risk proportion was 0.66, meaning that 66 percent of all cases of sudden cardiac death are 
associated with an abnormally prolonged QJc interval. 
Conclusions: Abnormal QTc prolongation on the ECG should be viewed as an 
independent risk factor for sudden cardiac death. 
INTRODUCTION 
In developed countries, sudden cardiac death is one of the major causes of cardiovascular 
mortality. Sudden cardiac death accounts for almost half of all coronary heart disease 
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deaths and is often the first and only manifestation of coronary heart disease.1-3 According 
to the most recent definition, sudden cardiac death is a natural death due to cardiac causes, 
heralded by abrupt loss of consciousness, within one hour after the onset of acute symptoms 
or an unwitnessed, unexpected death of someone seen in a stable medical condition less 
than 24 hours previously with no evidence of a non-cardiac cause.2 3 Much of this mortality 
is assumed to be caused by ventricular tachy-arrhythmias, and evaluation of risk factors is 
a major challenge when searching for treatments to reduce this risk.4 In search for non-
invasive risk factors to predict mortality, the heart rate corrected QJ' interval, the QJ'c 
interval, has been studied extensively. 4-14 1he QJ' interval on the surface electrocardiogram 
(ECG) represents the time from onset of ventricular depolarisation to completion of 
repolarization and prolongation has been associated with ventricular arrhythmias (e.g. 
Torsade de Pointes) that may trigger ventricular fibrillation and even sudden cardiac deathY 
There is an ongoing debate in the literature on the clinical significance of a prolonged QJ'c 
intervalY 16 17 Several large population-based studies, evaluating the association between 
the QJ'c interval and mortality in apparently healthy persons, did not find a consistent 
association between QTc prolongation and total or cardiovascular mortality.4 7-9 11 12 18 
Only few of these studies specifically addressed sudden cardiac death and when they did 
the number of cases was often too small to detect significant differences.5 8 10 
We investigated whether prolongation of the QJ'c interval is an independent risk factor for 
sudden cardiac death in a population of older adults. 
METHODS 
Setting, study population and baseline data collection 
The study is embedded in the Rotterdam Study. The Rotterdam Study is a prospective 
population-based cohort study, which started with a baseline visit between 1990 and 1993. 
All inhabitants of a suburb in Rotterdam, Ommoord, aged 55 years and over (10,275), 
were invited to participate. Of these, 7,983 (78%) gave their written informed consent 
and took part in the baseline examination. Objectives and methods of the Rotterdam 
Study have been described in detail elsewhere.19 All participants were visited at home for a 
standardized questionnaire and 7,151 were subsequently examined at the research center. 
A second follow up visit took place between 1993 through 1995. For the present study, 
follow-up started at baseline examination and lasted until January 1, 2000. 
Information on smoking was obtained during the home interview of the Rotterdam Study. 
During the research center visit non-fasting blood samples were obtained and serum total 
cholesterol was determined by an enzymatic procedure and high density lipoprotein (HDL) 
was measured similarly after precipitation of the non-HDL fraction. 20 Body mass index 
(BMI) was computed as weight divided by height squared. Hypertension was defined as 
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a systolic blood pressure >=160 mm Hg and/or diastolic blood pressure >=100 mm Hg 
and/or use of antihypertensive medication, encompassing grade 2 and grade 3 hypertension 
according to World Health Organization (WHO) criteria.21 Diabetes mellitus was defined 
as the use of blood glucose-lowering medication and/or a non-fasting or post-load serum 
glucose level of11.1 mmoVL or higher according to the WHO.Z2 A history of myocardial 
infarction was assessed by a self report checked with records from the general practitioner 
or cardiologist and /or electrocardiografic evidence. All reported myocardial infarctions 
were verified with the medical records and assessment has been described in detail earlier. 23 
Assessment of heart failure at baseline and during follow up has also been described in 
detail earlier. Briefly, prevalent cases were assessed by screening all medical records for 
the occurrence of at least two signs and symptoms suggestive of heart failure or the use of 
medication for the indication heart failure and review of all hospital discharge letters. Cases 
of incident heart failure were obtained by continuously monitoring the participants.24 25 
The ankle arm index (AAI) is the ratio of the systolic blood pressure at the ankle to the 
systolic blood pressure in the arm. According to the protocol of the Rotterdam Study the 
AAI was measured at both legs.26 
The Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, the 
Netherlands, approved the study. 
Outcome assessment 
Participants in the Rotterdam Study are continuously monitored for major events that 
occur during follow up, including incidence of heart failure, myocardial infarction and 
death. Information on vital status is obtained regularly from municipal health authorities 
in Rotterdam and from the general practitioners working in the district of Ommoord. In 
case of a fatal event, general practitioners (GPS) filled in a questionnaire relating to the 
circumstances of the death, including time since the occurrence of first symptoms until 
death, most likely cause of death according to the physician, and the time and place of 
death. Subsequently, research assistants gathered information about these events at the GP 
offices. All questionnaires and a copy of the medical records were used to assess if the death 
could be classified as a sudden cardiac death using the most recent definition: a natural 
death due to cardiac causes, heralded by abrupt loss of consciousness, within one hour after 
the onset of acute symptoms or an unwitnessed, unexpected death of someone seen in a 
stable medical condition less than 24 hours previously with no evidence of a non-cardiac 
cause.2 3 If death was witnessed and occurred within one hour after the start of symptoms 
we assumed it to be a sudden cardiac death, without additional review of the medical 
records for a medical history of cardiovascular disease or the presence of cardiovascular risk 
factors. In case of an unwitnessed death, evidence of cardiac causes was searched for using 
all available information. Two research physicians coded all reported events independently 
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according to the International Classification of Diseases, lOth edition (ICD-10, sudden 
cardiac death: 1.46).26 In case of disagreement, consensus was sought. Finally, a cardiologist, 
whose judgment was considered decisive, reviewed all events. 
ECG interpretation and measurement 
A 10 second 12-lead resting ECG (on average 8-10 beats) was recorded with an ACTA 
electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency of 500 Hz 
and stored digitally. All ECGs were processed by the Modular ECG Analysis System 
(MEANS) to obtain ECG measurements. The MEANS program has been evaluated 
extensively.27-29 MEANS determines common onsets and offsets for all12leads together 
on one representative averaged beat, with the use of template matching techniques.29 
The MEANS program determines the QT interval from the start of the QRS complex 
until the end of the T wave. To adjust for heart rate, Bazett 's formula (QTc=QT/~RR) 
was used.30 
European regulatory guidelines were used to categorize QTc prolongation into 3 
categories, for men and women separately. For women, the cut-off points were less than 
450 ms (normal), 450-470 ms (borderline) and more than 470 ms (prolonged), and 
for men less than 430 ms (normal), 430-450 ms (borderline), and more than 450 ms 
(prolonged) .31 In addition, we used different QTc thresholds varying from 440 ms to 
470 ms, based on the literature, because there is still discussion as to the most relevant 
cut-off points. 4 s 1-10 12 13 1s 32 33 
D igitally stored ECGs of 6134 (86% of the participants who visited the research center) 
participants who visited the research center were available at the time of the first visit. 
At the time of the second visit, 4415 (70% of the participants who visited the research 
center) digitally stored ECGs were available. Missing ECGs were mainly due to temporary 
technical problems with ECG recording. 
Statistical analysis 
Differences in baseline characteristics between participants with normal, borderline and 
abnormal QTc interval prolongation were examined with ANCOVA and adjusted for age. 
The relative risk (RR) (95% confidence interval) of the association between prolonged 
QTc interval and sudden cardiac death was estimated using a Cox's proportional hazards 
analysis.The QJc interval at the time of the first visit was taken as the independent variable. 
For those participants who also had a second ECG at the follow-up visit, we updated the 
exposure information at the time of the follow-up visit. All information concerning co-
morbidities (hypertension, diabetes, myocardial infarction, heart failure) was also updated 
at that time. Potential confounders were included in the multivariate model: age, sex, body 
mass index, hypertension, cholesterollhdl ratio, diabetes mellitus, myocardial infarction 
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and heart failure. Since Bazett's formula tends to under-correct for lower heart rates and 
over-correct for higher heart rates we also included heart rate in the model. Sensitivity 
analyses were performed using different QJc cut-off points. Because left bundle branch 
block can cause secondary repolarization changes and atrial fibrillation can cause difficulties 
in measuring QJ interval, analyses were performed also after exclusion of subjects with 
bundle branch block and atrial fibrillation at baseline. We also assessed the risk of sudden 
cardiac death in participants with at least one cardiovascular risk factor at baseline. In 
addition, we added interaction terms of QTc with age, hypertension, smoking, diabetes 
mellitus, myocardial infarction, and heart failure in the model. Finally, we calculated the 
attributable risk percent as (RR-1)/RR (x100).34 
RESULTS 
The mean follow-up time was 6.7 years (SD 2.3 years). During follow-up, 1407 (22.8%) 
participants died and 67 were lost to follow-up. We identified 125 sudden cardiac deaths 
during this period, yielding an incidence rate of approximately 3 per 1000 person years. 
TABLE 1 : BASELINE CHARACTERISTICS OF THE STUDY POPULATION STRATIFIED BY 
CATEGORY OF QTC PROLONGATION AT BASELINE* 
Characteristic All Normal Borderline Abnormal p (n;6134) (n;4344) (n;nog) (n;681) 
Age (mean, SD) 69.2 (9) 68.4 (8.9) 70.1 (8.8) 73.5 (9 D) <0.001 
Female sex 59.6% 64.9% 49.4% 42 .4% <0.001 
Smoking 22.7% 21.5% 27.1% 22.8% <0.001 
Total/HDL cholesterol ratio 5.2 5.2 5.3 5.4 <0.001 
BMI(kg/m2) 26.3 (3.7) <0.01 
Blood pressure 
Systolic (mmHg) 139.4 (22.3) 137.8 (21.9) 142.2 (22.2) 145.1 (23.4) <0.001 
Diastolic (mmHg) 73.5 (11.6) 72.9 (11.3) 75.3 (12.1) 75.0 (12.1) <0.001 
Hypertension 33 .6% 30.6% 39% 44.9% <0.001 
Diabetes mellitus 10.5% 8.5% 14% 17.8% <0.001 
Myocardial infarction 6.3% 5.2% 6.6% 12.9% <0.001 
Heart failure 3.2% 2.1% 3.6% 9.5% <0.001 
Values are means (SD) for continuous variables and percentages for dichotomous variables. 
Abbreviations RR=relative risk, CI=confidence interval, SD =standard deviation, HDL=high density lipoprotein, 
BMI=body mass index 
* Classification of QTc prolongation: 
normal men ~430 ms women ~450 ms 
borderline men 431-450 ms women 451-470 ms 
abnormal men ~451 ms women ~471 ms 
TABLE1 shows baseline characteristics of all participants with a normal, borderline and abnormal 
QJc interval. The prevalence of cardiovascular co-morbidity increased with an increasing QJc 
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interval. Women had a significantly longer QJc interval (435 ms, SD: 26) than men (426 ms, 
SD: 28) .The participants who died of sudden cardiac death had a significantly longer mean 
QTc interval: 441.9 msec (SD: 33.0) as compared to the other participants: 431.3 msec (SD: 
27.1).1he characteristics of the cases and non-cases are presented in TABLE2. 
TABLE 2 : BASE LINE CHARACTERISTICS OF NON-CASES AND CASES OF SUDDEN CARDIAC 
DEATH 
Characteristics at baseline Non cases (6009) SCD case (125) RR'(95%CI) 
Age(SD) 69.1 (9) 74.3 (8) 1.1 (1.0-1.1) 
Female sex 59.9% 44.8% 0.4 (0.3-0.6) 
Smoking 22.7% 17.6% 1.4 (0.9-2.7) 
Cholesterol/HDL ratio 5.2 5.5 1.1 (l.0-1.2) 
BMI 26.3 26.1 0.9 (0.9-1.0) 
Hypertension 33.2% 56.0% 2.4 (1.7-3.5) 
Diabetes mellitus 10.3% 23.2% 2.4 (1.6-3.4) 
Myocardial infarction 5.8% 28% 4.6 (3.1-6.9) 
Heart failure 2.9% 15.2% 4.5 (2.7-7.5) 
QTc interval (SD) 431.25 (27.1) 441.9 {33.0) 1.01 (1.00-1.02) 
Values are means (SD) for continuous variables and percentages for dichotomous variables, 
'RR adjusted for age and sex (age: sex adjusted and sex: age adjusted) 
p 
<0.000 
<0.000 
0.2 
0.04 
0.7 
<0.000 
<0.000 
<0.000 
<0.000 
<0.000 
Abbreviations RR=relative risk, CI=confidence interval, SD=standard deviation, HDL=high density lipoprotein (mmol/1), 
BMI=body mass index (kg/m2), age in years, QTc interval in msec. 
Borderline QJc prolongation was associated with a twofold increase in the risk of sudden 
cardiac death and abnormally prolonged QJc intervals with a threefold increased risk of 
sudden cardiac death as compared to reference QJc values in the fully adjusted model. 
( TABLE 3 AND FIGURE 1) The relative risk was most pronounced in the lower age group (age 55 
to 68 years) . 
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FIGURE 1 : RISK OF SCD AT DIFFERENT QTc CUT-OFF POINTS 
RR" (95% Cl) 
6,00 
5,00 
4,00 
3,00 
2,00 
1,00 
440 450 460 
QTc (msec) cut-offpoints 
470 
"adjusted for age, se.~, body mass index, cholesterol!HDL ratio, smoking, hypertension, diabetes, myocardial infarction, heart failure. 
TABLE 3 : QTc PROLONGATION AND RISK OF SUDDEN CARDIAC D EATH 
QTc prolongation' 
Normal (n=4344) 
Borderline (n=ll09) 
Abnormal (n=681) 
<median age (ss-68 yr) 
.?_median age (>68 yr) 
men 
women 
Normal (n=2314) 
Borderline (n=514) 
Abnormal (n=212) 
Normal (n=2003) 
Borderline (n=595) 
Abnormal (n=469) 
Normal (n=1523) 
Borderline (n=561) 
Abnormal (n=392) 
Normal (n=2821) 
Borderline (n=548) 
Abnormal (n=289) 
RR(95%CI)" 
1 (reference) 
2.3 (1.3-4 2) 
3.7 (2.0-6.9) 
1 (reference) 
5.0 (1.5-16.8) 
9.8 (2.7-35.1) 
1 (reference) 
1.7 (0.9-3.6) 
2.8 (1.4-5.9) 
1 (reference) 
2.4 (1.0-5.3) 
3.9 (1.8-8.4) 
1 (reference) 
2.3 (0.9-5.9) 
3.5 (1.3-9.8) 
Abbreviations: RR=relative risk, CI=confidence interval, reference= reference value 
• adjusted for age in sex-stratified analyses and adjusted for sex in age-stratified analyses 
RR (95% CI)"" 
1 (reference) 
1.6 (0.9-3.1) 
2.5 (1.3-4.7) 
1 (reference) 
3.7 (1.1-14.0) 
8.0 (2.1-31.3) 
1 (reference) 
1.3 (0.6-2.7) 
2.1(1.0-4.4) 
1 (reference) 
1.8 (0.8-4.1) 
2.6 (1.1-5.8) 
1 (reference) 
1.3 (0.5-3.7) 
2.5 (1.0-7.1) 
•• adjusted for age (only in se.~- stratified analyses), se.~ (only in age-stratified analyses), smoking, cholesterol!HDL ratio, Body 
Mass Index, hypertension, diabetes mellitus, myocardial infarction, heart failure and heart rate 
1 Classification of QTc prolongation: 
cut-off points: normal men 
borderline men 
abnormal men 
$430 ms 
431-450 ms 
~451 ms 
women 
women 
women 
$450 ms 
451-470 ms 
~471 msFigure 
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In persons with at least one cardiovascular risk factor at baseline, abnormal QTc prolongation 
was associated with a fourfold increase in the risk of sudden cardiac death (RR: 4.3; 2.2-8.6). 
Mter exclusion of subjects with left bundle branch block or atrial fibrillation, the risk of 
sudden cardiac death was significantly increased in both subjects with a borderline prolonged 
QTc interval (2.2; 95% CI:l.l-4.7) as well as in subjects with an abnormally prolonged QJc 
interval (RR: 3.4; 95% Cl: 1.7-6.7). As many studies used QJc interval classifications into 
two categories we also analyzed QJc prolongation classified in different categories using cut-
off points varying from 440 ms to 470 ms ( FIGURE 2). Using 440 ms as a cut-off point of QTc 
interval prolongation we observed a significant increase in the risk of sudden cardiac death 
after adjustment for age and sex (2.3: 95% Cl:1.4-3 .8), and this risk remained increased also 
after adjustment for risk factors (1.5; 95% Cl:l .0-2.2). None of the interactions we assessed 
with age, smoking, hypertension, diabetes mellitus, myocardial infarction, and heart failure 
were statistically significant. The increase in the risk of sudden cardiac death corresponded 
to an attributable risk proportion of0.66, meaning that in our study 66 percent of all cases of 
sudden cardiac death were associated with an abnormally prolonged QJc interval. 
DISCUSSION 
In this population-based study among older adults, an abnormally prolonged QTc interval 
was associated with a threefold increased risk of sudden cardiac death. In subjects below the 
median age of 68 years, a prolonged QJc was associated with a nearly eightfold increased 
risk. The risk estimates were independent of cardiovascular risk factors. In our analyses, we 
used the most recent regulatory guidelines to classifY QJc prolongation in three sex-specific 
categories.32 If we classified t..h.e QJc interval according to previously used cut-off levels, we 
also observed a significantly increased risk of sudden cardiac death starting at a cut-off point 
of 440 ms.The ankle arm index is considered to be a marker of atherosclerosis that is not only 
influenced by the presence of plaques but also by hemodynamic factors and vascular factors .36 
Since sub-clinical atherosclerotic disease can influence the QJc interval we also analyzed the 
effect of the ankle arm index as a marker for atherosclerosis on the risk of sudden cardiac 
death. The adjustment did not change the point estimates. Since Bazett's formula tends to 
under-correct for lower heart rates and over-correct for higher heart rates we also included 
heart rate in the model. This did, however, not change the risk estimate substantially. 
Results of several epidemiological studies evaluating total mortality and cardiovascular 
mortality in relation to QJc prolongation have yielded conflicting results4 7-12 18 37, and only 
few studies specifically addressed sudden cardiac death.5 8 In subjects referred for Holter 
monitoring, a QTc interval of more than 440 ms doubled the risk of sudden cardiac death.5 
In the Zutphen study, QJc prolongation of 420 ms or more was associated with a threefold 
increased risk of sudden cardiac death (3.0; 95% CI: 1.0-8.9) in elderly men (aged 65-85 years), 
but not in men aged 40-60 years. 8 The Framingham study failed to demonstrate an association 
of baseline QJc prolongation with total mortality, sudden death or coronary mortality. 9 1he 
Cardiovascular Health Study, on the other hand, demonstrated an association between a QJc 
interval of more than 450 ms and total mortality and in the Strong Heart Study, a QJc interval 
of 460 ms or more was associated with a twofold increased risk ofboth cardiac mortality and 
total mortality.12 In our study, we found a significantly increased risk of sudden cardiac death 
in subjects with a prolonged QJc interval after adjustment for other cardiovascular risk factors. 
In the Rotterdam Study, we previously found that QJc prolongation (>440 ms) was associated 
with increased risks of total and cardiovascular mortality. 7 In this study, however, a shorter 
follow-up time and only one baseline ECG were used and we did not specifically examine 
the relation with sudden cardiac death. The risk of sudden cardiac death in the present study 
was higher in the population aged 55 to 68 years. This may partly be explained by depletion 
of susceptible subjects at older age. The proportion of sudden cardiac death attributable to 
a prolonged QJc interval is larger in the younger age category. It should be emphasized, 
however, that the absolute risk of sudden cardiac death increases with age. 38 39 
The strength of our study lies in the fact that data were available on large group of subjects. 
The follow-up period is relatively long and enabled us to take advantage of the fact that a large 
part of the participants had two ECGs.There was little loss to follow-up and information on 
cardiovascular risk factors was accurately collected. The conflicting results in earlier studies 
may partly be explained by the cWferences in the definition of sudden cardiac death, cWferences 
in populations, in the classification of QJc prolongation or the use of general rather than 
sex-specific QJc cut-off points. We used the most recent European regulatory guidelines to 
classifY QJc prolongation.32 To our knowledge, this study is the first to use this sex-specific 
classification in a population-based study. In addition, in all studies QJc prolongation was based 
on one baseline ECG and related to outcomes that usually occurred many years later. 
Nevertheless, also our study has some limitations. First, we cannot exclude that some 
misclassification of outcome occurred. We were, however, able to take advantage of the 
fact that in most cases complete information of the facts surrounding death was available 
for review, including a questionnaire concerning the fatal event and in many cases the 
time between start of symptoms and death was documented. Second, also in our study 
misclassification of exposure may have occurred during follow-up since we related sudden 
cardiac death to QTc prolongation determined on ECGs that were measured before the 
event and QTc interval could have changed in the period between the last assessment and 
sudden cardiac death. Finally, our study population consisted of subject aged 55 years and 
older. Whether our findings also apply to other age groups requires further study. 
In conclusion, the results of our study show that abnormal QJc prolongation on the ECG 
should be viewed as an independent risk factor for sudden cardiac death. Two-third of the cases 
of sudden cardiac death is associated with an abnormal prolongation of the QJc interval. 
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CHAPTER4 
DRUGS ASSOCIATED WITH QTc 
PROLONGATION AND TORSADE DE 
POINTES 
ABSTRACT 
Background: Current regulatory guidelines, intended to predict whether a new drug carries 
an increased risk of serious cardiac arrhythmias, place much emphasis on the association of 
the pharmaceutical with QJc interval prolongation. 
In recent years, several lists have been published on drugs implicated in QJc prolongation 
and cardiac arrhythmias. To our knowledge, no population based ECG data are available on 
the association of drugs included in these lists and the length of the QTc interval in older 
adults. Therefore, we examined the association between these drugs and the duration of the 
QJc interval in a large prospective, community-based follow-up study. 
Methods and results: This study was conducted as part of the Rotterdam Study, a 
prospective population-based cohort study, which comprises 3105 men and 4878 women 
aged 55 years and older. 
The primary endpoint of the study was the length of the QTc interval. The index date 
was defined as the date of the ECG measurements and current use at the index date was 
calculated based on prescription information. The associations were examined by means of 
linear regression analysis. 
The current use of antipsychotics, cardiovascular medication, antidepressants and 
antihistamines was associated with a significantly increased QJc interval. Of the individual 
drugs, current use of clarithromycin, thioridazine, sotalol, amiodarone, disopyramide, 
indapamine, amitriptyline and promethazine was associated with a significant QTc interval 
prolongation. 
Conclusions: Drug-associated QTc interval prolongation is common in a population of 
community-dwelling elderly, even after exclusion of those on cardiovascular medication. 
INTRODUCTION 
The heart-rate corrected QT (QTc) interval from a 12-lead ECG is the traditional 
measurement for assessing the duration of the ventricular repolarization.1 Prolongation of 
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repolarization may result in early after depolarizations (EAD), which in turn may induce re-
entry and provoke Torsade de Pointes, which can develop to fatal ventricular arrhythmias.Z•3 
In the past decade, one of the most frequent causes of withdrawal or restriction of marketed 
drugs has been the prolongation of the QJc interval associated with Torsade de Pointes and 
fatal cardiac arrhythrnias.4 5 An increasing number of drugs, especially non-cardiac drugs has 
been recognized to delay cardiac repolarization and to induce Torsade de Pointes. 3 The issue 
of non-cardiac drugs associated with a pro-arrhythmogenic potential, has been identified as 
a considerable public-health problem.3 In recent years, several lists have been published on 
cardiac and non-cardiac drugs implicated in QTc prolongation and cardiac arrhythmias.6-9 
List 1 of the website of the International Registry for Drug-induced Arrhythmias 
maintained by the Georgetown University (http://www.qtdrugs.org/medical-pros/drug-
lists/drug-lists.htm), provides an up-to-date list of drugs that are reported to cause drug 
induced arrhythmias.9 These drugs are classified into 4 categories, varying from drugs that 
are generally accepted by authorities to have a risk of causing Torsade de Pointes (list 1) to 
drugs that, in some reports, have been weakly associated with Torsade de Pointes but that, 
when used in therapeutic dosages, are unlikely to increase the risk (list 4). In addition, De 
Ponti et al. have published a list of31 non-anti-arrhythmic drugs with pro-arrhythmogenic 
effects, based an a structured literature search.6 7 Although there is considerable overlap 
between the two lists, there are also some remarkable differences. For example, the anti-
arrhythmic drugs are only mentioned in list 1 and not in the list of De Ponti, as the latter 
focused on non-anti-arrhythmic drugs, while antidepressants, cardiovascular non-anti-
arrhythmic drugs and antihistamines are only included in the list of De Ponti et al. 
Current guidelines, intended to predict whether a new drug carries an increased risk of 
serious cardiac arrhythmias, place much emphasis on the association of the pharmaceutical 
with QTc interval prolongation.10 To our knowledge, no population-based ECG data are 
available on the association of drugs included in the existing lists and the length of the 
QTc interval in older adults. Therefore, we examined the association between drugs on 
these lists and the duration of the QTc interval in a large prospective, community based 
follow-up study. 
METHODS 
Setting, study population and baseline data collection 
This study is embedded in the Rotterdam Study. The Rotterdam study is a prospective 
population-based cohort study, which started with a baseline visit between 1990 and 
1993. The Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, the 
Netherlands, approved the study. All inhabitants of Ommoord, a suburb of Rotterdam, 
aged 55 years and over, were invited to participate (10,275). Of them, 7983 (78%) gave 
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their written informed consent and took part in the baseline examination. Objectives and 
methods of the Rotterdam Study have been described in detail elsewhere.11 At baseline, 
all participants were visited at home for a standardized questionnaire, and 7151 were 
subsequently examined at the research center. Since the start of the study, follow-up visits 
took place in the period 1993 through 1996 for the second visit and in the period between 
1997 through 1999 for the third visit. In addition to follow-up examinations, the total 
cohort is continuously monitored for major morbidity and mortality through linkage of 
general practitioner and municipality records. Furthermore, all drug prescriptions dispensed 
to participants by automated pharmacies are routinely stored in the database since January 
1, 1991. For the present study, follow-up started at the baseline examination and lasted 
until January 1, 2000. 
Assessment ofQTc interval 
The primary endpoint of the study was the length the QJc interval in msec. Hereto, 
a 10 sec 12-lead resting ECG (on average 8 to 10 beats) was recorded with an ACTA 
electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency of 500 Hz 
and stored digitally. All ECGs were processed by the Modular ECG Analysis System 
(MEANS) to obtain ECG measurements. The MEANS program has been evaluated 
extensively.12-14 MEANS determines common onsets and offsets for all12leads together 
on one representative averaged beat, with the use of template matching techniques. 13 The 
MEANS program determines the QJ interval from the start of the QRS complex until the 
end of the Twave. To adjust for heart rate, Bazett's formula (QTc=QT/.YRR) was usedY 
Digitally stored ECGs of 6134 (86%) participants were available at the time of the first 
visit, of 4415 participants (of 6315 participants visiting the research center, 70%) at the 
time of the second visit, and of 3806 participants at the time of the third visit (of 4797 
participants who visited the research center, 79%). Missing ECGs were mainly due to 
temporary technical problems with ECG recording. 
Exposure 
The exposure of interest was the use of QTc prolonging drugs, as specified in the two 
lists: list 1 from the internet based registry (http://www.qtdrugs.org/medical-pros/drug-
lists/ drug-lists.htm) and the list from the work of De Ponti et al. 6 7 9 16 Since not all 
drugs on these lists are licensed or prescribed in the Netherlands, some were not included 
in our analyses . Our analyses included: gastro-intestinal QTc prolonging medication: 
cisapride, domperidone; antimicrobial QTc prolonging medication: erythromycin, 
clarithromycin, co-trimoxazole; chloroquine; antipsychotic QTc prolonging medication: 
haloperidol, thioridazine; cardiovascular (anti-arrhythmic) QTc prolonging medication: 
amiodarone, disopyramide, quinidine, sotalol; cardiovascular (non anti-arrhythmic) 
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QTc prolongation medication: ketanserin, indapamine; antidepressant QTc prolonging 
medication: clomipramine, amitriptyline, doxepine, sertraline, mianserine; antihistamine 
QTc prolonging medication: diphenhydramine/dimenhydrinate, astemizole, terfenadine, 
promethazine. 
The index date was defined as the date of the ECG measurements. In order to classifY use 
at the index date, we calculated the duration of each prescription as the total number of 
units issued per prescription divided by the prescribed daily number of units. Current use 
was defined as use at the index date. 
Co-variates 
Clinical measures were obtained during the visits at the Rotterdam Study research 
center. In 1990-1993 non-fasting blood samples were obtained, while in 1997-2000 
blood samples were obtained after an overnight of fasting. Diabetes mellitus was defined 
as the use of blood glucose-lowering medication and/or a non-fasting serum glucose 
level of11.1 mmol!L or higher and/or a serum glucose levels~ 7mmolll (1997-2000)Y 
Hypertension was defined as a systolic blood pressure~ 160 mm Hg and/or diastolic 
blood pressure~ 100 mm Hg and/or use of antihypertensive medication, encompassing 
grade 2 and grade 3 hypertension according to World Health Organization (WHO) 
criteria. 18 Assessment of myocardial infarction at baseline and during follow-up was 
assessed by hospital discharge diagnosis or in case a patient was not hospitalized, 
when signs and symptoms, analysis of the standard 12-lead electrocardiogram and 
cardiac enzyme data were diagnostic of a myocardial infarction, and has been described 
in detail earlierY 20 Assessment of heart failure at baseline and during follow-up 
was assessed by the presence of signs and symptoms suggestive of heart failure and 
the use of medication for the indication heart failure and has also been described in 
detail earlier. 21 22 
Statistical analysis 
Differences in baseline characteristics were examined with a Chi-square test for 
dichotomous variables and at-test or Mann-Whitney test for continuous variables. The 
association of exposure to QTc prolonging drugs and QTc interval duration was examined 
by means of linear regression analysis. Analyses were adjusted for age, sex and additionally 
for diabetes mellitus, hypertension, myocardial infarction and heart failure since these 
factors may influence the duration of the QTc interval. Because repeated measures for 
the same subject are correlated, we included all measurements in one model, a repeated 
measurement analysis, taking into account correlation within persons. All repeated 
measurements analyses were performed using SAS software, version 8.2 using the MIXED 
procedure within SAS (PROC MIXED). 
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RESULTS 
Overall 14,013 ECGs were available, 5768 in men and 8245 in women ( TABLE 1). The 
overall median age was 69 years (interquartile range (IQR): 63-74) and women were 
significantly older than men. The mean QTc interval was significantly longer in women 
than in men (TABLE 1). Overall, 615 current users of QTc prolonging drugs were identified 
in our population. Significantly more women used QJc prolonging medication (TABLE 2). 
This was predominantly related to the more frequent use of several drugs in women, such 
as antidepressants and domperidone. 
TABLE I : CHARACTERISTICS OF THE STUDY POPULATION 
Overall Men Women 
Overall number of observations 14,013 5,768 (41.2%) 8,245 (58.8%) 
Age in years 69.9 (8.5) 68.9 (7.8)' 70.5 (8.9)' 
QTc (mean, SD) in msec 430.0(26.5) 425.0 (27.8)" 433.4 (25.0}" 
ECGvisit ' 5216 2113 3103 Number of observations 
Age (mean, SD) in years 68.9 (9.3) 67.6 (8.3)" 69.8 (9.8)' 
QTc (mean, SD) in msec 430.7 (27.3) 425.1 (28.5)" 434.5 (25.9)" 
ECGvisit ' 4991 2057 2934 Number of observations 
Age (mean, SD) in years 69.4 (8.4) 68.4 (7.6)" 70.1 (8 .9)" 
QTc (mean, SD) in msec 427.9 (26 .9) 423.2 (27.3)" 431.2 (24.4 )' 
ECGvisit' 3806 1598 2208 Number of observations 
Age (mean, SD) in years 71.9 (7.0) 71.4 (6.6)' 72.2 (7.2)' 
QTc (mean, SD) in msec 431.8 (25.9) 427.3 (27.4)" 435.0 (24.2)" 
Values are mean, SD 
SD= standard deviation 
' P <0.0001 
The use of anti psychotics, cardiovascular medication, antidepressants and antihistamines was 
associated with a significantly increased QJc interval. Of the individual drugs, current use of 
clarithromycin, thioridazine, sotalol, amiodarone, disopyramide, indapamine, amitriptyline 
and promethazine was associated with a significant QTc interval prolongation. Mter 
exclusion of all current users of cardiovascular QJc prolonging medication (amiodarone, 
chloroquine disopyramide, quinidine, sotalol, indapamine and ketanserin) the results did 
not change sunstantially. The current use of clarithromycin, thioridazine, amitriptyline and 
promethazine remained associated with a significantly prolonged QTc interval. From the 
drugs listed on both lists, current use of thioridazine and clarithromycin was associated with 
a significantly increased QJc interval. 
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TABLE 2: MEDICATION AND QTc INTERVAL PROLONGATION 
Medication Users Men Women ProlonJiation QTc ProlonJiation QTc 
(n) (%) (%) interv (95% CI)' interv (95% CI)" 
All QTc prolonging medication 615 212 (3.7)A 403 (4.9)A 9.5 (7.6-11.4) B 8.8 (6.9-10.7) 
Gastrointestinal medication 147 0.4 ([-3.3]-4.2) 0.3 ([-3.4]-4.0) 
Cisapride 101 32 (0.6) 69 (0.8) 0.2 ([-4.2]-7.8) 0.2 ([-4.6]-4.2) 
Domperidone 46 10 (0.2) A 36 (0.4)¥ 0.9 ([-6.1]-7.8) 1.2 ([-5.7]-8.1) 
Antibacterials 18 9 (0.2) 9 (0.1) 2.8 ([-7.0] -12.6) 2.8 ([-6 .9]-12.6) 
Erythromycin 2 1(0.0) 1(0.0) -5.0 ([-33 .0]-22.9) -5.5 ([-33.5]-22.4) 
Clarithromycin 0(0.0) 3 (0.0) 39.7 (44.4-65.0) B 37.9 (12.6-62.7) B 
Co-trirnoxazol 7 3 (0.1) 4(0.0) -8.8 ([-24.4] -6.8) -8.3 ([-23.9]-7.3) 
Chloroquine 6 5 (0.1) 1(0.0) 2.9 ([-14.0] -19.7) 3.3 ([-13.5]-20.2) 
Antipsychotics 17 6 (0.1) 11 (0.1) 12.2 (0.3 -24.0) B 12.0 (0.2-23.8) B 
Thioridazine 6 2 (0.0) 4(0.0} 25.7 (4.7-46.6) B 25.2 (4.4-46.0) B 
Haloperidol 11 4(0.1} 7 (0.1) 5.8 ([-8.7]-20.2) 5.7 ([ -8.7]-20.0) 
Cardiovascular medication 265 110 (1.9) 155 (1.9) 16.8 (14.0-19.7) B 15.5 (12.6-18.4) B 
Anti arrhythmics 223 95 (1.6) 128 (1.6) 17.6 (14.5-20.7) B 16.2 (13.1-19.3) B 
Sotalol 130 34 (0.9) 76 (0.9) 14.4 (10.6-18.3) B 13.1 (9.2-16.9) B 
Amiodarone 66 34 (0.60 32(0.4) 20.2 (14.3-26.1) B 17.7 (11.8-23.6) B 
Disopyramide 21 6 (0.1) 15 (0.2) 27.1 (16.8-37.5) B 26.8 (16.5-37.2) B 
Quinidine 7 6 (0.1) 15 (0.2) 14.9 ([-4.1]-33 .9) 15.6 ([-3.3]-35.6) 
Other cardiovascular 44 15 (0.3) 29 (0.4) 11.2 (3 .7-18.7) B 10.1 (2.6-17.6) B 
Indapamine 16 11 (0.2) 17 (0.2) 12.7 (3.2-22.1) B 13.0 (3.6-22.5) B 
Ketanserine 28 4(0.2) 12 (0.1) 8.7([-3.7] -21.0) 5.6 ([-7.2]-17.5) 
Antidepressants 154 38 (0.7) A 116 (1.4) A 6.1 (2.2-10.0) B 6.0 (2.2-9.9) B 
Clomipramine 22 5 (0.1) 17 (0.2) 6.8 ([-3.1]-16.8) 7.0 ([-3.0]-16.9) 
Amitriptyline 96 27 (0.5) A 69 (0.8) A 8.7 (3.8-13.5) B 8.6 (3.7-13.4) B 
Doxepine 6 1 (0.0) 5 (0.1) -7.8([-27.9]-10.4) -9.3 ([-28.4[-9.9) 
Mianserine 31 5(0.1) • 26 (0.3) A -0.8 ([-9.7]-8.0) -0.8 ([-9.6]-7.9 ) 
Antihistamines 41 12 (0.2) 29 (0.4) 8.2 (1.6-14.8) B 7.9 (1.3-14.5) B 
Diphenhydramine 2 (00) 0 (0.0) -19.7 ([-48.7]-9.4) -19.4 ([-48.5] -9.6) 
Astemizole 1(0.0) 2 (0.0) 3.1 ([-20.1]-26.2) 3.6 ([-19.5]-26.7) 
Terfenadine 20 5 (0.1) 15 (0.2) 8.5 ([-0.8]-17.7) 7.5 ([-1.8] -16.7) 
Promethazine 16 4 (0.1) 12 (0.1) 13.0 (1.9-24.0) B 13.5 (2.5-24.6) B 
Since some subjects use more than 1 drug, numbers do not add up to the total number of subjects 
QTc interval in msec. CI =Confidence Interval 
' adjusted for age and sex 
" adjusted for age and sex, diabetes mellitus, hypertension, myocardial infarction, and heart failure 
A P <0.05 Chi square test 
8 P <0.05 linear regression analysis 
List 1 includes also: bepridil, sparfloxacine, chlorpromazine, droperidol, mesoridazine, pimozide, halofantrine, arsenic trioxide, 
levomethadyl, pentamidine. 
D e Ponti' s list includes also: lidof!azine, grepaf!oxacin, chlorpromazine, droperidol, sultopride, pimozide, protriptyline, 
zimeldine, pentamidine, tacrolimus and terodiline 
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DISCUSSION 
The results of our study in a population of older adults, showed a significant association 
between the current use of several, but not all, drugs on two widely used lists which have 
been associated with QTc interval prolongation andlorTorsade de Pointes. Current use of 
clarithromycin, thioridazine, sotalol, amiodarone, disopyramide, indapamine, amitriptyline, 
and promethazine was associated with a significant increase in the length of the QJc 
interval. Although all listed drugs have been reported to be associated with Torsade de 
Pointes or cardiac arrhythmias, significant associations were not found for a number of 
these drugs.6 7 9 It is possible that avoiding known QTc prolonging drugs in high-risk 
patients precluded the finding of an association. As a significant number of users, also 
with known risk factors, were identified in our study population, this seems not to be the 
explanation. The cross-sectional nature of the study prohibited us to determine if the drugs 
were the cause of the QTc prolongation or QTc prolongation was already present before 
the start of the drug.This study design, however, would not have prohibited the finding of 
an association between a listed drug and QTc prolongation, if present and does not explain 
the absence of an association for a large number of drugs.The fact that we did not find a 
significant QJc prolongation could also be explained by a small number of current users 
of some drugs. For thioridazine, however, we found a significant prolongation of the QTc 
interval despite a small number of users. 
It is known that some drugs associated with QJc prolongation are devoid of torsadogenic 
effects, whereas others seem not to be associated with a significant QTc prolongation, 
but are still considered to be associated with cardiac arrhythmias.5 8 23 Virtually all QJc 
prolonging drugs act by blocking the rapid component of the delayed rectifier potassium 
channel (I1) through blockade of the human ether a go-go related gene (HERG). 
Unfortunately this finding is not specific, since many drugs that do not seem to cause 
Torsade de Pointes, also block this current.5 Amiodarone blocks Ikr, is associated with a 
significant QJc prolongation, yet rarely causes Torsade de Pointes. 3 5 8 1herefore, it is likely 
that other pharmacological actions are also involved. These actions might preventTorsade 
de Pointes, either directly (by blunting early after depolarizations) or indirectly (by blunting 
the prolongation of the action potential). 5 1he problem is that some drugs do not prolong 
the QTc interval, yet are implicated in the occurrence of cardiac arrhythmias and Torsade 
de Pointes. 8 23 1he antihistamine terfenadine, a potent Ikr blocker, did not prolong the QTc 
interval, not in our study nor in earlier studies. Nevertheless, this drug has been associated 
with serious cardiac arrhythmias leading to its withdrawal. These are believed to occur 
mostly when there was concurrent use of inhibitors of cytochrome P450 CYP3A4.5 8 23 24 
Thus, it seems to be difficult to predict whether a drug will cause Torsade de Pointes based 
on its effect on the length of the QJc interval alone. 
Much emphasis has been placed on the potential pro-arrhythmic effects of pharmaceuticals 
that are associated with QTc interval prolongation in recent guidelines.10 Recently, 
collaborating researchers from several pharmaceutical industries published an extensive 
review of QTc prolonging drugs and their ability to bind to HERG channels in relation to 
free plasma concentrations. 8 It was shown that, in general, drugs with a small margin (i.e. 
drugs that bind to the potassium channels in concentrations close to therapeutic plasma 
concentration) had a high risk of serious cardiac arrhythmias while drugs with a high 
margin had a lower risk. In this review, cisapride, astemizole and terfenadine were shown 
to have a very low margin, suggesting a high risk of cardiac arrhythmias, while amiodarone 
has a very high margin, which is in line with its known low risk ofTorsade de Pointes.8 
This margin between HERG binding capacity and free plasma concentration might be 
a helpful tool in the prediction of the risk ofTorsade de Pointes, and might be more 
important as an indicator of risk for cardiac arrhythmias. 
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CHAPTER 5 
ANTIPSYCHOTICS AND THE RISK OF 
SUDDEN CARDIAC DEATH 
ABSTRACT 
Background: Antipsychotics have been associated with QTc prolongation and cases 
of sudden cardiac death. Only few epidemiologic studies, however, investigated this 
association. We performed a case-control study to investigate the association between 
the use of antipsychotics and sudden cardiac death in a well-defined community 
dwelling population. 
Methods and Results: We performed a population-based case-control study in the IPCI 
project, a longitudinal observational database with complete medical records from 150 
general practitioners in the Netherlands. All instances of death between January 1, 1995 
and April1, 2001 were manually reviewed. Potential cases of sudden cardiac death were 
classified on the basis of the time between onset of cardiovascular symptoms and death. 
To each case, up to ten random controls were matched on year of birth, gender, date of 
sudden death and practice. Exposure at the index date was categorised as three mutually 
exclusive groups of current use, past use and non-use. Furthermore, dose- and duration-
effect relationships were studied. 
The study population comprised 554 cases of sudden cardiac death and 4463 matched 
controls. Current use of antipsychotics was associated with a three-fold risk increase of 
sudden cardiac death (adjusted OR: 3.3; 95% CI: 1.8-6.2).1he risk of sudden cardiac death 
was highest among butyrophenone antipsychotics (OR: 7.3; 95% CI: 2.8-18.8), users of 
more than 0.5 DDD per day (OR: 9.8; 95% CI: 2.1-44.6) and among short-term (::: 90 
days) users (OR: 5.0; 95% CI: 2.1-12.1). For witnessed cases (n=334), the association with 
current antipsychotic use was higher (OR 4.7; 95% CI: 2.0-10.8) than for unwitnessed 
cases (OR: 2.4; 95% CI: 0.9-6.3). 
Conclusion: The results of our study indicate that current use of antipsychotics in a general 
population is associated with an increased risk of sudden cardiac death, even at a low dose 
and in persons who use antipsychotics for other indications than schizophrenia. The risk 
of sudden cardiac death seems to be highest among recent starters but remains elevated 
during long-term use. 
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INTRODUCTION 
In developed countries, sudden cardiac death is one of the major causes of cardiovascular 
mortality. According to the most recent definition, sudden cardiac death is a natural death 
due to cardiac causes, heralded by abrupt loss of consciousness within one hour after the 
onset of acute symptoms or an unwitnessed, unexpected death of someone seen in a stable 
medical condition less than 24 hours previously with no evidence of a non-cardiac cause.12 
Since the early sixties, sudden cardiac death has been reported with antipsychotic use in case 
reports. 3-5 Although the precise mechanism remains uncertain, several have been suggested 
including peripheral vasodilatation, leading to cardiovascular collapse, oral laryngeal-
pharyngeal dystonia, acute myocarditis or cardiomyopathy.6 Particular attention has been 
paid to the ability of anti psychotics to prolong the QJc interval, which may result in torsade 
de Pointes and other cardiac arrhythmias. 6-8 Only few epidemiological studies have addressed 
the issue of sudden cardiac death and antipsychotic use. They found an increased risk of 
sudden cardiac death during the use of antipsychotics, varying from 1.7 to 5.3.8-10 These 
studies, however, were either small and performed in hospitalised psychiatric patients or 
were performed in administrative databases with little information on potential confounders. 
Moreover, because of the inability to validate the diagnosis of sudden cardiac death in medical 
records, most of these studies may have suffered from misclassi:fication of the outcome. 
We performed a case-control study on the association between the use of anti psychotics 
and sudden cardiac death in a well-defined community dwelling population with complete 
coverage of all relevant health care information. 
METHODS 
Setting 
All data were retrieved from the Integrated Primary Care Information (IPCI) project, a 
longitudinal observational database, containing data from computer-based medical patient 
records of a group of 150 general practitioners (GPs) in the Netherlands. In the Dutch 
health care system, the GP has a pivotal role by acting as a gatekeeper for all medical care. 
Details of the database have been described elsewhere. 11 12 Briefly, the database contains 
the complete medical records on approximately 500,000 patients. The electronic records 
contain coded and anonymous data on patient demographics, symptoms (in free text), 
diagnoses (using the International Classification for Primary Care 13 and free text) from 
GPs and specialists, referrals, laboratory :findings, hospitalisations, and drug prescriptions, 
including their indications and dosage regimen. To maximise completeness of the data, 
general practitioners participating in the IPCI project are not allowed to maintain a system 
of paper-based records besides the electronic medical records. The system complies with 
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European Union guidelines on the use of medical data for medical research and has been 
proven valid for pharmaco-epidemiological research in several validation studies that 
evaluated the quality of the available information.11 The Scientific and Ethical Advisory 
Board of the IPCI project approved this study. 
Source population 
The source population comprised all subjects o£18 years and older, registered with a general 
practitioner participating in the IPCI project for at least one year. Subjects with a diagnosis 
of cancer were excluded from the source population, since in these patients the cause of 
death is often difficult to assess. The study period started on January 1, 1995 and ended on 
April 1, 2001. All subjects were followed until death, transferral out of practice, last data 
draw down or end of the study period, whichever came first. 
Case and control definition 
The computerised medical and demographic data were screened for all deaths, which occurred 
during the study period. The medical records of all identified cases of death were reviewed 
manually to assess whether death could be classified as sudden cardiac death. Validation was 
performed independently by two physicians blinded to exposure (SMJMS, GSB) and in case 
of discrepancy, a third expert (BHChS) arbitrated. Assessment was based on the most recent 
definition of sudden cardiac death. 1 2 Cases were classified as (probable) sudden cardiac death 
if the medical record indicated that death occurred within one hour after the onset of acute 
symptoms and if the following wording was found in the free text: "sudden cardiac death", 
"acute cardiac death", "mors subita", "sudden death", "died suddenly", "died unexpectedly", or 
if this was an unwitnessed, unexpected death of someone seen in a stable medical condition 
less than 24 hours previously and with no evidence of a non-cardiac cause (e.g. pneumonia, 
convulsion, choking or stroke). Suicides were excluded. To each case of sudden cardiac death, 
up to ten controls were randomly drawn from the source population matched on age (year of 
birth), gender, and practice. The index date was defined as the date on which sudden cardiac 
death occurred in cases. This date was also the index date for matched controls. 
Exposure definition 
In order to assess the use of antipsychotics at the index date, we calculated the duration of 
use for each antipsychotic as the total number of units (capsules/tablets) per prescription 
divided by the prescribed daily number of these units. Exposure at the index date was 
categorised into three mutually exclusive groups of current, past and non-use. Use of 
anti psychotics was defined as current if the index date fell within a period of use or within 
a maximum of30 days after the end of the last prescription (to deal with carry-over effects). 
Past use was defined as discontinuation of an antipsychotic, more than 30 days before the 
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index date. If patients had no prescription for an antipsychotic prior to the index date they 
were considered non-exposed. Among current users we evaluated the effect of duration 
(~ 90 days; > 90 days continuously), type of antipsychotic (phenothiazines, butyrophenones, 
thioxanthenes, lithium and other), indication for the antipsychotic prescription and the daily 
dose in defined daily dose equivalents (DDD), as defined by the World Health Organisation.14 
One DDD-equivalent represents the recommended daily dose for an adult for the indication 
schizophrenia. In order to evaluate dose response effects the daily dose of anti psychotics was 
categorised into less than or equal to 0.5 DDD, and more than 0.5 DDD. 
Co-variates and risk factors 
Known risk factors and other co-variates for sudden cardiac death were gathered from the 
medical records through computerised searches and manual assessment. The co-variates 
which were evaluated included cerebro- and cardiovascular ischemia (history of myocardial 
infarction, stroke, and angina pectoris), heart failure, hypertension, diabetes mellitus, 
arrhythmia, hypercholesterolemia, smoking and alcohol abuse. Ischemia and heart failure 
were assessed, based on the diagnoses provided by the general practitioner and by specialists 
in the medical records. Hypertension was identified through the diagnoses in the medical 
records, the use of antihypertensive medication and/or the assessment of blood pressure 
measurements, according to the guidelines of the World Health Organisation (a blood 
pressure exceeding 140 mm Hg systolic and/or 90 mm Hg diastolic)Y Diabetes mellitus, 
arrhythmias and hypercholesterolemia were identified through diagnoses in the medical 
records from GPs and specialists and/or the use of antidiabetic, anti-arrhythmic or lipid 
lowering medication. Information on smoking and alcohol abuse was obtained from the 
medical records. As concomitant medication we considered among others antidepressants, 
anxiolytics, hypnotics, cardiovascular and known QTc prolonging medication. Current 
use of these drugs was defined as use at the index date. The indication for the use of 
antipsychotics, classified according to the DSM IV 16, was obtained from the prescription 
records. We evaluated the effect of social economic status (SES), by including a variable on 
health care insurance, which is a proxy for income (all below an income of about 25.000 
dollars a year have sick fund insurance, and those above have a private insurance). 
Statistical analysis 
The relative risk for sudden cardiac death associated with anti psychotics was estimated by 
calculation of the odds ratios (95% confidence interval) using conditional logistic regression 
analyses. Co-variates which were univariately associated with sudden cardiac death (at 
a p< 0.1 level) were initially included in the regression analyses. Factors that changed 
the point estimate of the association between antipsychotic drug use and sudden cardiac 
death by more than 10% 17 were kept in the final model (diabetes mellitus, arrhythmias, 
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hypertension, cerebra-and cardiovascular ischemia, use of diuretics, use of ACE-inhibitors, 
and use of anxiolytidhypnotic medication). In addition smoking and alcohol abuse were 
included in the model because these are known risk factors for sudden cardiac death. We 
investigated potential effect modification by age and gender and performed subanalyses 
to evaluate potential misclassification of sudden cardiac death by splitting the outcomes 
between witnessed and unwitnessed death. To evaluate a possible dose-effect relation, a 
trend test was performed. Furthermore, we evaluated potential confounding by indication 
by providing risk estimates for current antipsychotic use in patients with the indication 
schizophrenia and with current antipsychotic use for other indications. 
RESULTS 
In the source population (n= 250,000), 582 cases of sudden cardiac death were identified, 
representing an incidence rate of sudden cardiac death of almost 1 per 1000 person-years 
per year in the source population. No controls could be matched to 28 cases, and these cases 
were excluded from further analyses. Hence, the study population comprised 554 cases 
of sudden cardiac death and 4463 matched controls (approximate case:control ratio 1:8). 
There were 334 witnessed (60.3%) and 220 unwitnessed (39.7%) cases of sudden cardiac 
death. The median age of the study population was 71 years and approximately 60% were 
male. Despite matching on year of birth, the median age of cases was higher than the 
median age of all controls (74 years and 71 years respectively) since more controls were 
available for younger cases than for elderly cases ( TABLE 1). Autopsy had been performed in 
only seven cases but these were all compatible with a cardiac origin of sudden death. All 
known potential risk factors for sudden cardiac death were associated with an increased 
risk, notably ischemic cerebro- and cardiovascular disease, hypertension, arrhythmia, 
diabetes mellitus, heart failure, hypercholesterolemia, smoking and alcohol abuse (TABLE 1). 
As expected, use of cardiovascular medication was associated with sudden cardiac death as 
well. There was no association between socio economic status and sudden cardiac death. 
Current use of antipsychotics was associated with a three-foldly increased risk of sudden 
cardiac death (adjusted OR: 3.3; 95% CI: 1.8-6.2). Past use of antipsychotics was not 
associated with an increased risk of sudden cardiac death (TABLE z).The risk of sudden cardiac 
death was highest among individuals using butyrophenone anti psychotics, predominantly 
pipamperone and haloperidol. Furthermore, the risk was highest among users of a daily 
dose higher than 0.5 DDD, and among short-term(~ 90 days) users. The risk of sudden 
cardiac death increased significantly with higher doses (p<0.001). However, also in persons 
who used antipsychotics at a daily dose~ 0.5 DDD, or continuously for more than 90 days 
the risk of sudden cardiac death was significantly increased. The majority of current users 
did not receive antipsychotics for schizophrenia. 
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TABLE 1 : DEMOGRAPHICS, DISTRIBUTION OF CO-VARIATES AND USE OF CONCOMITANT 
MEDICATION IN CASES AND CONTROLS 
Characteristic Cases (n=ss4) Controls (n=4463) Odds ratio• (95% CI) 
Gender 
Male 326 (59%) 2657 (60%) 
Age (median) 74YR 71 YR 
ssyr 67 (12.1%) 736 (164%) 
s6-6syr 77 (13.9%) 792 (17.7%) 
66-75yr 175 (31.6%) 1551 (34.8%) 
> 75 yr 235 (42.4%) 1390 (31.1%) 
Sudden cardiac death 
Witnessed 334 (60.3%} 
Co-morbidities 
Ischaemic Cerebra-/Cardiovascular Disease 203 (37%) 780 (17%) 2.6 (2.1-3.2) 
Hypertension 359 (65%) 2562 (57%) 1.3 (1.0-1.6) 
Arrhythmia 114 (21%) 469 (11%) 2.1 (2.1-3 .2) 
Diabetes mellitus 182 (33%) 871 (20%} 2.0 (1.6-2.5) 
Smoking 9 2 (17%) 469 (11%) 2.2 (1.6-2.9) 
Alcohol abuse 32 ( 6%} 137 ( 3%} 2.1 (14-3.3) 
Heart failure 141 (25%) 283 ( 6%) 5.0 (3.9-6.4) 
Hypercholesterolemia 47 ( 8%} 266 ( 6%} 1.7 (1.2-2.4) 
Concomitant cardiovascular drugs 
B-blocking agents 71 (13%) 491 (11%) 1.2 (0.9-1.6) 
Diuretics 135 (24%) 484(11%) 2.4(1.9-3.1) 
Ca-blocking agents 63 (11%) 295 (7%) 1.7 (1.3-2.3) 
ACE-inhibitors 100 (18%) 378 ( 8%) 2.4 (1.8-3.0) 
ATII-blocking agents 19 (3%} 66(2%) 2.5 (1.5-4.3) 
Lipid lowering agents 31 ( 6%} 206 ( 5%) 1.4(1.0-2.1) 
Cardiac glycosides 56 (10%} 125 ( 3%) 3.4 (2.4-4.9) 
Anti-arrhythrnics 7( 1%) 32 (1%) 1.6 (0.7-3.9) 
• All odds ratios are matched for age, gender, practice and calendar time 
Twelve patients (5 cases and 7 controls) met the criteria for diagnoses of schizophrenia 
or schizo-affective disorders, whereas 44 patients (14 cases and 30 controls) received 
antipsychotics for other psychiatric diseases such as organic psychosis, dementia, stress, 
anxiety or bipolar depression. The risk of sudden cardiac death in current users not meeting 
the criteria for the diagnosis of schizophrenia or schizo-affective disorders was significantly 
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higher than in non-users (OR: 3.3; 95% CI: 1.6-6.6) and was not significantly different 
from those with the diagnosis schizophrenia (OR: 3.4; 95% Cl: 0.9-12.8). 
TABLE 2: RISK OF SUDDEN CARDIAC DEATH AND THE USE OF ANTIPSYCHOTIC MEDICATION 
Use of antipsychotic medication Cases Controls OR* OR** 
(n=ss4l (n=4463) (95% CI) (95%CI) 
Non-use 520 4352 1.0 (reference) 1.0 (reference) 
Past use IS 74 1.4 (0.8-2.4) 1.1 (0.6-2.0) 
Current use 19 37 3.7 (2.0-6.7) 3.3 (1.8-6.2) 
Type of antipsychotic used a b 
Non-use 520 4352 1.0 (reference) 1.0 (reference) 
Butyrophenones 12 13 6.1 (2.6-14.1) 7.3 (2.8-18.8) 
Thioxanthenes 3.4 (0.5-32.6) 2.9 (0.3-32.9) 
Other anti psychotics 2 7 2.6 (0.5-13.1) 1.9 (0.3-11. 8) 
Lithium 9 2.4 (0.6-9.3) 1.5 (0.3-8.3) 
Phenothiazines 12 1.7 (0.4-7.7) 0.8 (0.2-3 .8) 
Daily dose 
Non-use 520 4352 1.0 (reference) 1.0 (reference) 
~o.sDDD 14 33 3.0 (1.6-5.8) 2.8 (1.4-5.6) 
> o.sDDD" .. 4 8.8 (2.2-34.4) 9.8 (2.1-44.6) 
Duration of use 
Nonuse 520 4352 1.0 (reference) 1.0 (reference) 
~go days 10 15 4.4 (1.9-10.3) 5.0 (2.1-12.1) 
>go days 9 22 3.2 (1.4-7.1) 2.5 (1.1-6.0) 
* Odds ratios matched for age, gender, practice and calendartime 
•• Odds ratio matched for age, gender, practice and calendartime, adjusted for diabetes mellitus, arrhythmias; use of diuretics, 
ACE-inhibitors, am.:iolyticslhypnotics; hypertension, smoking, alcohol abuse and cerebro/cardiovascular ischemia. 
*** trendtest p<0.0001 
a Anti psychotics included: Butyrophenones: haloperidol, pipamperone, bromberidol, benperidol. Phenothiazines: 
chloorpromazine, levopromazine, triflupromazine, perphenazine, prochlorperazine, trifluorazine, perazine, thioridazine, 
periciazine. Other: pimozide, clozapine, olanzapine, risperidone. Thioxanthenes: flupentixol, zuclopenthixol 
b Since some patients used > 1 antipsychotic, numbers do not add up 
For witnessed cases of death, the association with current antipsychotic use was higher (OR 
4. 7; 95% Cl: 2.0-10.8) than for unwitnessed cases (OR: 2.4; 95% Cl: 0.9-6.3). Stratified 
analyses showed that the risk of sudden cardiac death in users of anti psychotics tended to 
be higher in male users (OR 4.9; 95% CI: 1.7-13.0) than in female users (OR 2.9; 95% 
Cl: 1.3-6.4) and higher in patients younger than or equal to 65 (OR 5.5; 95% Cl: 1.00-
31.1) than in patients older than 65 years of age (OR 3.1; 95% CI: 1.6-6.1). None of these 
interactions, however, were statistically significant. 
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DISCUSSION 
The results of our study indicate that current use of anti psychotics in a community dwelling 
population is associated with an increased risk of sudden cardiac death, even at a low dose 
and in persons who use antipsychotics for other indications than schizophrenia. Mter 
adjustment for known confounding factors, current use of antipsychotics was associated 
with a more than tripled risk of sudden cardiac death. The risk was highest among the 
users of butyrophenone anti psychotics but not significantly different from the other 
antipsychotics, possibly due to low numbers. Unlike some other studies, we did not find an 
association with thioridazine but this drug was hardly used in our study population. 9 10 The 
risk of sudden cardiac death was slightly but not significantly lower after prolonged use of 
anti psychotics, which might be the result of depletion of susceptibles. 
A consistent finding in all studies on the association between antipsychotic use and sudden 
cardiac death is that there seems to be a positive dose response relationship. 6-10 A potential 
mechanism by which antipsychotic agents might induce sudden cardiac death relates to 
their capacity to prolong the QJc interval, which seems to be dose-related.18 However, the 
exact role of QJc prolongation in torsade de pointes, ventricular arrhythmias and sudden 
cardiac death has not been resolved yet.6 18-20 Antipsychotics seem to share the ability to 
antagonise the rapid component of the delayed rectifier potassium current, which leads to 
a variable lengthening of the action-potential. QJ prolongation is only a surrogate marker 
of cardiotoxicity and there is no consensus on the degree of QJ prolongation that becomes 
clinically relevant. In our study, also low doses of antipsychotics were associated with a 
significantly increased risk of sudden cardiac death. In the Tennessee Medicaid cohort study, 
the risk of sudden cardiac death was greater in women and in those ~ 65 years. 8 In contrast, we 
found that the risk of sudden cardiac death tended to be higher in males and in those younger 
than 65 years of age. The fact that in our study elderly women predominantly used a low dose 
(s 0.5 DDD), while younger males mostly used a high dose might explain this finding. 
Our findings are consistent with earlier studies in which a higher rate of sudden cardiac 
death was found in patients taking antipsychotic drugs.8-10 In two retrospective cohort 
studies among schizophrenic patients the use of anti-psychotics was associated with a 
significantly increased risk of sudden cardiac death. Reilly et al found that thioridazine use 
was associated with a 5 fold increased risk of sudden cardiac death in psychiatric in-patients. 
Most of these studies, however, had limitations. First, patient populations in these studies 
included only cases with schizophrenia, either hospitalised 9 or in an outpatient setting. 8 10 
Therefore, it was impossible to determine whether findings were due to the disease 
(confounding by indication) or to the antipsychotic drugs taken. Second, two studies used 
data from Medicaid programs. These data pertain to a skewed population of people from 
lower socio-economic classes with a high cardiovascular risk profile, and these Medicaid 
databases have little or no information on important potential confounders. Third, for 
exposure assessment these studies used a fixed length of 30 days for a prescription since 
the exact dosing regimen was unknown. This may have caused exposure misclassification 
because under real life circumstances dose variation will lead to different prescription 
lengths, and consequently to varying exposure windows.21 Finally the outcome can 
often not be assessed validly in such databases since death and the reason for death are 
poorly registered and have to be proxied by assuming that not returning for health care 
consumptions means that the patient died. 10 
In our population, we were able to take advantage of the fact that in the Dutch health 
care system all medical information (including specialist and hospital care) is collected at 
practices that cover the general population instead of selected socio-economic groups. As a 
consequence, there was extensive information available on drug use, potential confounders 
and the circumstances surrounding death. Moreover, data allowed for subanalysis of different 
indications which confirmed that sudden cardiac death is associated with antipsychotic use 
rather than with schizophrenia itself. 
Nevertheless, also our study has some limitations. First, we cannot exclude that some 
misclassification of outcome occurred. We may have missed some deaths although this will 
be minimal, since death is consistently registered by general practitioners. In contrast to 
other studies 8 10, we could reduce misclassification by the possibility to differentiate between 
witnessed and unwitnessed cases.The percentage of unwitnessed deaths in our population 
was 39.2%, which is in line with earlier findings.20 22 1he risk of witnessed sudden cardiac 
death alone was more than quadrupled in current antipsychotic users, while the risk in 
the unwitnessed cases was lower. This is consistent with the fact that misclassification 
will occur more often in unwitnessed cases. In the latter group, some deaths might have 
been of non-cardiac origin and this could explain the lower risk estimates. Second, not all 
acute deaths may have been of cardiac origin. We had pathological autopsy information 
only for 7 cases, in these instances the cause of death was cardiac. Third, misclassification 
of exposure may have occurred since we used outpatient prescription data and we had no 
information as to whether the prescription was actually filled and taken. It is likely, however, 
that such exposure misclassification will be random and will be evenly distributed among 
cases and controls. Therefore, the reported estimate is probably a conservative one. Fourth, 
the number of exposed cases in our study unfortunately prohibited us from comparing 
individual antipsychotic agents. 
In conclusion, the results of our study indicate that current use of anti psychotics in a general 
population is associated with an increased risk of sudden cardiac death, even at a low dose 
and in persons who use antipsychotics for other indications than schizophrenia. The risk 
of sudden cardiac death seems to be highest among recent starters but remained elevated 
during long-term use. 
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CHAPTER6 
NON-CARDIAC OTc PROLONGING 
DRUGS AND THE RISK OF SUDDEN 
CARDIAC DEATH 
ABSTRACT 
Background: To assess the association between the use of non-cardiac QTc prolonging 
drugs and the risk of sudden cardiac death. 
Methods and Results: A population-based case-control study was performed in the 
Integrated Primary Care Information (IPCI) project, a longitudinal observational database 
with complete medical records from over 500,000 persons. All deaths between January 1, 
1995 and September 1,2003 were reviewed. Sudden cardiac death was classified based on 
time between onset of cardiovascular symptoms and death. To each case, up to 10 random 
controls were matched for age, gender, date of sudden death and general practice. The 
exposure of interest was the use of non-cardiac QTc prolonging drugs. Exposure at the 
index date was categorized into 3 mutually exclusive groups of current use, past use, and 
non-use. The study population comprised 775 cases of sudden cardiac death and 6297 
matched controls. Current use of any non-cardiac QJc prolonging drug was associated with 
a significantly increased risk of sudden cardiac death (adjusted OR: 2. 7, 95% CI: 1.6-4. 7). 
The risk of death was highest in women, and in recent starters. 
Conclusion: The use of non-cardiac QTc prolonging drugs in a general population is 
associated with an increased risk of sudden cardiac death. 
INTRODUCTION 
In developed countries, sudden cardiac death is one of the major causes of cardiovascular 
mortality.1 According to the most recent definition, sudden cardiac death is a natural 
death due to cardiac causes, heralded by abrupt loss of consciousness within one hour 
after the onset of acute symptoms or an unwitnessed, unexpected death of someone seen 
in a stable medical condition less than 24 hours previously with no evidence of a non-
cardiac cause. 1-3 Probably, the large majority of cases of sudden cardiac death is due to 
ventricular fibrillation.2 4 1he major unanswered question in sudden cardiac death, however, 
is which precipitating event causes arrhythmia in an otherwise stable patient. Probably 
it is a complex interplay between myocardial injury, chronic and acute coronary events, 
autonomic tone, electrolyte state, drugs and genetic factors that determines the occurrence 
of a life threatening arrhythmia. 5 6 
In the past decade, one of the most frequent causes of drug restriction or withdrawal has been 
prolongation of the QTc interval associated with fatal cardiac arrhythmias. Lengthening of 
QTc interval represents the prolongation of the action potential and is used as a surrogate 
marker for the prediction of this serious adverse drug effect. 7 The website of the International 
Registry for Drug-induced Arrhythmias maintained by the Georgetown University (http:/ I 
www.qtdrugs.org/medical-pros/drug-lists/drug-lists.htm) provides an up-to-date list of 
drugs that prolong the QTc Interval and/or Induce Torsade de Pointes or Ventricular 
Arrhythmia. 8 The researchers have classified drugs into 4 categories varying from drugs that 
are generally considered to confer a risk ofTorsade de Pointes (list 1) to drugs that, when 
used in usual dosages, are unlikely to increase the risk (list 4). This potentially fatal adverse 
reaction is not only associated with cardiovascular drugs, but also with non-cardiovascular 
drugs. The risk of arrhythmias and sudden cardiac death during the use of non-cardiac QJc 
prolonging drugs has attracted considerable clinical and regulatory attention. 7 9 
Therefore, our objective was to assess the risk of sudden cardiac death and the use of non-
cardiac QJc prolonging drugs in a case-control study in a well-defined general population 
with complete coverage of all relevant health care information. 
METHODS 
Setting 
All data were retrieved from the Integrated Primary Care Information (IPCI) project, 
a longitudinal observational database, containing data from computer-based medical 
records of a group of 150 general practitioners (GPs) in the Netherlands. In the Dutch 
health care system, the GP has a pivotal role by acting as a gatekeeper for all medical care. 
Nearly every citizen is enrolled in the practice of a GP independent of health status.10 
Details of the database have been described elsewhere.10 11 Briefly, the database contains 
the complete medical records on approximately 500,000 citizens. The electronic records 
contain coded and anonymous data on demographics, symptoms (in free text), diagnoses 
(using the International Classification for Primary Care12 and free text) from GPs and 
specialists, referrals, laboratory findings, hospitalizations, and drug prescriptions, including 
their indications and dosage regimen. To maximize completeness of the data, general 
practitioners participating in the IPCI project are not allowed to maintain a system of 
paper-based records besides the electronic medical records. The project complies with 
European Union guidelines on the use of medical data for medical research and has been 
proven valid for pharmaco-epidemiological research in several validation studies that 
evaluated the quality of the available information.11 The Scientific and Ethical Advisory 
Board of the IPCI project approved this study. 
Source population 
The source population comprised all subjects of 18 years and older, who were registered 
with a general practitioner participating in the IPCI project for at least 1 year. Subjects 
with a diagnosis of cancer were excluded from the source population, since in these patients 
the cause of death is often difficult to assess and usually not unexpected. The study period 
started on January 1, 1995 and ended on September 1, 2003. All subjects were followed 
until death, transferal out of practice, date oflast data collection or end of the study period, 
whichever came first. 
Case and control definition 
The computerized medical and demographic data were screened for deaths that occurred 
during the study period. The medical records of identified cases of death were reviewed 
manually to assess whether death could be classified as sudden cardiac death. Validation 
was performed independently by two physicians who were blinded to exposure (SMJMS, 
GSB) and in case of discrepancy, a third expert (BHChS) arbitrated. Case assessment 
was based on the most recent definition of sudden cardiac death: a natural death due to 
cardiac causes, heralded by abrupt loss of consciousness within one hour after the onset of 
acute symptoms or an unwitnessed, unexpected death of someone seen in a stable medical 
condition less than 24 hours previously with no evidence of a non-cardiac cause.1-3 Cases 
were classified as (probable) sudden cardiac death if the medical record indicated that death 
occurred within one hour after the onset of cardiovascular symptoms and if the following 
wording was found in the free text: "sudden cardiac death", "acute cardiac death", "mors 
sub ita", "sudden death", "died suddenly", "died unexpectedly", or if this was an unwitnessed, 
unexpected death of someone seen in "good health" or in a stable medical condition less 
than 24 hours previously and without evidence of a non-cardiac cause (e.g. pneumonia, 
convulsion, choking or stroke). Suicides were excluded. To each case of sudden cardiac 
death, up to ten controls were randomly drawn from the source population matched on age 
(year ofbirth), gender, and practice. Ifless than 10 controls were available, all of them were 
included. The index date was defined as the date on which sudden cardiac death occurred 
in the cases. This date was also the index date for matched controls. 
Exposure definition 
The exposure of interest was the use of non-cardiac QTc prolonging drugs, as specified in 
the most recent version of list 1 (Drugs that are generally accepted by authorities to have 
a risk of causing Torsade de Pointes) from the International Registry for Drug-induced 
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Arrhythmias maintained by the Georgetown University (http://www.qtdrugs.org/medical-
pros/drug-lists/drug-lists.htm)8 and comprise the following non-cardiac QJc prolonging 
drugs: chloroquine, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, 
erythromycin, halofrantine, haloperidol, levomethadyl, mesoridazine, pentamidine, 
pimozide, sparfloxacin, and thioridazine. As not all drugs are licensed, marketed or 
prescribed in the Netherlands, some of these drugs were not included in our analyses. Our 
analyses included: gastro-intestinal QTc prolonging medication: cisapride, domperidone; 
antibiotic QTc prolonging medication: erythromycin, clarithromycin, and antipsychotic 
QTc prolonging medication: chlorpromazine, haloperidol, pimozide and, thioridazine. In 
order to classify use at the index date, we calculated the duration of each prescription, as 
the total number of units issued per prescription divided by the prescribed daily number 
of units. Exposure at the index date was categorized into three mutually exclusive groups 
of current, past and non-use. To account for the differences in prescription patterns of 
non-cardiac QJc prolonging drugs, different risk windows were specified. For non-cardiac 
QTc prolonging drugs normally prescribed for shorter periods of time (gastrointestinal 
medications and antibiotics), use was defined as current if the index date fell within a period 
of use or within a maximum of 7 days after the end of the last prescription (to account for 
carry-over effects). For drugs usually prescribed for longer periods of time (antipsychotics), 
use was defined as current if the index date fell within a period of use or within a maximum 
of 30 days after the end of the last prescription. Past use was defined as discontinuation 
of a non-cardiac QTc prolonging drug more than 7 days (gastrointestinal or antibiotic 
medication) or 30 days before the index date (antipsychotic medication). If patients had no 
prescription for any type of non-cardiac QTc prolonging drug prior to the index date they 
vtere considered non-exposed. Among current users we evaluated the effect of duration (~ 
90 days and > 90 days continuous use), type of non-cardiac QTc prolonging drug and the 
current daily dose used in defined daily dose equivalents (DDD), as defined by the World 
Health Organization.13 One DDD-equivalent represents the recommended daily dose for 
an adult for the main indication. To evaluate dose response effects the current daily dose 
of a non-cardiac QTc prolonging drug was categorized into less than 1 DDD equivalent, 
and 1 DDD equivalent or more. 
Co-variates and risk factors 
Known risk factors for sudden cardiac death and other co-variates were gathered from the 
medical records through computerized searches and manual validation. The co-variates 
that were evaluated included cerebro-vascular and cardiovascular ischemia (history of 
myocardial infarction, stroke, and angina pectoris), heart failure, hypertension, diabetes 
mellitus, arrhythmia, hypercholesterolemia, smoking and alcohol abuse. Cerebro-vascular 
ischemia, cardiovascular ischemia and heart failure were assessed, based on the diagnoses 
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provided by the general practitioner and specialists in the medical records. Hypertension 
was identified through the diagnoses in the medical records, the use of antihypertensive 
medication and/or the blood pressure measurements, meeting the guidelines of the World 
Health Organization (a blood pressure exceeding 140 mm Hg systolic and/or 90 mm 
Hg diastolic).14 Diabetes mellitus, arrhythmias and hypercholesterolemia were identified 
through diagnoses in the medical records from GPs and specialists and/or the use of anti-
diabetic, anti-arrhythmic or lipid lowering medication. Information on smoking and alcohol 
abuse was obtained from the free text in the medical records. As concomitant medication we 
considered amongst others diuretics, ACE inhibitors and other cardiovascular medication. 
Current use of concomitant medication was defined as use at the index date. We evaluated 
the effect of social economic status (SES), by including a variable on health care insurance, 
which is a proxy for income (all below an income of about 25.000 dollars a year have sick 
fund insurance, and those above have a private insurance). 
Statistical analysis 
The relative risk for sudden cardiac death during the use of non-cardiac QTc prolonging 
drugs was estimated by calculation of the odds ratios (95% confidence interval) using 
conditional logistic regression analyses. We evaluated risk factors and confounders one 
by one, by including one factor with the exposure variable. Subsequently, we performed a 
bivariate evaluation for potential multicollinearity of confounders. Thereafter, co-variates 
that were univariately associated with sudden cardiac death (at a P<0.1level) were included 
in the regression analyses. Mter doing this for each factor separately we retained a list of 
all factors that changed the point estimate of the association between non-cardiac QTc 
prolonging drugs and sudden cardiac death by more than 5%, which were included in 
the final model. 15 We investigated potential effect modification by age and gender and 
performed sub-analyses to evaluate potential misclassification of sudden cardiac death by 
splitting the outcome between witnessed and unwitnessed death. To evaluate a possible 
dose-effect relation, a trend test was performed. We calculated the population attributable 
risk (PAR) percentage.16 
RESULTS 
In the source population, 806 cases of sudden cardiac death were identified, representing an 
incidence rate of sudden cardiac death of almost 1 per 1000 person-years. As we adhered 
strictly to the matching criteria to ensure internal validity, the 31 cases (4%) for whom no 
controls could be found, were excluded from further analyses . Hence, the study population 
comprised 775 cases of sudden cardiac death and 6297 matched controls (approximate case: 
control ratio 1:8).1he median age of the study population was 72 years and approximately 
61% were male. Despite matching for age (year ofbirth), the median age of cases was higher 
than the median age of all controls (7 4 years and 72 years respectively) since more controls 
were available for younger cases than for elderly cases (TABLE 1).1here were 437 witnessed 
(56.4%) and 338 unwitnessed (43.6%) cases of sudden cardiac death. All known potential 
risk factors were associated with an increased risk for sudden cardiac death, notably 
ischemic cerebro-vascular and cardiovascular disease, hypertension, arrhythmia, diabetes 
mellitus, heart failure, hypercholesterolemia, smoking and alcohol abuse. As expected, use of 
cardiovascular medication was associated with sudden cardiac death as well ( TABLE 1) .There 
was no association between socio economic status and sudden cardiac death. 
Current use of non-cardiac QJc prolonging drugs was associated with an almost threefold 
increased risk of sudden cardiac death ( TABLE 2). Past use of non-cardiac QJc prolonging 
drugs was not associated with an increased risk of sudden cardiac death. The risk was higher 
among recent starters ($ 90 days) of non-cardiac QTc prolonging drugs (TABLE 2).1he risk was 
significantly increased in users of gastro intestinal medication and antipsychotics.The risk of 
sudden cardiac death was not significantly increased in antibiotic users, probably due to the 
limited number of exposed cases. Antibiotics were only U:sed for less than 90 days and only 
in a dosage of 1 DDD equivalent or more.Therefore, we could not assess duration and dose 
response relationships (TABLE 2).1he risk of sudden cardiac death was increased to a larger 
extent in users of a higher daily dose of gastro-intestinal or of antipsychotic medication. 
The risk was highest in subjects using antipsychotics, predominantly haloperidol. In users 
of gastrointestinal medication the risk of sudden cardiac death was significantly increased 
in users of domperidone in contrast to cisapride users, although a threefold higher risk of 
sudden cardiac death in cisapride users could not be excluded (TABLE 2). 
For witnessed cases of death, the association with current use of non-cardiac QTc 
prolonging drugs was higher (OR 2.9; 95% CI: 1.5-5.9) than for unwitnessed cases (OR: 
2.3; 95% CI: 1.0-5 .4), but this difference was not statistically significant. Stratified analyses 
showed that the risk of sudden cardiac death in users of non-cardiac QTc prolonging 
medications tended to be higher in women (OR 3.1; 95% CI: 1.5-6.4) than in men (OR 
2.3; 95% CI: 1.0-5.1) and higher in patients older than 65 years (OR 2.7; 95% CI: 1.5-
4.9) than in patients 65 years or younger (OR2.3; 95% CI: 0.6-8.1), but none of these 
differences were statistically significant. The incidence of sudden cardiac death in our 
population was almost 1 per 1000 person years.17 Based on the findings in this study the 
population attributable risk percentage of non-cardiac QJc prolonging medication could 
be calculated as 2%.16 
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TABLE 1 : DEMOGRAPHICS, DISTRIBUTION OF CO-VARIATES AND USE OF CONCOMITANT 
MEDICATION IN CASES AND CONTROLS 
Characteristic Cases Controls Odds ratio' 
(n=ml (n=6297) (95% CI) 
Gender 
Male 465 (60%) 3842 (61%) 
Female 310 (40%) 2455 (39%) 
Age (mean, SD) 71 YR,l3 69 YR,l3 
~ssyr 95 (12.3%) 1032 (16.4%) 
s6-6syr 108 (13.9%) 1127 (17.9%) 
66-7syr 224 (28.9%) 2014 (32.0%) 
> 75YI 348 (44.9%) 2124(33.7%) 
Sudden cardiac death 
Witnessed 437 (56.4%) 
Unwitnessed 338 (43.6%) 
Co-morbidities 
Ischaemic Cerebro-/Cardiovascular Disease 246 (32%) 1022 (16%) 2.3 (1.9 -2.7) 
Hypertension 444(57%) 3134 (SO%) 1.3 (1.1-1.5) 
Arrhythmia 151(19%) 670 (11%) 1.9 (1.6-2.4) 
Diabetes mellitus 230 (30%) 1058 (17%) 2.0 (1.7-2.4) 
Smoking 98 (12.6%) 495 (8%) 2.2 (1.7-2.9) 
Alcohol abuse 87 (11%) 536 (8%) 1.7 (1.3 -2.3) 
Heart failure 219 (28%) 468 (7%) 4.8 (3.9-5.8) 
Hypercholesterolemia 47(6.1%) 266 (4.2%) 1.7 (1.2-2.4) 
Concomitant cardiovascular drugs 
!?.-blocking agents 113 (14.6%) 727 (11.5%) 1.3 (1.0-1.6) 
Diuretics 190 (24.5%) 677 (10.8%) 2.5 (2.0-3.1) 
Calcium channel-blockers 81 (10.5%) 446(7.1%) 1.5 (1.1-1. 9) 
ACE-inhibitors 146 (18.8%) 590 ( 9.4%) 2.2 (1.8-2.8) 
AT!l-blocking agents 27 ( 3.5%) 108 ( 1.7%) 2.1 (1.4-3.3) 
lipid lowering agents 45 ( 5.8%) 348 ( 5.5%) 1.2 (0.9-1.7) 
Cardiac glycosides 74( 9.5%) 168 ( 2.7%) 3.3 (2.4-4.5) 
Anti-arrhythmics 11 ( 1.4%) 47(0.7%) 1.8 (0.9-3.6) 
Abbreviations: ACE= angiotensin converting enzyme; C a=Calcium; ATII= angiotensin II receptor antagonist; Cl= confidence 
interval, SD= standard deviation 
. All odds ratios are calculated taking matching for age, gender, practice and calendar time into consideration 
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TABLE 2 : RISK OF SUDDEN CARDIAC DEATH AND THE USE OF NON-CARDIAC QTc 
PROLONGING MEDICATION 
----
Use of non-cardiac OTc Cases Controls OR' OR" 
prolonging medication (n=775) (n=6297) (95% CI) (95% CI) 
Overall 
Nonuse 653 5544 1.0 (reference) 1.0(reference) 
Past use 98 696 1.2 (0.9-1.5) 0.9 (0.7-1.2} 
Current use 24 57 3.4 (2.0-5.6) 2.7 (1.6-4.7) 
Current use of different QTc 
prolonging medications 
Gastrointestinal drugs 1 13 43 2.7 (1.4-5.0) 2.1 (1.1-4.2) 
Cisapride 4 29 1.2 (0.4-3.5) 1.2 (0.4-3.3) 
Domperidone 9 15 5.4 (2.2-12.7) 3.8 (1.5-9.7) 
Antipsychotic drugs 7 9 5.1 (1.8-14.4) 5.0 (1.6-15.3) 
Chlorpromazine 1 
Haloperidol 6 8 4.7 (1.5-14.4) 5.6 (1.6-18 .7) 
Pimozide 
Antibiotic drugs 4 5.4 (1.4-22.1) 3.7 (0.9-15.7) 
Erythromycin 1 
Clarithrornycin 3 3.7 (0.8 -17.0} 3.2 (0.7-15.0) 
Duration of u se in current users 
Non use 653 5544 1.0 (reference) l.O(reference) 
.s. go days 17 28 4.5 (2.4 -8.6) 3.6 (1.9-7.2) 
>go days 7 29 2.1 (0.9-7.2) 1.7 (.07-4.2) 
DDD 
Gastrointestinal drugs 13 43 
oDDD 12 2.2 (0.6-8.0) 2.0 (0.5-7.4) 
>lDDD 10 31 2.7 (1.3-5.8) 2.2 (1.0-4.8) 
Antipsychotic drugs 7 9 
oDDD 5 8 5.0 (1.5-17.0) 4.8 (1.4-16.1) 
>1DDD 2 2 6 .1 (0.3-124) 6.4 (0.3-129.1) 
Antibiotic drugs 4 
<lDDD 
~1DDD 4 5.6 (1.4-22.5) 3.8 (0.9-16 O) 
Abbreviations: OR=Odds Ratio; CI=Confidence Interval; DDD=Defined Daily Dose equivalent; Ref= reference 
• Odds ratios matched for age, gender, practice and calendar time 
" Odds ratio matched for age, gender, practice and calendar time, adjusted for diabetes mellitus, arrhythmias, heart failure; hyperten-
sion, smoking, alcohol abuse and cerebrovascular and cardiovascular ischaemia, current use of diuretics and cardiac glycosides. 
1 Since one patient used domperidone and cisapride concomitantly, numbers do not add up 
2 Test for trend P<O.OOS 
go 
DISCUSSION 
The results of our study indicate that current use of non-cardiac QJc prolonging drugs in a 
general population is associated with a significantly increased risk of sudden cardiac death. 
After adjustment for known confounding factors, current use of non-cardiac QTc 
prolonging drugs was associated with an almost threefold increased risk of sudden cardiac 
death.The risk was higher in women than in men. This is in line with earlier findings that 
women seem to be more susceptible to drug induced cardiac arrhythmias than men. 7 18 
Drug induced Torsade de Pointes are a significant cause of morbidity and mortality and 
non-cardiac drugs have been implicated in an increasing number of cases. 7 19-21 Prolongation 
of the QJc interval, ventricular arrhythmias and Torsade de Pointes have been associated 
with cisapride use in anecdotal reports. These case reports raised concern, but could not be 
confirmed in cohort- and case control analyses in the UK and Canada and in some studies 
no substantial increase in the QTc interval could be identified.7 Our results are in line with 
these findings. 22 1his is not surprising, since life-threatening arrhythmias during cisapride 
use in adults are believed to occur predominantly when there is concurrent use of inhibitors 
of cytochrome P450 CYP3A4, such as itraconazole, ketoconazole or macrolides.This was not 
the case in our population. Domperidone seemed an attractive, safer alternative to cisapride. 
Our findings of a significantly increased risk of sudden cardiac death in domperidone users, 
however, suggest that domperidone should not be viewed as a low risk alternative to cisapride 
and are in line with earlier results.23 Unfortunately the number of exposed cases in our study 
prohibited us from analyzing the macrolides individually. At a FDA advisory committee 
meeting the relative reporting rate ofTorsade de Pointes was increased in clarithromycin 
users and the risk was highest shortly after initiating therapy, as was also the case in our 
data.24 Case reports have since long suggested that erythromycin is associated with an 
increased risk ofTorsades the Pointes and recent research has shown a twofold increase in the 
rate of sudden cardiac death in current erythromycin users.25 Since the early sixties, sudden 
cardiac death has been reported with antipsychotic use in case reports and epidemiological 
studies.26-28 Also in our study the use of antipsychotics, particularly haloperidol is associated 
with a significant increase in the risk of sudden cardiac death. 
Many drugs can prolong the QTc interval.19 21 29 30 QJ prolongation however, is a surrogate 
marker with an imperfect predictive value for fatal cardiac arrhythmias and sudden cardiac 
death and it is difficult to predict whether a drug will cause Torsade de Pointes.21 For the 
vast majority of drugs known to induce QTc prolongation, it has been demonstrated that the 
slowing of the action potential is a consequence of the blockage of the rapid component of 
the delayed rectifier potassium channel (11) through blockade of the human ether a go-go 
related gene (HERG).21 31-33 1he extent to which blocking of this channel results in Torsade 
de Pointes or sudden cardiac death, however, is highly variable among subjects. 7 20 22 34-36 
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A unifYing concept "reduced repolarization reserve" has been used to explain this variable 
risk.36 Current evidence also suggests that 5 to 10% of persons in whom cardiac arrhythmias 
occur carry a (silent) mutation in one of the genes responsible for the congenital long QT 
syndrome.37 38 
In our population, we were able to take advantage of the fact that in the Dutch health 
care system all medical information (including specialist and hospital care) is collected at 
practices that cover the general population instead of selected socio-economic groups. As a 
consequence, there was extensive information available on drug use, potential confounders 
and all the circumstances surrounding death. Nevertheless, our study has some potential 
limitations. First, we cannot exclude that some misclassification of outcome occurred. We may 
have missed some deaths although this will be minimal, since death is consistently registered 
by general practitioners. Second, not all acute deaths may have been of cardiac origin. We 
determined sudden cardiac death, however, on the basis of the full medical records and all 
circumstances surrounding the death were available. Recently, an evaluation comparing 
different methods to determine the incidence of sudden cardiac death, suggested that this 
method provides a very reliable way of determining sudden cardiac death cases.3 In addition, 
we could reduce misclassification by differentiating between witnessed and unwitnessed 
cases of sudden cardiac death. The percentage of unwitnessed deaths in our population was 
43.6% which is in line with earlier findings.3 39 The risk of witnessed sudden cardiac death 
associated with the use of non-cardiac QTc prolonging drugs was higher than the risk of 
unwitnessed sudden cardiac death. This may be consistent with the fact that misclassification 
will occur more often in unwitnessed cases. In addition, slight misclassification of exposure 
may have occurred since we used outpatient prescription data and we had no information 
as to whether the prescription was actually filled and taken. It is likely however, that such 
exposure misclassification will be random and will be evenly distributed among cases and 
controls. Although we adjusted for all known confounders residual confounding may exist, 
but is unlikely to explain the strong association we have observed. 
In conclusion, our findings suggest that the current use of non-cardiac QTc prolonging 
drugs in a general population is associated with an increased risk of sudden cardiac death. 
Although prolongation of the QJc interval by non-cardiac drugs is not an unusual finding, 
potentially fatal arrhythmias and sudden cardiac death are relatively uncommon. Our results 
suggest that 320 cases of sudden cardiac death can be attributed to the use of non-cardiac 
QTc prolonging medication in the Netherlands on a yearly basis.16 17 This is important, 
because regulatory authorities have to evaluate the clinical significance of QTc prolongation 
observed in relatively small clinical trials without cases of sudden cardiac death. 
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CHAPTER 7 
INHALED fS-AGONISTS AND THE RISK 
OF SUDDEN CARDIAC DEATH 
ABSTRACT 
Background: Several studies have evaluated the association between use of inhaled B-2 
adrenergic receptor agonists and sudden cardiac death, but with contradictory results. 
Therefore we set out to assess the association between use of inhaled B-agonists and the risk 
of sudden cardiac death in a general population and in patients with Chronic Obstructive 
Pulmonary Disease. 
Methods and results: A population-based case-control study in the Integrated Primary 
Care Information (IPCI) project, a longitudinal medical record database and a nested 
case cross-over study to further analyze current use of B-agonists and the risk of sudden 
cardiac death in patients with COPD were performed. All deaths betweenJanua:ry 1,1995 
and September 1, 2003 were reviewed. Sudden cardiac death was classified based on time 
between onset of cardiovascular symptoms and death. To each case, up to 10 controls were 
matched. The exposure of primary interest was use of inhaled B-agonists.The relative risk of 
sudden cardiac death was estimated by calculation of odds ratios (95% confidence interval) 
using conditional logistic regression analyses. The study population comprised 775 cases 
and 6297 matched controls. In the case-control study in the general population as well as in 
the case-crossover analysis restricted to CO PD patients, current use of inhaled B-agonists 
was associated with a significantly increased risk of sudden cardiac death (OR: 1.5; 95% 
CI: 1.1-2.1 and OR: 4.8; 95% CI: 1.5-15.1 respectively). 
Conclusion: Inhaled B-agonists may increase the risk of sudden cardiac death although a 
causative role of CO PD itself cannot be excluded 
INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem and 
one of the leading causes of morbidity and mortality. 1 2 Bronchodilation therapy is central 
to the symptomatic management ofCOPD.2 
Due to their effects on the sympathetic nerve system, bronchodilators are known to have 
a variety of cardiac adverse effects. Evidence that bronchodilator therapy may increase 
cardiovascular morbidity and mortality has been accumulating over the years, especially 
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for inhaled J3,-agonists.4-10 A recent meta-analysis of randomized placebo-controlled trials 
showed an increased risk for adverse cardiovascular events in patients with obstructive 
airway disease using B-agonistsY 
Inhaled B-2 adrenergic receptor agonists (B-agonists) increase heart rate, prolong the 
duration of the action potential, and may cause hypokalemia, compared to placebo. These 
factors may all increase the risk of cardiovascular adverse events, including sudden cardiac 
death. 11 Several case-control studies have evaluated the association between inhaled 
B-agonists and cardiac arrest or sudden cardiac death, but not all found a significant increase 
in risk in patients with COPD.4 59 10 12 
Therefore, we assessed the association between use of bronchodilators, specifically 
B-agonists, and the risk of sudden cardiac death in a case-control analysis in a well-defined 
general population with complete coverage of all relevant health care information. In 
addition, we used a nested case-crossover design to further analyze the association between 
use of J3,-agonists and the risk of sudden cardiac death in patients with COPD. 
METHODS 
Setting 
All data were retrieved from the Integrated Primary Care Information (IPCI) project, 
a general practice research database with data from computer-based patient records 
from a group of 150 general practitioners (GPs) in the Netherlands. In the Dutch health 
care system, the GP has a pivotal role by acting as a gatekeeper for all medical careY 
Details of the database have been described elsewhere.14 15 Briefly, the database contains 
the complete medical records on approximately 500,000 patients. The electronic records 
contain coded and anonymous data on patient demographics, symptoms (in free text), 
diagnoses (using the International Classification for Primary Care16 and free text) from 
GPs and specialists, referrals, laboratory findings, hospitalizations, and drug prescriptions, 
including their indications and dosage regimen. To maximize completeness of the data, 
general practitioners participating in the IPCI project are not allowed to maintain a system 
of paper-based records besides the electronic medical records. The system complies with 
European Union guidelines on the use of medical data for medical research and has been 
proven valid for pharmaco-epidemiological research in several validation studies that 
evaluated the quality of the available information.14 15 1he Scientific and Ethical Advisory 
Board of the IPCI project approved this study. 
Source population 
The source population comprised all subjects of 18 years and older, who were registered 
with a general practitioner participating in the IPCI project for at least 1 year. Subjects with 
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a diagnosis of cancer were excluded from the source population, since in these patients the 
cause of death is often difficult to assess.The study period started January 1, 1995 and ended 
September 1, 2003. All subjects were followed until death, transferral out of practice, date 
oflast data collection or end of study period, whichever came first. 
Case and control definition 
The computerized medical and demographic data were screened for all deaths that 
occurred during the study period. The full medical records of identified cases of death were 
reviewed manually to assess whether death could be classified as sudden cardiac death. 
Validation was performed independently by two physicians blinded to exposure (SMJMS, 
GSB) and in case of discrepancy, a third expert (BHChS) arbitrated. Assessment was 
based on the most recent definition of sudden cardiac death16 17: sudden unexpected 
death within 1 hour of symptom onset (witnessed) or within 24 hours of having been 
observed alive and symptom free (unwitnessed). All patients with an identifiable non-
cardiac cause and all patients with cancer were excluded. Cases of sudden cardiac arrest 
associated with trauma, violent death, drowning, overdose and suicide were also excluded. 
For each case of sudden cardiac death, up to ten controls were randomly drawn from the 
source population matched on age (year of birth), gender, and practice. The index date 
was defined as the date on which sudden cardiac death occurred in cases. This date was 
also the index date for matched controls. 
To limit confounding by indication we conducted a nested case-crossover analysis 
restricted to patients with COPD. In this analysis, each case of sudden cardiac death 
served four times as its own control period with index dates 3, 6, 9 and 12 months 
preceding death. In the case-crossover design the occurrence of an acute event (in this 
study sudden cardiac death) following a transient exposure is compared with exposure in 
the same person prior to disease onset. This design eliminates many, although not all, of 
the confounding factors . 19-23 
Exposure definition 
To classifY exposure to each type ofbronchodilator (inhaled or oral £?,-agonists, anticholinergics 
and xanthines) at the index date, we calculated the duration of use for each prescription as 
the total number of units per prescription divided by the prescribed daily number of these 
units. Exposure at the index date was subsequently categorized into three mutually exclusive 
groups of current, past and non-use. Use ofbronchodilator medication was defined as current 
if the prescription duration covered the index date or if it stopped less than 30 days before (to 
account for carry-over effects). Past use was defined as discontinuation of the bronchodilator 
more than 30 days before the index date. If patients had no prescription during the study 
period prior to the index date they were considered non-exposed. 
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Among current users of inhaled i!,-agonists, we evaluated the effect of duration of use in two 
groups (:$ 90 days: short term users; > 90 days: long term users), the type (long acting or short 
acting inhaled i!,-agonists), and the effect of concomitant use of inhaled corticosteroids. 
In the nested case-crossover design, exposure was determined in the three months-
periods preceding the index date. Exposure status at the index date was also categorized 
into three mutually exclusive groups of current, past and non-use. Use of bronchodilator 
medication was defined as current if the prescription duration covered the index date or if 
it stopped less than 30 days before (to account for carry-over effects) . Past use was defined 
as discontinuation of the bronchodilator between 90 and 30 days before the index date. If 
patients had no prescription for the specific class ofbronchodilator medication in the three 
months prior to the index date they were considered non-exposed. 
Co-variates and risk factors 
Risk factors for sudden cardiac death and co-variates were gathered from the medical records 
through computerized searches and manual validation. Co-variates evaluated included: 
cerebra- and cardiovascular ischemia (history of myocardial infarction, stroke, and angina 
pectoris), heart failure, hypertension, diabetes mellitus, arrhythmia, hypercholesterolemia, 
smoking and alcohol abuse. COPD, ischemia and heart failure were assessed, based on the 
diagnoses provided by the general practitioner and specialists in the medical records. 
Hypertension was identified through the diagnoses in the medical records, the use of 
antihypertensive medication and/or the assessment of blood pressure measurements, 
according to the guidelines of the World Health Organization (blood pressure exceeding 
140 mm Hg systolic and/or 90 mm Hg diastolic).24 Diabetes mellitus, arrhythmias and 
hypercholesterolemia -vvere identified through diagnoses in the medical records from GPs 
and specialists and/or the use of antidiabetic, anti-arrhythmic or lipid lowering medication. 
Information on smoking and alcohol abuse was obtained from the medical records. 
As concomitant medication we considered antibiotics, inhaled and oral corticosteroids, 
mucolytics, hypnotics, anxiolytics, antipsychotics, non-cardiac QTc prolonging drugs and 
cardiovascular medication. Current use of these drugs was defined as use at the index 
date, except for inhaled steroids and mucolytics for which we applied the same exposure 
classification as for bronchodilators. 
In the case-crossover study, which by design adjusts for stable intra-individual 
confounders we assessed time-varying co-morbidity, concomitant drug use and severity 
ofCOPD in each 3 month period before the index date. Severity ofCOPD was assessed 
based on the use of antibiotics for respiratory tract infections, the use of oral steroids 
for COPD, the occurrence of exacerbations, the use of oxygen, and hospitalizations for 
respiratory tract disease. Patients with use of oxygen, oral steroid for COPD, occurrence 
of exacerbation or hospitalization were defined as more severely diseased patients. 25 
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The severity was assessed at each index date and could vary over time. 
Statistical analysis 
The relative risk of sudden cardiac death associated with each class of bronchodilator 
medication was estimated by calculation of the odds ratios (95% confidence interval) using 
conditional logistic regression analyses. Co-variates univariately associated with sudden cardiac 
death (at a p < 0.1level) were initially included in the regression analyses. Factors that changed 
the point estimate of the association between current use of inhaled B-agonists and sudden 
cardiac death by more than 10%25 were kept in the final model (heart failure and smoking). 
We investigated potential effect modification by age and gender with interaction terms, and 
performed sub-analyses in patients using beta-blockers and patients with a cardiovascular 
history. In the case-crossover study, the relative risk of sudden cardiac death associated with 
the use of inhaled B-agonists was estimated by calculation of the odds ratios (95% confidence 
interval) using conditional logistic regression analyses. Also in this analysis, co-variates that 
changed the point estimate of the association between current use of inhaled B-agonists and 
sudden cardiac death by more than 10% were kept in the final model (use of anticholinergics, 
season of the sudden cardiac death, use of inhaled steroids, and use of antibiotic medication 
for respiratory tract infections) . Each case served as its own control period in 4 periods of3 
months preceding the occurrence of sudden cardiac death. As in this analysis each case could 
differ up to one year in age with the control period we did an additional analysis to explore 
the effect of residual confounding by age. A sub-analysis was conducted in which the control 
periods were restricted to those with an index date 3 months prior to the date of death. In this 
way each case had one control period with an age difference of3 months. 
RESULTS 
In the source population 806 cases of sudden cardiac death were identified, yielding an 
incidence rate of sudden cardiac death of almost 1 per 1000 persons per year.27 No controls 
could be matched to 31 cases, and these cases were excluded from further analyses. Hence, 
the study population comprised 775 cases of sudden cardiac death and 6297 matched 
controls (approximate case:control ratio 1:8). The median age of the study population 
was 72 years and approximately 60% was male. There were 437 witnessed (56.4%) 
and 338 unwitnessed (43.6%) cases of sudden cardiac death. All known potential risk 
factors for sudden cardiac death were associated with an increased risk, notably ischemic 
cerebro-vascular and cardiovascular disease, hypertension, arrhythmia, diabetes mellitus, 
heart failure, hypercholesterolemia, COPD, smoking and alcohol abuse. Current use 
of antipsychotics, non-cardiac QTc prolonging medication, as well as cardiovascular 
medication was associated with sudden cardiac death ( rABLE 1). 28 29 
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TABLE 1 : DEMOGRAPHICS, DIST RIBUTION OF CO-VARIATES AND US E OF CONCOMITANT 
MEDICATION I N CASES AND CONT ROLS 
Characteristic Cases (n=775l Controls (n=6297) Odds ratio ' (95% CI) 
Gender 
Male 465 (60%) 3842 (61%) 
Female 310 (40%) 2455 (39%) 
Age (median) 74YR 71YR 
~55 yr 95 (12.3%) 1032 (16.4%) 
55-65 yr 108 (13.9%) 1127 (17.9%) 
66-75 yr 224 (28.9%) 2014 (32.0%) 
> 75YI 348 (44.9%) 2124(33.7%) 
Su dden cardiac death 
Witnessed 437 (56.4%) 
Unwitnessed 338 (43.6%) 
Co-morbidities and other cofactors 
Ischaernic Cerebro-/Cardiovascular Disease 246 (32%) 1022 (16%) 2.3 (1.9-2.7) 
Hypertension 444 (57%) 3134 (SO%) 1.3 (1.1-1.5) 
Arrhythmia 151 ( 19%) 670 (11%) 1.9 (1.6-2.4) 
Diabetes mellitus 230 ( 30%) 1058 (17%) 2.0 (1.7-2.4) 
Heart failure 219 ( 28%) 468 (7%) 4.8 (3.9-5.8) 
Hypercholesterolemia 47(6.1%) 266 (4.2%) 1.7 (1.2-2.4) 
COPD 65 (8 .4%) 387 (6.1%) 1.3 (10-1.8) 
Alcohol abuse 87 (11%) 536 (8%) 1.7 (1.3-2.3) 
Smoking 98(12.6%) 495 (8%) 2.2 (1.7-2.9) 
Concomitant drugs 
B-blocking agents 113 (14.6%) 727 (11.5%) 1.3 (1.0-1.6) 
Diuretics 190 (24.5%) 677 (10.8%) 2.5 (2.0-3.1) 
Ca-blocldng agents 81 (10.5%) 446 (7.1%) 1.5 (1.1-1.9) 
ACE-Inhibitors 146 (18.8%) 590 (9.4%) 2.2 (1.8-2.8) 
ATII-blocklng agents 27 ( 3.5%) 108 (1.7%) 2.1(1.4-3.3) 
lipid lowering agents 45 ( 5.8%) 348 ( 5.5%) 1.2 (0.9-1.7) 
Cardiac glycosides 74 ( 9.5%) 168 ( 2.7%) 3.3 (2.4-4.5) 
Anti-arrhythmics 11 ( 1.4%) 47(0.7%) 1.8 (0.9-3.6) 
Antibiotics 12 (1.5%) 60(1%) 1.5 (0.8-7.8) 
Anti psychotics 17 (2.2%) 40(0.6%) 3.4(1.9-6.1) 
Non-cardiac QTc prolonging drugs 16 (2.1%) 47(0.7%) 2.8 (1.5-5.0) 
Inhaled Corticosteroids 49 (6.3%) 195 (3.1%) 2.1 (1.5-2.9) 
Oral corticosteroids 15 (1.9%) 70 (1.1%) 1.6 (0.9-2.9) 
Abbreviations: CI=confidence interval; COPD= Chronic Obstructive Pulmonary Disease; Ca=Calcium; ACE= angiotensin 
converting enzyme; ATII= angiotensin II receptor antagonist 
' All odds ratios are matched for age, gender, practice and calendar time 
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Current use of anticholinergics, and xanthines was also associated with an increased risk of 
acute sudden cardiac death, the strongest association was observed with xanthines (TABLE 2). 
Current use of inhaled JS-agonists was associated with a 50% increased risk of acute sudden 
cardiac death (TABLE 2) . 
TABLE 2 : RISK OF SUDDEN CARDIAC DEATH AND THE USE OF BRONCHODILATOR 
MEDICATION 
Use of bronchodilator medication' Cases Controls OR' OR'' 
(n=775) (n=6297) (95% CI) (95%CI) 
Oral or inhaled B agonists 
Current oral B agonists 4.6 (0.7-30.5) 2.6 (0.3-23.5) 
Past oralE agonists 17 0.5 (0.07-4.0) 0.3 (0.03-2.2) 
Current inhaled B agonists 63 234 2.3 (1.7-3.1) 1.5 (1.1-2.1) 
Long-acting' 23 92 2.1 (1.3- 3.4) 1.6 (1.0-2.6) 
Short-acting' 46 160 2.3 (1.6-3.3) 1.5 (1.0-2.2) 
5_90 days 35 107 2.6 (1.7-3.9) 1.7 (1.1-2.6) 
> 90 days 28 127 2.0 (1.3-3.1) 1.4 (0.9-2.2) 
With inhaled corticosteroids 38 149 0.8 (0.6-1.0) 1.0 (0.8-1.4) 
without inhaled corticosteroids 25 85 1.7 (1.0-2.7) 1.6 (1.0-2.6) 
Past inhaled B agonists 55 381 1.3 (1.0-1.8) 1.0 (0.7-1.3 
Long-acting 23 105 1.9 (1.2-3.0) 1.2 (0.7-2.0) 
Short-acting 57 376 1.4(1.0-1.9) 1.0 (0.8-1.4) 
Other bronchodilators 
Anticholinergics 
Current 42 137 2.5 (1.7-3.6) 1.7 (l.l-2.5) 
Past 45 224 1.6 (1.1-2.3) 1.1 (0.8-1.6) 
Xanthines 
Current 9 17 4.6 (1.9-11.0) 3.3 (1.3-8.4) 
Past 10 17 5.4 (2.4-12.1) 4.2 (1.8-9.9) 
' All odds ratios are matched for age, gender, practice and calendar time 
" All odds ratio matched for age, gender, practice and calendar time, adjusred for heart failure and smoklng. Reference 
category: non-use 
' Since some patienrs used > 1 bronchodilator, numbers do not add up. Jl-agonists include: salbutamol, terbutaline, fen otero!, 
salmeterol, formoterol. Long acting inhaled Jl-agonists salmeterol, formoterol. Short acting inhaled Jl-agonists salbutamol, 
terbutaline, fenoterol. Inhaled corticosteroids include: beclomethasone, budesonide, flunisolide, betamethasone, fluticasone. 
Anticholinergics: ipratropium. Xanthines: theophylline 
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TABLE 3 : ASSOCIATION BETWEEN USE OF INHALED B-AGONISTS AND SUDDEN CARDIAC 
DEATHS IN COPD PATIENTS (CASE- CROSSOVER ANALYSIS) 
Use of inhaled :B- agonists' Cases Controls OR* OR** 
(n=6s} (n=26o} (95% CI} (95%CI} 
Overall 
Inhaled :B agonists 
Non-use 38 186 l.O(reference} 1.0 (reference} 
Past use 21 2.4 (0.7-8.4} 1.6 (0.4-6.0} 
Cunentuse 22 53 5.6 (2.0-15.6} 4.8 (1.5-15.1} 
long-acting 8 28 1.6 (0.6-6.7} 1.4 (0.3 -6.8} 
Short -acting 14 31 3.3 (1.3-8.6} 2.6 (0 9-7.7} 
withiCS 9 24 8.1 (1.4-47.9} 7.3 (1.2-46.0} I 
without!CS 13 29 5.0 (1.6-15.1} 3.6 (1.1-12.3) 1 
Anticholinergics 17 48 1.9 (0.9-4.3} 1.8 (0.8-4.1} 
Xanthines 4 9 5.8 (0.5-65.6} 7.8 (0.6-00.6} 
Oral B agonists 0 
Restriction of controls 3 months before 
Inhaled :B-agonists 
Non-use 38 44 1.0 (reference} 1.0 (reference) 
Past use 1.5 (0.3-7.0) 1.5 (0.2-9.8) 
Current use 22 14 6.0 (1.1-2.7) 8.8 (1.1-71.4) 
* Odds ratios matched for age, gender, practice and calendar time 
Odds ratio matched for age, gender, practice and calendar time, adjusted for the use of anticholinergics (for the inhaled 
11-agonists only), inhaled corticosteroids, severity of disease, season and the use of antibiotics for airway infections 
I Odds ratio matched for age, gender, practice and calendar time, adjusted for the use of anticholinergics, severity of clisease, 
season and the use of antibiotics for airway infections 
1 Since some patients used > 1 bronchodilator, numbers do not add up 
Inhaled 11-agonists include: salbutamol, terbutalinc, fenoterol, salmeterol, formoterol. 
Long acting inhaled 11-agonists salmeterol, formoterol 
Short acting inhaled 11-agonists salbutamol, terbutalinc, fenoterol 
Inhaled corticosteroids include: beclomethasone, budesonide, flunisolidc, betamcthasone, fluticasonc 
Anticholinergics: ipratropium 
Xantb..ines: theophylline 
Mucolytics : acetylcysteine 
The risk was higher in short-term users of 1?,-agonists (recently started): OR: 1. 7 (95o/o CI: 
1.1-2.6) than in longer-term users: OR: 1.4 (95o/o CI: 0.9-2.2).1he risk was also slightly 
higher during current use of short-acting inhaled 1?,-agonists than in during use of long 
acting inhaled 1?,-agonists. However, the risk of sudden cardiac death was elevated only in 
patients using inhaled 1?,-agonists but without inhaled corticosteroids. In order to further 
evaluate our findings we analyzed the risk of sudden cardiac death in patients without the 
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diagnosis ofCOPD.The risk in those without the diagnosis ofCOPD was also significantly 
increased: OR: 1.7 (95% CI: 1.1-2.7) . 
Stratified analyses showed differences in B-agonists associated risks however, none of the 
tests for effect-modification were significant. The relative risk associated with current use 
of inhaled B-agonists was 1.7 (95% CI: 1.2-2.4) in subjects older than 65 and 1.0 (95% CI: 
0.5-2.2) in those 65 years and younger. It was also slightly higher in women (OR: 2.0; 95% 
CI: 1.2-3.5) than in men (OR: 1.3; 95% CI: 0.9-2.0). For witnessed cases, the risk of sudden 
cardiac death was somewhat higher in patients using inhaled B-agonists (OR: 1.6; 95% CI: 
1.0-2.4), than for unwitnessed cases (OR: 1.5; 95% CI: 0.9-2.5) .1he antagonistic effect 
of B-blockers may neutralise the effects of inhaled B-agonists. Indeed in patients using 
B-blockers the risk associated with inhaled B-agonists was lower: OR: 0.4 (95% CI: 0.04-
4.0) than in patients not using B blockers OR: 1.6 (95% CI: 0.9-2.6) . In patients with 
a cardiovascular disease history, current use of inhaled B-agonists was associated with a 
significant increase in the risk of sudden cardiac death: OR: 1.8 (95% CI: 1.1-3.1). 
In the case-crossover analysis that was restricted to acute sudden death cases with COPD, 
current use of inhaled B-agonists was associated with a significantly increased risk of sudden 
cardiac death: OR: 4.8 (95% CI: 1.5-15.1) (TABLE3).1he risk of sudden cardiac death was 
higher in patients using inhaled B-agonists in combination with inhaled corticosteroids 
than in patients using inhaled B-agonists without inhaled corticosteroids but this difference 
was not statistically significant. The risk of sudden cardiac death associated with use of 
inhaled B-agonists remained after restriction of the controls to those with an index date 3 
months before the date of death. In the case-crossover analysis, there was also an increased 
risk with anticholinergics and xanthines but this increase was not significant. 
DISCUSSION 
The results of our study indicate that current use oflong-acting and short-acting B-agonists 
is associated with an increased risk of sudden cardiac death, both in the general population 
as well as in COPD patients. However, also xanthines and anticholinergics were associated 
with an increased risk of sudden cardiac death, but the association with anticholinergics 
was only observed in the general population. 
Nevertheless also in the Lung Health Study an unexpected, small and non significant increase 
in death from cardiovascular causes was reported in COPD patients treated regularly with 
ipatropium. 30 Xanthine derivatives have been associated with cardiac arrhythmias previously. 
Due to their toxicity their use is restricted to the most severely affected patients.The increased 
risk of sudden cardiac death we found is therefore not unexpected. 8 31 32 
Inhaled B-agonists have been associated with an increased risk of cardiovascular events 
previously.3 4 8 9 33 However, the currently available studies have yielded conflicting results. 
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In a case-control study, the use of inhaled :8.-agonists was not associated with a significantly 
increased risk of primary cardiac arrest in COPD patients, but it was in asthma patients.9 
An earlier case-control study suggested that the use of theophylline and :8.-agonists was 
associated with an increased risk of cardiac arrest in patients with heart disease.8 In a nested 
case-control study, evaluating the entire population, the risk of myocardial infarction (fatal 
and non fatal) was increased in patients using :8.-agonists, whereas another case-control 
study, restricted to patients with COPD, showed no increase in risk. 4 11 Attribution of 
mortality to COPD or to therapy is difficult, since COPD is a risk factor for sudden 
cardiac death. COPD patients are known to have an increased risk of cardiac arrhythmia. 
Several factors, such as hypoxia and hypokaliemia may contribute to the development of 
arrhythmias and sudden cardiac death.34 
As our study examined the use of :8.-agonists in the entire population, a large part of the 
population did not have obstructive lung disease. Since COPD is a known risk factor 
for sudden cardiac death, we adjusted in the analyses for this confounder. In addition we 
assessed the risk of sudden cardiac death in a nested case cross-over design, restricted to 
COPD patients. In this analysis the current use of inhaled :8.-agonists was associated with 
a more than fourfold increase in risk of sudden cardiac death. Due to the design we could 
not completely adjust for age since the patients in the control period were always younger 
(up to one year) than the cases. However, the association remained if we restricted the 
analysis to the control period in the three months before the index date. In contrast to the 
findings in the total population, the use of inhaled corticosteroids in the case-crossover 
analysis in COPD patients was associated with a higher risk of sudden cardiac death. We 
have tried to adjust for severity, but as the FEVl (Forced Expiratory Volume in one second) 
is not available in many patients we classified severity ofCOPD based on the need to seek 
medical help, which is helpful to classifY the most severely ill patients.25 Nevertheless there 
still might be residual confounding by severity. 
In our population, we were able to take advantage of the fact that in the Dutch health 
care system all medical information (including specialist and hospital care) is collected at 
practices that cover the general population instead of selected socio-economic groups. As a 
consequence, there was extensive information available on drug use, potential confounders 
and the circumstances surrounding death. Nevertheless, also our study has limitations. First, 
we cannot exclude that some misclassification of outcome occurred. We may have missed 
some deaths although this will be minimal, since general practitioners have pivotal role in the 
Dutch health care system and they register death consistently. Second, not all acute deaths 
may have been of cardiac origin, especially in patients with COPD. Primary ventilatory death 
is, however, usually not unexpected and mostly not sudden. 35 Moreover, the complete medical 
records of all patients are available and we had information concerning all circumstances 
surrounding death, including the full medical history. Recently, an evaluation comparing 
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different methods to determine the incidence of sudden cardiac death, suggested this method 
provides probably the most reliable way of determining sudden cardiac death.18 We could 
in addition reduce misclassification by differentiating between witnessed and unwitnessed 
cases. The percentage of unwitnessed deaths in our population was 43.6% which is in line 
with earlier findings.36 1he risk associated with use of inhaled ~-agonists was significantly 
increased in witnessed sudden cardiac death, while it was lower for unwitnessed deaths.This 
is consistent with the fact that misclassification will occur more often in unwitnessed cases. 
In the latter group, some deaths might have been primarily of ventilatory origin instead of 
cardiac origin. Third, in COPD the effects of drugs studied are susceptible to confounding 
by disease severity (confounding by indication). Severity of disease and presence of co-
morbidities may play an important role in therapy choice. We tried to reduce confounding 
by indication by conducting a case cross-over study, where each case acts as its own control, 
thereby minimizing the confounding by severity and co-morbidities.19 21 However, residual 
confounding by intra-individual time-varying factors cannot be excluded. In addition, 
misclassification of exposure may have occurred since we used outpatient prescription data 
and had no information as to whether the prescription was filled and was actually taken. 
However, as COPD is a disease that requires significant assistance with bronchodilation, we 
can expect that most were taken.11 In addition, it is likely that such exposure rnisclassification 
will be random and will be evenly distributed among cases and controls. As in earlier research, 
also in our study protopathic bias might have occurred, meaning the prescription of a ~­
agonist has been driven by the symptoms that may herald serious cardiovascular problems. 3 4 
To address this bias we performed additional analysis after the exclusion of all patients who 
received the first prescription for a short acting ~-agonist within 3 days before the index date. 
This did, however, not change the findings substantially, ( 0 R adjusted for inhaled ~-agonists: 
1.5; 95% CI:l.1-2.1) in the case control study nor in the case cross over study( OR adjusted: 
4.0; 95% CI: 1.3-13.1). Protopathic bias alone can therefore not the explain our findings. 
Inhaled ~-agonists have been the mainstay of therapy for asthma and COPD since 
the 1960s, with significant improvement in peak flow and respiratory symptoms.1 10 37 
Evidence that their use is associated with an increase in morbidity and mortality has been 
accumulating over past decades. Many elderly patients with underlying cardiovascular 
diseases have concomitant COPD and many patients with COPD have underlying 
cardiovascular disease. At the end stage of the disease it is often difficult to discriminate 
between these two diseases and confounding can easily occur. In our study we have tried 
to address this issue by several different methods. The results of our study suggest that 
inhaled ~-agonists may increase the risk of sudden cardiac death although a causative role 
ofCOPD itself cannot be excluded. 
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CHAPTER 8 
DISCUSSION 
Sudden cardiac death is a major health problem. Many causes of sudden cardiac death are 
known, yet seldom is one single cause sufficient to provoke a life-threatening arrhythmia. 
Sudden cardiac death is a multifactorial process and probably represents a probabilistic 
event in which each of the risk factors comprises only a small fraction of the process. In 
this chapter, the main findings of this research and the main methodological limitations of 
pharmaco-epidemiological studies are discussed to facilitate a proper interpretation of the 
results described in this thesis. 
MAIN FINDINGS 
In the first part of this thesis, we estimated the incidence of sudden cardiac death, evaluated 
the QJc interval as a non invasive predictor of sudden cardiac death and the effect of drugs 
on the length of the QTc interval. In the second part, we assessed the association between 
the use of drugs and sudden cardiac death. 
QTc interval 
Drugs 
The incidence of sudden cardiac death 
The incidence rate of sudden cardiac death varies between 0.5-2 per 1000 persons annually, 
depending on populations studied and the definitions and the methods used to study the 
incidence.1-3 Death certificate-based retrospective surveillance that uses out of hospital 
death as a proxy for sudden cardiac death results in an overestimation of the incidence 
of sudden cardiac death. 1 4 We used the IPCI database to assess the incidence of sudden 
cardiac death in a well-defined general population according to the most recent definition of 
sudden cardiac death: sudden unexpected death within 1 hour of symptom onset (witnessed) 
or within 24 hours of having been observed alive and without symptoms (unwitnessed). All 
patients with an identifiable non-cardiac cause were excluded and all patients with cancer 
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were excluded. Cases of sudden death associated with trauma, violent death, drowning, 
overdose and suicide were also excluded. This population-based database with data from 
general practice has many advantages.Thanks to the pivotal role of the general practitioner 
in the Dutch health care system, all relevant medical data are usually available at the general 
practice leveL The presence of both disease data and prescription data facilitates studies 
on the association between drugs and disease. Moreover, the complete medical records 
of all patients are available. Therefore, we had information concerning all circumstances 
surrounding death, including the full medical history. Recently, an evaluation comparing 
different methods to determine the incidence of sudden cardiac death, suggested that this 
method provides a very reliable way of determining sudden cardiac death.4 
QTc interval 
In search for non-invasive risk factors to predict mortality the heart rate corrected QT 
interval, the QTc interval, has been studied extensively.5-17 Prolongation of the QJc interval 
has been associated with ventricular arrhythmias (e.g. Torsade de Pointes) that may trigger 
ventricular fibrillation and sudden cardiac death. We evaluated whether prolongation of 
the QTc interval was an independent risk factor for sudden cardiac death in a population 
of older adults in the Rotterdam study. In the Rotterdam study, a prospective population-
based cohort study, data are available on a large group of older adults and the follow-up 
period is relatively long. This enabled us to take advantage of the fact that the majority of 
participants had two ECGs, in contrast to many other studies evaluating the QTc interval. 
In addition, in almost all cases extensive information of the facts surrounding death was 
available for review, including a questionnaire concerning the fatal event and in many cases 
the time between start of symptoms and death was documented. 
The QT interval and its correction formulas gained clinical importance already in 1957, with 
the description of the Long QJ syndrome and its association with sudden cardiac death.18 19 
Although the degree of QJc prolongation in itself does not seem to be directly predictive 
of pro-arrhythmia, it has been shown that it is associated with early after depolarizations, 
that can lead to Torsade de Pointes and sudden cardiac death. QJc prolongation in itself 
may not be enough to cause fatal arrhythmias and may require the presence of other 
risk factors. Nevertheless, the QTc interval has become a surrogate marker for the risk 
ofTorsade de Pointes and sudden cardiac death.20 The QJc interval represents a surface 
ECG measurement of the action potential duration. Many factors affect the QTc interval, 
including heart rate, autonomic system activity, cardiac diseases and congenital long QJ 
syndromesY 19 In 1920, Bazett examined the mathematical relationship of QJ to RR 
interval and found that the QJ interval divided by the square root of the RR interval was a 
constant: QTc, the corrected QT interval.21 Although the shortcomings of this correction 
have long been recognized, it has gained a widespread use. Many alternative methods have 
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been proposed since Bazett's original article in 1920, but all had their own shortcomings and 
limitations, and none proved to be superior to the Bazett's formula for the QJc interval. 19 
Another important reason for us to use Bazett's formula was that the major part of the 
existing literature employs the same correction and Bazett's formula is used in the definition 
of the long QJ Syndrome. We used the European regulatory guidelines to categorise QTc 
prolongation into 3 sex specific categories for the first time in a population-based study.22 
In the past decade, one of the most frequent causes of withdrawal or restriction of marketed 
drugs has been the prolongation of the QJc interval associated with Torsade de Pointes 
and fatal cardiac arrhythmias.20 23 In the area of drug development and drug testing the 
QJc interval prolongation has become an accepted surrogate marker for the risk of cardiac 
arrhythmia.19 The recent European guidelines, intended to predict whether a new drug 
carries an increased risk of serious cardiac arrhythmias, also place much emphasis on the 
association of the pharmaceutical with QJc prolongation. 22 Although an increasing number 
of drugs, especially non-cardiac drugs has been recognized to delay cardiac repolarization 
and to induce Torsade de Pointes2\ no population based ECG data are available on the 
association of these drugs and the length of the QTc interval in older adults. In our study, 
we did not find an association between the prolongation of the QJc interval and the use 
of all drugs, known to be implicated in the occurrence of fatal cardiac arrhythmias. 25 26 
Although QTc prolongation has become an established surrogate marker for pro-
arrhythmia, there is no clear understanding of what is "good" and what is "bad" QTc 
prolongation.19 Virtually all QTc prolonging drugs act by blocking the rapid component 
of the delayed rectifier potassium channel (Ikr) through blockade of the human ether a go-
go related gene (HERG). Clinical and experimental studies of drugs that inhibit HERG 
currents showed that HERG channel inhibition does not necessarily lead to acquired long 
QJc syndrome and severe cardiac arrhythmias with the risk of sudden cardiac death.27 28 
With the increased knowledge of the molecular action of drugs on HERG channels, 
it becomes apparent that multiple molecular actions are involved. Moreover the broad 
diversity in response to pharmacological treatment among individuals could be explained 
by a combination of factors rather than by inhibition ofHERG channels alone, combining 
factors such as underlying pathology, physiology and genetic susceptibility. 
The lists of drugs that prolong the QJc interval are long, and comprise several different 
classes. There is no reliable threshold below which prolongation of the QTc interval is 
considered to be free of risk. 19 Although the use of QTc prolonging medication can 
predispose to Torsade de Pointes, there is still a paucity of information that can help 
clinicians to make optimal informed decisions on how to best minimise the risk for this 
serious complication, as is also illustrated by our findings. Although all drugs evaluated have 
been implicated in the occurrence of serious cardiac arrhythmias, we could nevertheless not 
identifY significant QTc prolongation in all drugs.25 26 
ng 
Drugs as a potential risk factor for sudden cardiac death 
Some drugs are associated with QTc prolongation but devoid of torsadogenic effects, 
whereas others seem not to be associated with QJc prolongation, but are still considered to 
be associated with cardiac arrhythmias.27 Despite its clinical and regulatory importance the 
potentially pro-arrhythmogenic effect of drugs on the QJc interval is not well understood.29 
QTc interval prolongation per se does not always seem to be pro-arrhythmogenic. 
Amiodarone, for example significantly prolongs the QJc interval, but rarely causes Torsade 
de Pointes.20 Terfenadine, a potent Ikr blocker on the other hand has been withdrawn from 
the market because of its potential to induce Torsade de Pointes. The prolongation of the 
QTc interval caused by terfenadine however, is only minimal.20 
Thus, it seems to be difficult to predict whether a drug will cause Torsade de Pointes based 
on its effect on the length of the QJc interval or on its potency to block the Ikr channel. The 
pro-arrhythmogenic threshold is not a sharp one and Torsade de Pointes can occur after 
only a minimal prolongation of the QTc interval. The clinical manifestations ofTorsade de 
Pointes vary from transient palpitations, dizziness and syncope, but can also degenerate into 
ventricular fibrillation and sudden cardiac death, in approximately 20% of the cases.20 29 
Therefore, we have assessed in the second part of this thesis the association between the 
risk of sudden cardiac death and the current use of certain drugs known to prolong the 
QJc interval. 
Spontaneous reporting of adverse drug reactions has been the mainstay of pharmacovigilance 
for many years. The signal provided by spontaneous reporting systems and also by case 
reports may be the start of subsequent clinical and pharmaco-epidemiological research. At 
first thought, a prospective randomised controlled trial might seem the most ideal method 
for quantifYing a potential adverse event. Although the importance of randomisation cannot 
be overestimated, there are many situations where a randomized clinical trial is not suitable. 
For example, a clinical trial can only detect the more frequent adverse drug effects. To 
detect a relative risk of2 (with an Dof0.05 and a J1, ofO.l) of a disease with a background 
incidence of 0.1 %, a study would need to include at least 21,000 patients, making such 
studies extremely expensive and time consuming.30 In these situations, observational 
methods of pharmacovigilance can be used instead. Carefully designed and conducted 
pharmaco-epidemiological studies, specifically observational (non-interventional, non-
experimental) studies, are important tools in pharmacovigilance for assessing the risk of 
rare adverse events such as sudden cardiac death. In order to study the possible association 
between drugs and sudden cardiac death, we performed several case-control studies in the 
IPCI database. We evaluated the association between the use of antipsychotics and the risk 
of sudden cardiac death. In our study, the current use of antipsychotics was associated with 
an increased risk even at a low dose and also in persons who used anti psychotics for other 
indications than schizophrenia. Anti psychotics seem to share the ability to antagonise the 
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rapid component of the delayed rectifier potassium channel (Ikr) through blockade of the 
HERG gene. This in turn can lead to variable action potential prolongation and cardiac 
arrhythmias . Also the current use of non-cardiac QTc prolonging drugs, as specified on 
the website from the International Registry for Drug-induced Arrhythmias (http://www. 
qtdrugs.org/medical-pros/drug-lists/drug-lists.htm) was associated with an increased risk 
of sudden cardiac death. The extent to which blocking of the rapid component of the 
delayed rectifier potassium channel (Ikr) results in Torsade de Pointes or sudden cardiac 
death, is highly variable among subjects. A unifYing concept "reduced repolarization reserve" 
has been used to explain this variable risk. Current evidence also suggests that 5 to 10% of 
persons in whom cardiac arrhythmias occur carry a (silent) mutation in one of the genes 
responsible for the congenital long QT syndrome.20 The last study addressed the risk of 
sudden cardiac death associated with the use of inhaled !S-2 adrenergic receptor agonists. 
Here the blockade of the HERG channel does not seem to play a major role to explain 
the effects of the !S-agonists. Inhaled !S-2 adrenergic receptor agonists increase heart rate, 
prolong the duration of the action potential, and may cause hypokalemia. These factors 
may all increase the risk of cardiovascular adverse events, including sudden cardiac death. 
A complicating factor is that Chronic Obstructive Pulmonary Disease itself is a known risk 
factor for sudden cardiac death. The results of our study suggested that inhaled IS agonists 
may increase the risk of sudden cardiac death although a causative role of COPD itself 
cannot be excluded. 
METHODOLOGICAL CONSIDERATIONS 
Non-experimental, observational, pharmaco-epidemiological studies have an important 
role in assessing the risk of rare adverse reactions such as drug-induced cardiac arrhythmias. 
The validity of observational studies is frequently questioned because of potential bias 
and confounding, but careful design and analysis may deal with most of these problems. 
The two main observational approaches in pharmaco-epidemiology are cohort and case-
control designs. 30 In the cohort design, the frequency of the adverse events is compared 
between patients with and without the exposure of interest. Our studies that evaluated 
the QTc interval were embedded in the Rotterdam study, a prospective population-based 
cohort study, which started with a baseline visit between 1990 and 1993. All inhabitants 
of a suburb in Rotterdam, Ommoord, aged 55 years and over (10,275) were invited to 
participate. 
In this study a large population of older adults is included in a follow-up. The advantages 
are that the follow-up duration is relatively long and extensive information is available on 
all participants. In addition to follow-up surveys, the total cohort is continuously being 
monitored for major morbidity and mortality through linkage of general practitioner and 
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municipality records . Furthermore, all drug prescriptions dispensed to participants by 
automated pharmacies are routinely stored in the database since January 1,1991. 
All information is gathered before, and irrespective of, the outcome under study from the 
large majority of the study participants. This limits the chance of selection and information 
bias. Confounding by indication or contra indication may bias the study results. In non-
experimental studies the allocation of treatment is by definition not random. Therefore, if 
we assume that prescribing is rational, the prognosis of patients receiving treatment will 
obviously differ from those not being treated. The untreated patients will generally not have 
an indication for the treatment under study. Therefore, the treated patients will probably 
have a higher rate of any disease that the drug is intended to treat (or cure). Consequently, 
a drug that is intended to treat a patient may seem to enhance the risk rather than to 
decrease it. If the treatment under study is contra-indicated in high-risk patients with 
underlying diseases, confounding by contra-indication may occur. It is possible that in our 
cross sectional study, QJ'c prolonging drugs were not prescribed to patients at high risk. 
As a significant number of users, also with known risk factors, were identified in our study 
population this seems, however, not likely. 
Other major issues in pharmaco-epidemiology pertain to the definition of drug exposure. 
Accurate and complete information on drug exposure is essential to avoid information bias. 
The use of pharmacy records in the Rotterdam study bypasses the potential for recall bias, 
as these data are gathered continuously and independently of outcome. However, even with 
the use of pharmacy records, misclassification of exposure may occur, since patients might 
not have taken the medication as prescribed. This bias will often be non-differential and 
will then lead to an underestimation of the true effect. A cohort study is not a very efficient 
way to study the association between drugs and sudden cardiac death since this adverse 
drug reaction has a low frequency. Therefore if the outcome of interest is uncommon, a 
case-control design is mostly followed. In case-control studies, drug exposure is compared 
between patients with and without the outcome of interest.The case-control design is an 
efficient way to study rare outcomes since exposure is only measured in patients with the 
outcome and in a sample of the source population. An important limitation of case-control 
studies is their vulnerability to bias. Inclusion of cases and controls may depend on their 
exposure status (selection bias) and patients with the disease may recollect former drug 
exposure more accurately (information- or recall bias) . 
These arguments apply, however, to de novo initiated case-control studies and not to already 
existing databases, where data are gathered prospectively, without knowledge of later 
formulated research questions and before the adverse event has occurred. The Integrated 
Primary Care Information (IPCI) project is a large database, which contains the computer-
based full medical patient records from a group of 150 general practitioners (GPs) in the 
Netherlands. We used the IPCI database to assess the incidence of sudden cardiac death 
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and to perform the case-control studies described in this thesis. Another advantage of data 
being collected prospectively during general practitioner visits and recorded in the database 
is the relatively short period of time in which studies can be performed. This is especially 
important in pharmacovigilance, as safety issues often require fast but valid reactions. A 
potential problem with database studies concerns the limited possibility for adjustment 
for other risk factors . Automated databases often tend to have little or no information on 
important potential confounders. In addition, they sometimes include data from a skewed 
population of people from lower socio-economic classes, such as in de Medicare databases 
in the U.S.A. Since the exact dosing regimen in many databases is unknown a fixed length 
of30 days for a prescription is often used for exposure assessment, causing misclassification 
of exposure. These disadvantages do not apply to the IPCI database since it contains the 
complete medical records of all patients irrespective of economic status. Moreover, extensive 
information is available on drug use and potential confounders. The use of prescription data 
bypasses the potential for information bias from doctor or patient (recall bias), as these data 
are gathered before and irrespective of the outcome/adverse event under study. Prescription 
data form a reliable and precise source of information. Misclassification of exposure may, 
however, still have occurred in our studies since we used outpatient prescription data and 
had no information as to whether the prescription was actually filled and taken. It is likely, 
however, that such exposure misclassification will be random, evenly distributed among 
cases and controls and will therefore lead to an underestimation of the true effect. 
Also case-control studies are susceptible to confounding by indication. Confounding 
by indication was an issue in the case-control study evaluating the association between 
antipsychotics and sudden cardiac death. Schizophrenia, one of the indications for 
antipsychotic drugs, is also a risk factor for sudden cardiac death and may therefore act 
as a confounder. However, we found that the risk for sudden cardiac death was similarly 
increased in patients using antipsychotics for schizophrenia as in patients taking these 
drugs for other indications. In the case-control study of non-cardiac QTc prolonging drugs, 
we restricted our evaluation to the non-cardiac drugs thereby minimizing confounding by 
indication that might have been occurred in cardiac QJc prolonging drugs that are used in 
the treatment of arrhythmias. 
A special form of confounding by indication is confounding by severity, in which the 
severity of the disease that forms the indication for treatment rather than the disease 
itself constitutes an important factor in the choice of therapy. In Chronic Obstructive 
Pulmonary Disease (COPD) the severity of the disease and presence of co-morbidities 
may play an important role in therapy choice. The effects of drugs studied in this 
disease are therefore susceptible to confounding by severity. We tried to reduce this 
confounding by conducting a case-crossover study, nested in our case-control study. 
The case-crossover design is a special type of matched case-control study. 31-33 In this 
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design, each case acts as its own control, thereby minimizing confounding by severity 
and co-morbidities. The underlying assumption is that the cases themselves are the 
best representatives of the study base from which the case emerged. An advantage 
of this design is that the controls inherently fully adjust for stable intra-individual 
confounders and risk factors . However, residual confounding cannot be excluded in 
our last study, especially not by time-varying confounders. 
FUTURE DIRECTIONS 
Sudden cardiac death is by its nature unpredictable. Studying sudden cardiac death is 
complex as there are many different fields of research involved. In this thesis, the objective 
was to increase our knowledge of drugs as a potential cause of sudden cardiac death, the role 
of the QTc interval in sudden cardiac death and the effects of drugs on the QTc interval. 
Although some pieces of the puzzle have been identified, increased knowledge has at the 
same time further illuminated the fact that there are still many more questions and issues 
that need to be addressed 
Research has shown that QTc interval prolongation as a predictor of this serious adverse 
event might be imperfect both for individual patients and for populations. The link between 
drugs, HERG blockade, the prolongation of QJ'c interval, Torsade de Pointes, and sudden 
cardiac death is unclear, and reliable identification of the pro-arrhythmic potential of drugs 
remains a challenge. None of the predictors currently known seems to be able to reliably 
predict the risk ofTorsade de Pointes. Recent work showed that, in general, drugs with a 
small HERG/free plasma concentration margin (i.e. drugs, which bind to the potassium 
channels in concentrations close to therapeutic plasma concentration) had a high risk of 
serious cardiac arrhythmias while drugs with a high margin had a lower risk.27 Other recent 
work corroborated these findings. De Bruin et al showed that drugs that bind to HERG 
channels in concentrations close to or lower than plasma concentrations have a high risk of 
adverse reports of serious ventricular arrhythmia and sudden cardiac death in the WHO-
UMC databases, indicating a higher pro-arrhythmic risk.34 This margin between HERG 
binding capacity and free plasma concentration might be a helpful tool in the prediction 
of the risk ofTorsade de Pointes in future drug development. 
This highlights the importance of also understanding the molecular mechanisms that 
underlie HERG channel blockade. Despite recent advances, the knowledge of the molecular 
action of drugs on HERG channels is still immature. The individual molecular mechanisms 
of a drug action on the HERG channel may play an important role since it determines the 
pro-arrhythmogenic potential of a drug. Although blockade ofHERG channels requires 
channel opening for most compounds, inhibition ofHERG channels by amiodarone and 
chlorpromazine involves inhibition of closed channels. It has also been hypothetized that 
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additional drug action on different ion channels and/ or receptors may reduce the pro-
arrhythmic potential of HERG blockers. In particular, additional inhibition of calcium 
currents and/or additional beta adrenoceptor blockade have been suggested to play a role 
in limiting the pro-arrhythmic effects ofHERG channel blockers.20 27 29 
Finally, the clinical presentation of adverse events in an individual patient is also determined 
by genetic background. In the future, screening of patients at high risk for sudden cardiac 
death may include genetic screening. Risk prediction based on familial and genetic 
characteristics are in their infancy, but offer promise of better prediction. 35 Recent work 
supports the possibility that silent mutations can contribute to increased susceptibility 
to sudden cardiac death.36 Studies suggest that polymorphisms coding for ion channels 
genes are surprisingly common. Spontaneous and inherited variations in the genes coding 
for rare inherited arrhythmia syndromes are being found on an almost daily basis.There is 
now good evidence for the existence of at least 10 such variations with overall populations 
frequencies of at least 5% and the discovery has only just begun.20 These estimates do 
not include variations in possible "modifYing" genes. These seem to include alterations in 
the genes for cholinergic and adrenergic pathways and other regulatory molecules that 
control regional expression of different electrogenic proteins in various cardiac tissues.37 
Heterogeneity in the individual response to drugs is a major problem in clinical practice and 
in drug development. When several patients are prescribed the same recommended dose 
of a certain drug, the drug can be efficacious in most, have little or no effect in other and/ or 
result in adverse drug reactions, sometimes fatal, in a small group of patients.38 39 Besides 
the importance of clinical factors that determine the variability in drug response, including 
age, gender, concomitant therapy and co-morbidities, it is clear that genetic factors have a 
large impact on efficacy and toxicity of drugs. 
The quest for effective and safe drugs continues and pharmaco-epidemiological research 
will remain an important tool in the assessment of risk benefit profile and safety of drugs in 
the population at large. Pharmacogenetic studies assessing the variability in drug responses 
attributed to hereditary factors, such as genetic polymorphism will become more and more 
important. As a result of further research maybe individual genetic tailored therapy will 
become reality and prevent serious adverse events. 
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CHAPTER 9 
SUMMARY / SAMENVATTING 
Sudden cardiac death is a major health problem. Many causes of sudden cardiac death are 
known, yet seldom is one single cause sufficient to provoke a life-threatening arrhythmia. 
Sudden cardiac death is a multifactorial process and probably represents a probabilistic 
event in which each of the risk factors comprises only a small fraction of the process. 
In Chapter 1, a general introduction of sudden cardiac death is given. The term sudden 
cardiac death pertains to an unexpected death from cardiac causes within a short time 
period and has been described throughout history. Ventricular tachy-arrhythmia is the 
final fatal mechanism in approximately 85% of all cases of sudden cardiac death. Brady-
arrhythmias and pulse-less electrical activity occur less frequently and generally in hearts 
with more advanced disease. Despite progress in clinical profiling and interventions, sudden 
cardiac death remains an important clinical problem. 
Chapter 2 focuses on the magnitude of sudden cardiac death in the general population. 
The commonly used estimate of 300,000 sudden cardiac deaths in the United States has 
not been based on formal epidemiological studies, but has rather been derived from the 
estimation that there were 600,000 cardiovascular deaths annually, of which 50% were 
assumed to be sudden. We used the IPCI database to assess the incidence of sudden cardiac 
death in a well-defined general population according to the most recent definition of sudden 
cardiac death: sudden unexpected death within 1 hour of symptom onset (witnessed) or 
within 24 hours ofhaving been observed alive and symptom free (unwitnessed).This study 
showed that the incidence of sudden cardiac death in the Dutch population is around 
1/1000 per year, and that the incidence increases with age and varies by gender, calendar 
month and week days. 
Chapter 3 evaluates the heart rate corrected QT interval, the QTc interval, as a non-
invasive risk factor to predict sudden cardiac death. The QT interval on the surface 
electrocardiogram (ECG) represents the time from onset of ventricular depolarization 
to completion of repolarization. Prolongation of repolarization has been associated with 
ventricular arrhythmias (e.g. Torsade de Pointes) that may trigger ventricular fibrillation 
and even sudden cardiac death.This study was conducted as part of the Rotterdam Study, 
a prospective population-based cohort study, which comprises 3105 men and 4878 women 
aged 55 years and older. The QTc interval on the ECG was determined during the baseline 
visit (1990-1993) and the first follow-up examination (1993-1995). During an average 
follow-up period of 6.7 years, 125 subjects died from sudden cardiac death. European 
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regulatory guidelines were used to categorize QTc prolongation into 3 sex specific 
categories. In addition, we used different QTc thresholds varying from 440 ms to 470 
ms, based on the literature, because there is still discussion as to the most relevant cut-off 
points. An abnormally prolonged QJc interval (> 450 ms in men, > 470 ms in women) 
was associated with a threefold increased risk of sudden cardiac death, after adjustment for 
age, sex, body mass index, hypertension, cholesterol/hdl ratio, diabetes mellitus, myocardial 
infarction and heart failure. In subjects with an age below the median of 68 years, the 
corresponding relative risk was almost 8. The results of our study show that abnormal 
QJc prolongation on the ECG should be viewed as an independent risk factor for sudden 
cardiac death. Two-third of the cases of sudden cardiac death is associated with an abnormal 
prolongation of the QTc interval. 
In Chapter 4, we examined the association between drugs, listed as QTc prolonging and 
the duration of the QJc interval in a large prospective, community-based follow-up study. 
This study is embedded in the Rotterdam Study. In recent years, several lists have been 
published on drugs implicated in QTc prolongation and cardiac arrhythmias. In list 1 of 
the web site of the International Registry for Drug-induced Arrhythmias maintained by 
the Georgetown University, an up-to-date list is published. In this list, the QJc prolonging 
drugs are classified into 4 categories, varying from drugs that are generally accepted by 
authorities to have a risk of causing Torsade de Pointes (list 1) to drugs that, in some 
reports, have been weakly associated with Torsade de Pointes but that, when used in usual 
dosages, are unlikely to increase the risk (list 4). In addition, De Ponti et al have published a 
list of31 non-anti-arrhythmic drugs with pro-arrhythmogenic effects, based on a structured 
literature search. Overall, 14,013 ECGs were available, 5768 in men and 8245 in women. In 
this population, 615 current users of QJc prolonging drugs were identified. Significantly 
more women used QTc prolonging medication than men. This was predominantly related 
to the more frequent use of antidepressants and domperidone in women. The results of our 
study showed an association between the current use of several, but not all, drugs listed on 
the two lists and prolongation of the QTc interval in a population of older adults. Virtually 
all QTc prolonging drugs act by blocking the rapid component of the delayed rectifier 
potassium channel (11) encoded by the human ether a go-go related gene (HERG). 
Unfortunately, this finding is not specific since many drugs that do not seem to cause 
Torsade de Pointes, also block this current. Therefore, it is likely that other pharmacological 
actions are also involved. These actions might prevent Torsade de Pointes, either directly 
(by blunting early after depolarizations) or indirectly (by blunting the prolongation of the 
action potential). Much emphasis has been placed on the potential pro-arrhythmic effects 
of pharmaceuticals that are associated with QTc interval prolongation in recent guidelines. 
Paradoxically, however, increased knowledge has illuminated the fact that the current 
predictors of this serious adverse event might be imperfect both for individual patients and 
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for populations. Post-marketing surveillance seems to remain an important tool in assessing 
the torsadogenic effects in newly marketed drugs in the general population. 
In Chapter 5 the risk of sudden cardiac death in current users of antipsychotics was 
assessed. This study used data from the Integrated Primary Care Information (IPCI) project 
in the Netherlands. The IPCI project is a general practice research database, containing 
the complete medical records on approximately 500,000 patients. The electronic records 
contain coded and anonymous data on patient demographics, symptoms, diagnoses from 
GPs and specialists, referrals, laboratory findings, hospitalizations, and drug prescriptions, 
including their indications and dosage regimen. To maximize completeness of the data, 
general practitioners participating in the IPCI project are not allowed to maintain a system 
of paper-based records besides the electronic medical records. The study period started on 
January 1, 1995 and ended on September 1, 2001. All subjects were followed until death, 
transferal out of practice, date oflast data collection or end of the study period, whichever 
came first. In the source population, 582 cases of sudden cardiac death were identified, 
representing an incidence rate of sudden cardiac death of almost 1 per 1000 person-years 
in the source population. No controls could be matched to 28 cases, and these cases were 
excluded from further analyses. Hence, the study population comprised 554 cases of sudden 
cardiac death and 4463 matched controls. The results of our study indicate that current use 
of anti psychotics in a community dwelling population is associated with an increased risk 
of sudden cardiac death, even at a low dose and in persons who use anti psychotics for other 
indications than schizophrenia. Mter adjustment for known confounding factors, current 
use of antipsychotics was associated with a more than tripled risk of sudden cardiac death. 
The risk was highest among the users ofbutyrophenone anti psychotics but not significantly 
different from the other antipsychotics, possibly due to low numbers. Unlike some other 
studies, we did not find an association with thioridazine but this drug was hardly used in 
our study population. 
In Chapter 6, we evaluated the risk of sudden cardiac death in current users of non-cardiac 
QJc prolonging medication. In this study, we also used the IPCI database. The study period 
started on January 1, 1995 and ended on September 1, 2003. All subjects were followed 
until death, transferal out of practice, date oflast data collection or end of the study period, 
whichever came first. The exposure of interest was the use of non-cardiac QTc prolonging 
drugs, as specified in the most recent version of list 1 (Drugs that are generally accepted by 
authorities to have a risk of causing Torsade de Pointes) from the International Registry 
for Drug-induced Arrhythmias maintained by the Georgetown University (http://www. 
qtdrugs.org/medical-pros/drug-lists/drug-lists.htm). In the source population, 806 cases of 
sudden cardiac death were identified, representing an incidence rate of sudden cardiac death 
of almost 1 per 1000 person-years. No controls could be matched to 31 cases, and these 
cases were excluded from further analyses. Hence, the study population comprised 775 
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cases of sudden cardiac death and 6297 matched controls. The results of our study indicate 
that current use of non-cardiac QTc prolonging drugs in a general population is associated 
with a significantly increased risk of sudden cardiac death. Mter adjustment for known 
confounding factors, current use of non-cardiac QTc prolonging drugs was associated with 
an almost threefold increased risk of sudden cardiac death. The risk was higher in women 
than in men. This is in line with earlier findings that women seem to be more susceptible to 
drug induced cardiac arrhythmias than men. Our results suggest that 320 cases of sudden 
cardiac death can be attributed to the use of non-cardiac QTc prolonging medication in 
the Netherlands on a yearly basis. 
The association between use of bronchodilators, specifically E,-agonists, and the risk of 
sudden cardiac death in a case-control analysis in a well-defined general population, the 
IPCI database, is presented in Chapter 7. In addition, we used a nested case-crossover 
design to further analyze the association between use of E,-agonists and the risk of sudden 
cardiac death in patients with COPD. The study period started on January 1, 1995 and 
ended on September 1, 2003 and the study population comprised 775 cases of sudden 
cardiac death and 6297 matched controls. In the case-crossover study, which by design 
adjusts for stable intra-individual confounders, we assessed time-varying co-morbidity, 
concomitant drug use and severity of COPD in each 3 month period before the index 
date. Severity of COPD was assessed based on the use of antibiotics for respiratory tract 
infections, the use of oral steroids for COPD, the occurrence of exacerbations, the use of 
oxygen, and hospitalizations for respiratory tract disease. Patients with use of oxygen, oral 
steroid for COPD, occurrence of exacerbation or hospitalization were defined as more 
severely diseased patients. The results of our study indicate that current use oflong-acting 
and short-acting E,-agonists is associated with an increased risk of sudden cardiac death, 
both in the general population as well as in COPD patients. However, also xanthines and 
anticholinergics were associated with an increased risk of sudden cardiac death, but the 
association with anticholinergics was only observed in the general population. Attribution 
of mortality to COPD or to therapy is difficult, since COPD is a risk factor for sudden 
cardiac death. COPD patients are known to have an increased risk of cardiac arrhythmia. 
Although the results of our study suggest that inhaled £1-agonists may increase the risk of 
sudden cardiac death a causative role ofCOPD itself cannot be excluded. 
In the general discussion in Chapter 8 the main findings of the studies presented in this 
thesis are discussed and the methodological issues are addressed. In addition suggestions 
for future research are considered. 
Acute hartdood vormt een aanzienlijk gezondheidsprobleem. Er zijn vele oorzaken van 
acute hartdood bekend. Er is echter maar zelden slechts een duidelijke oorzaak aan te 
wijzen voor het ontstaan van een levensbedreigende ventriculaire ritmestoornis. 
Acute hartdood is een complex probleem, waarbij elke afzonderlijke (risico) factor slechts 
een kleine rol speelt in het hele proces. 
Hoofdstuk 1 bevat een algemene inleiding over acute hartdood. De term 'acute hartdood' 
wordt gebruikt voor een niet verwachte dood als gevolg van cardiale oorzaken binnen een 
korte tijd na het ontstaan van de eerste symptomen. De term acute hartdood wordt al vroeg 
in de geschiedenis gebruikt. Ventriculaire tachycardie is het uiteindelijke fatale mechanisme 
in ongeveer 85% van de gevallen van acute hartdood. Bradycardie en elektromechanische 
dissociatie komen veel minder frequent voor. Ondanks de vooruitgang in het opsporen 
van risicofactoren en de verbeterde mogelijkheden tot interventie blijft acute hartdood een 
belangrijk klinisch probleem. 
Het v66rkomen, de incidentie, van acute hartdood in een algemene populatie is onderwerp 
van hoofdstuk2. De veel gebruikte schattingvan 300.000 acute hartdoden in de Verenigde 
Staten is niet gebaseerd op onderzoek, maar is afgeleid van de veronderstelling dat ongeveer 
50% van het totale aantal cardiovasculaire doden, acute hartdood betreft. Wij hebben 
gebruik gemaakt van de IPCI gegevens om de incidentie van acute hartdood te bepalen in 
een goed gedefinieerde populatie. We hebben hierbij gebruik gemaakt van de meest recente 
definitie van acute hartdood. Acute hartdood is een plotseling, onverwacht overlijden 
binnen 1 uur na het begin van de symptomen (als er getuigen aanwezig zijn) ofbinnen 24 
uur nadat iemand voor het laatst gezien is en symptoomvrij was (indien er geen getuigen 
zijn). De incidentie van acute hartdood is in ons onderzoek 1 per 1000 personen per jaar. 
De incidentie van acute hartdood neemt toe met het stijgen van de leeftijd, verschilt tussen 
mannen en vrouwen en varieert per maand en per dag van de week. 
De vraagstelling in hoofdstuk3 betreft de voorspellende waarde van de lengte van het QJc 
interval, als niet invasieve factor voor het optreden van acute hartdood. Het QTc interval 
op het elektrocardiogram (ECG) weerspiegelt het begin van de ventrikeldepolarisarie tot 
de voltooiing van de repolarisatie. Verlenging van het QTc interval kan aanleiding geven 
tot het optreden van hartritmestoornissen, zoals Torsade de Pointes, die ventrikelfibrilleren 
kunnen uitlokken en kunnen leiden tot acute hartdood. Dit onderzoek maakte gebruik van 
de data van de Rotterdam Studie, een grootschalig, prospectiefbevolkingsonderzoek van 
7983 personen van 55 jaar en ouder. Het QJc interval op het ECG werd bepaald bij het 
eerste bezoek (1990-1993) en het tweede vervolgbezoek (1993-1995). In deze tijd (met 
een gemiddelde vervolgduur van 6, 7 jaar) stierven 125 personen een acute hartdood. Wij 
hebben de Europese richtlijnen van de EMEA (European Medicines Agency) gebruikt om 
de lengte van het QTc interval in 3 geslachtsspecifieke categorieen in te delen. Bovendien 
hebben we verschillende grenzen van het QTc interval, varierend van 440 msec tot 470 
msec onderzocht, gebaseerd op eerdere studies. Een abnormaal verlengd QTc interval 
(meer dan 470 msec voor vrouwen en meer dan 450 msec voor mannen) was geassocieerd 
met een drie maal hogere kans op acute hartdood, na correctie voor andere risicofactoren, 
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zoals leeftijd, geslacht, BMI (body mass index), hypertensie, cholesterol!hdl ratio, diabetes 
mellitus, myocard infarct en hartfalen. 
Bij mensen onder de 68 jaar was het risico zelfs 8 keer verhoogd. Uit onze studie blijkt dat 
verlenging van het QTc interval een onafhankelijke risicofactor is voor het optreden van 
acute hartdood. Twee derde van de gevailen van acute hartdood is geassocieerd met een 
abnormale verlenging van het QTc interval. 
In hoofdstuk 4 bestudeerden we het verb and tussen gebruik van geneesmiddelen, waarvan 
bekend is dat ze hartritmestoornissen en QTc verlenging kunnen veroorzaken, en de lengte 
van het Q]'c interval op het ECG. Dit onderzoek maakt, evenals het voorgaande, gebruik 
van de gegevens van de Rotterdam Studie. De laatste tijd is er veel gepubliceerd over 
geneesmiddelen die QTc verlenging kunnen veroorzaken. Lijst 1 van de website van de 
International Registry for Drug-induced Arrhythmias (http:/ /www.qtdrugs.org/medical-
pros/drug-lists/drug-lists.htm) bevat een recente lijst, die regelmatig wordt bijgewerkt. 
Deze bestaat uit 4 categorieen geneesmiddelen, varierend van geneesmiddelen waarvan 
het algemeen geaccepteerd is dat ze ernstige hartritmestoornissen kunnen veroorzaken 
(lijst 1) tot geneesmiddelen waarvan weliswaar gevailen van Q]'c verlenging beschreven 
zijn maar die bij normaal verantwoord gebruik niet geassocieerd lijken met ernstige 
hartritmestoornissen (lijst 4). Daarnaast hebben de Ponti en collegae een lijst samengesteld 
van 31 QTc verlengende geneesrniddelen met pro aritmogene effecten (hierop staan geen 
geneesmiddelen, die bedoeld zijn om ritmestoornissen te behandelen) gebaseerd op 
literatuuronderzoek. Er waren in de Rotterdam Studie 14.013 ECGs beschikbaar voor 
dit onderzoek, 5768 bij mannen en 8245 bij vrouwen. In deze populatie gebruikten 615 
personen een Q]'c verlengend middel op het moment van de registratie van het ECG. 
Significant meer vromven dan mannen gebruikten QJc verlengende middelen. Dit verschil 
werd vooral veroorzaakt doordat vrouwen vaker antidepressiva en vaker domperidone 
gebruikten dan mannen in onze populatie. Uit deze studie blijkt een verband tussen een 
aantal, maar niet aile, geneesmiddelen van de beide lijsten en Q]'c verlenging in een groep 
van oudere volwassenen. Bijna aile middelen die QTc verlenging veroorzaken doen dat 
door bei:nvloeding van de snelle kaliumstroom (Ikr) via het vertraagde kalium kanaal, 
dat gecodeerd wordt door het HERG (humane ether-a-go-go) gen. Helaas is dit geen 
specifi.eke bevinding, want een groot aantal middelen blokkeert dit kanaal maar veroorzaakt 
geen Torsade de Pointes. Het is daarom waarschijnlijk dat andere electrofysiologische 
eigenschappen ook een rol spelen. Deze effecten kunnen Torsade de Pointes voorkomen 
of door directe effecten (door "early after depolarisations" te dempen) of door indirecte 
effecten (door de verlenging van de actiepotentiaal te verminderen). In de recente richtlijnen 
is veel nadruk gelegd op het feit dat geneesrniddelen, die geassocieerd zijn met ernstige 
hartritmestoornissen, ook een verlenging van het Q]'c interval veroorzaken. Paradoxaal 
genoeg lijkt met de toename in kennis de voorspelbaarheid van deze ernstige bijwerking 
niet groter te worden. Het zorgvuldig volgen van geneesmiddelen nadat ze op de markt zijn 
gekomen (postmarketing surveillance) blijft een heel belangrijk middel om torsadogene 
effecten in nieuwe geneesmiddelen op te sporen. 
Onderzoek naar het risico op acute hartdood bij personen, die antipsychotica gebruiken, 
is onderzocht in hoofdstuk 5. In dit onderzoek gebruikten we de gegevens van de 
Integrated Primary Care Information (IPCI) project, een database met de complete 
medische gegevens van ongeveer 500.000 personen. De elektronische gegevens bevatten 
de gecodeerde en geanonimiseerde gegevens over demografie, symptomen, diagnoses van 
huisartsen en specialisten, verwijzingen, laboratorium gegevens, ziekenhuisopnames en 
geneesmiddelenrecepten met hun indicatie en dosering. Om te zorgen dat de data zo 
compleet mogelijk zijn, gebruiken de huisartsen die deelnemen aan het IPCI project, 
uitsluitend elektronische medische dossiers en geen papieren dossiers. Het onderzoek 
betreft de periode van 1 januari 1995 tot 1 september 2001. Aile personen werden gevolgd 
tot overlijden, verhuizen ofhet einde van het onderzoek. In onze bron populatie hebben wij 
582 gevallen van acute hartdood gevonden. Dit komt overeen met een incidentie van acute 
hartdood van 1 per 1000 personen per jaar. Bij 28 gevallen van acute hartdood zijn geen 
controles gevonden en deze zijn van de verdere studie uitgesloten. Onze studiepopulatie 
bestond uit 554 gevallen van acute hartdood en 4463 controles, gematched op leeftijd 
(geboortejaar), geslacht en praktijk. Uit de resultaten van deze studie blijkt dat het gebruik 
van antipsychotica geassocieerd is met een verhoogd risico op acute hartdood, ook in lage 
doses en bij mensen die antipsychotica gebruiken voor andere indica ties dan schizofrenie. 
Na correctie voor andere risicofactoren was het gebruik van antipsychotica geassocieerd met 
een drievoudig hoger risico op acute hartdood. Het risico was het hoogste in de gebruikers 
van butyrophenonen, maar niet significant anders dan bij gebruikers van andere middelen, 
misschien door de lage aantallen. In tegenstelling tot andere studies, vonden wij geen 
verhoogd risico bij gebruikers van thioridazine maar dit geneesmiddel werd nauwelijks 
gebruikt in onze studiepopulatie. 
In hoofdstuk 6 evalueren we het risico op acute hartdood bij gebruikers van niet cardiale 
QTc verlengende middelen. Ook hier hebben we gebruik gemaakt van de gegevens van de 
IPCI database. De studieperiode loopt van 1 januari 1995 tot 1 april2003. Aile personen 
werden ook voor dit onderzoek gevolgd tot overlijden, verhuizen of het einde van het 
onderzoek. De geneesmiddelen, die we hebben bestudeerd, staan vermeld op de meest 
recente versie van lijst 1 van het internationale register van geneesmiddelen gei:nduceerde 
ritmestoornissen ( International Registry for Drug-induced Arrhythmias maintained by 
the Georgetown University, h ttp:l /www. qtdrugs. org/ medical-pros/ drug-lists/ drug-lists. 
htm). In de bronpopulatie hebben we 806 gevallen van acute hartdood gevonden. Bij 31 
gevallen waren geen controles beschikbaar en deze werden van het verdere onderzoek 
uitgesloten. De studie populatie bestond uit 775 gevallen van acute hartdood en 6297 
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controles, gematched op leeftijd (geboortejaar), geslacht en prakrijk. Uit de resultaten van 
deze studie blijkt dat het gebruik van niet cardiale QTc verlengende middelen de kans op 
acute hartdood significant verhoogt. Na correctie voor andere risicofactoren is het risico 
bij gebruikers van niet cardiale QJc verlengende middelen bijna driemaal hoger. Het risico 
was groter voor vrouwen dan voor mannen. Dit past bij eerdere bevindingen dat vrouwen 
gevoeliger zijn voor geneesmiddel gei:nduceerde hartritmestoornissen dan mannen. Onze 
studie laat zien dat 320 gevallen van acute hartdood per jaar in Nederland het gevolg 
kunnen zijn van niet cardiale QTc verlengende middelen. 
De associatie tussen het gebruik van bronchodilatoren, in het bijzonder J.?, agonisten, en 
de kans op acute hartdood in een case controle studie in een algemene populatie wordt 
besproken in hoofdstuk 7. Naast de case controle opzet hebben we ook een "nested 
case crossover" onderzoek gedaan om de mogelijke associatie verder te onderzoeken. 
De studie periode liep van 1 januari 1995 tot 1 april 2003. In de case crossover studie, 
hebben we co-morbiditeit en gelijktijdig medicatie gebruik en ernst van de chronische 
obstructieve longziekte onderzocht als tijdsafhankelijke variabelen in iedere 3 maandelijkse 
periodes in het jaar voorafgaande aan de indexdatum. De ernst van de chronische 
obstructieve longziekte hebben we vastgesteld aan de hand van antibiotica gebruik voor 
luchtweginfecties, het gebruik van orale steroi:den voor longaandoeningen, het optreden van 
exacerbaties, het gebruik van zuurstof en ziekenhuisopname voor luchtwegaandoeningen. 
Patienten met zuurstofgebruik, orale steroi:den, exacerbaties of ziekenhuisopname werden 
beschouwd als ernstiger ziek. De resultaten van dit onderzoek wijzen in de richting van een 
associatie tussen het gebruik van langwerkende en kortwerkende £-agonisten en de kans 
op acute hartdood, zowel in de hele populatie als in patienten met chronische obstructieve 
longziekte. Ookxanthines en anticholinergica lijken de kans op acute hartdood te verhogen. 
De associatie met anticholinergica werd aileen in de gehele populatie gezien. Het is vaak 
moeilijk om vast te stellen of het overlijden veroorzaakt is door de therapie of door de 
chronische obstructieve longziekte, omdat chronisch obstructieve longziekte zelf een risico 
is voor het optreden van acute hartdood. In de algemene discussie, hoofdstuk 8, worden de 
belangrijkste resultaten en methodologische aspecten van het onderzoek besproken. Tot 
slot worden suggesties gegeven voor mogelijk toekomstig onderzoek. 
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DANKWOORD 
De afgelopen jaren heb ik me vaak als ''Alice in wonderland" gevoeld en ik heb ongelooflijk 
veel mogen leren. Een groot aantal mensen heeft mij tijdens deze wonderbaarlijke reis 
geholpen. Graag wil hen hier bedanken. 
Allereerst wil ik natuurlijk mijn beide promotoren Profdr. B.H.Ch. Stricker en Profdr. 
].van der Lei en mijn copromotor Dr. M.C.J.M. Sturkenboom bedanken. 
Bruno, voordat ik aan dit onderzoek begon, vermoedde ik al wel waar voor mij knelpunten 
zouden liggen. Ik ben er dan ook regelmatig tegen aangelopen, en jij ook. Dank voor je vaak 
eindeloze geduld, voor je kritische benadering van mijn werk, je aanstekelijke enthousiasme, 
je stortvloed aan ideeen, je associatieve gesprekken, de gezelligheid, je vertrouwen en je 
bereidheid bij nacht en ontij voor me klaar te staan. 
J ohan, bedankt voor de inspirerende werkomgeving, je relativerende gesprekken, je steun 
en je betrokkenheid bij het wel en wee van mijn onderzoek. 
Miriam, jouw gestructureerde manier van werken, je analytische kijk en methodologische 
kennis, de efficiente wijze waarop je steeds hoofd- en bijzaken weet te onderscheiden, 
en je werklust maken werken met jou tot een bijzondere ervaring. Mijn dank, niet aileen 
hiervoor, maar ook voor je hulp bij het luchtwegenstuk zo kort na de geboorte van Anouk,je 
vermogen een dip te spotten voordat die echt optreedt en je opbeurende woorden, is groot. 
Dankzij jou en Bruno heb ik de afgelopen 4 jaar niet aileen als een wonderbaarlijke reis, 
maar ook als "betaald buitenspelen'' ervaren met vele leerzame, leuke en gedenkwaardige 
momenten, gesprekken en discussies. Ik hoop dan ook van harte dat we onze samenwerking 
in de toekomst kunnen voortzetten. 
Leden van de kleine commissie, Profdr. H .G.M. Leufkens, Profdr. L.J.L.M.Jordaens en 
Dr. J. C .M. Witteman wil ik graag bedanken voor hun bereidheid het concept te lezen, van 
hun oordeel te voorzien en voor hun aandeel in de promotiecommissie. 
Jacqueline, bedankt voor je bereidheid je enorme methodologische kennis met mete delen 
en je kritische blik op mijn artikelen. Profdr L.J.L.M.J ordaens wil ik bedanken voor zijn 
enthousiasme, waarmee hij bereid was het manuscript in ontvangst te nemen en te lezen 
(hartdDood (!)is inderdaad wel heel erg dood!). Een speciaal woord van dank ook aan Bert 
Leufkens. Bert, wie had dit ooit kunnen denken toen we tijdens de Hank Schut cursus (het 
beste jaar natuurlijk) het FOZ scenario presenteerden? Samen met Bruno heb jij aan de 
basis gestaan van het DIA (drug induced arrhythmia) project en ik vind het heel bijzonder 
dat je nu ook bij de afronding bent. 
Bij de afdeling medische informatica heb ik me altijd welkom gevoeld door de open en 
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warme sfeer, mede dankzij Desiree, lneke, Sylvia en Ria (en de gratis koffie!). 
Zonder Geert en Jeanne, die mij wegwijs hebben gemaakt in de IPCI database, was ik nooit 
zo snel aan mijn gegevens gekomen.Jeanne,jouw kennis van Foxpro, je kritische blik en 
vooral je rust zijn geweldig. Geert, mijn prins op het witte paard als het om programmeren 
ging, dank voor hetwillen vervullen van die rol. Katia (de eerste van de 3 musketiers), naast 
wetenschap, IPCI, Foxpro en analyses hebben we ook op ailerlei andere, misschien wel 
belangrijkere, gebieden informatie kunnen uitwisselen. Als we volgende keer een kamer 
delen, zal ik het niet meer zo laat maken. 
Voor aile vragen over ECGs kon ik altijd bij Jan Kors terecht. Jan, jouw zorgvuldige 
en kritische blik, je snelle reacties op mijn mail*s, je bereidheid tijd vrij te maken en onze 
prettige discussies heb ik in de afgelopen jaren erg gewaardeerd. Hopelijk komt er een vervolg! 
Profdr. A. Hofman wil ik bedanken voor het inspirerende en zeer aanschouwelijke 
epidemiologieonderwijs en voor de mogelijkheid te werken op zijn afdeling. 
Ook de collega's van epidemiologie, Annette ( een betere buuv kun je je niet wensen, succes 
met je opleiding), Arlette, Annemarieke, Dominique, Hok Hay, Isabella, Lonneke, Marieke, 
Shamila en Stephanie wil ik bedanken. Altijd kon ik voor wijze raad bij jullie aankloppen 
varierend van time-dependent cox proportional hazard analyses, data in ergo, repeated 
measurements of een tweede gaatje in het oor van mijn dochter. 
Mijn collega's van farmaco-epidemiologie: Albert-Jan, Bert, Bettie, Cornelis, Claire, Dika, 
Fernie, Geert, Georgio, Gysele, Hedy, Ingo, Katia, Mariette, Loes, Martina en Mendel 
zorgden steeds voor een goede sfeer, zowel tijdens het werk als daarbuiten, voor troost 
bij teleurstellingen, opbouwende kritiek bij presentaties en voor leerzame en gezellige 
stafbesprekingen. 
Een extra woord van dank aan Gysele, Loes, Mariette, Cornelis en later ook Albert Jan en 
Claire, betere kamergenoten kon ik me niet wensen. Gysele, naast je guile lach heb ik je 
inzet en onze discussies bij hetvalideren van mijn uitkomsten erg gewaardeerd (echtwaar!). 
Loes, erg fijn om af en toe ook een "apothekersblik'' binnen handbereik te hebben. Laten 
we nog eens gaan eten! Mariette, bedankt voor het delen van je statistische kennis en aile 
andere zaken. Cornelis, dank voor de hulp bij valideren in ERGO en de gezelligheid, ook 
bij onze Haagse "verplichtingen''. Samen met Albert-Jan vormde je voor mij een prettige 
liaison tussen Rotterdam en Den Haag. Albert-Jan (dank voor aile genetische informatie) 
en Claire (dank voor de hulp bij de laatste administratieve loodjes),jullie hebben de leegte 
na het vertrek van Gysele en Mariette goed opgevuld, veel succes met jullie onderzoek. Heel 
veel dank ook voor het aannemen van mijn telefoontjes en de hand- en spandiensten, die 
telkens nog nodig bleken. 
Wim Hop en Paul Mulder ben ik dankbaar voor het belangeloos beschikbaar stellen van 
hun statistische kennis en hun tijd, ook voor 'zomaar' een praatje. 
Nano heeft menige huwelijkscrisis weten te bezweren door computercrashes snel en 
efficient op te lossen, als een illegale crack toch niet zo goed bleek. 
Frank van Rooij ben ik dankbaar voor zijn bereidheid elke keer weer de laatste ERGO data 
door te mailen en zijn geduldige uitleg. 
Marieke, collega DIA onderzoekster in Utrecht, (ik heb me dankbaar laten inspireren door jouw 
prachtige boekje!), al hebben onze gesprekken niet veel gezamenlijke projecten opgeleverd, het 
was wel altijd zinnig en gezellig. Hopelijk volgen er nog de nodige congressen. 
Zonder Ria en }annie was het vast nog moeilijker geweest om Bruno in Den Haag op te 
sporen.Jullie steun en hulp heb ik erg gewaardeerd. 
Profdr. J.H. Kingma, Herre, wij kennen elkaar al uit mijn "vorige" leven. Jij was er al toen 
ik mijn eerste (soms wankele, en wellicht ietwat marketing gekleurde) stappen zette op het 
gebied van cardiologie en onderzoek. Inmiddels hoop ik veel te hebben bijgeleerd. Heel veel 
dank voor jouw kennis, inzicht en het feit dat je naast aile drukte toch tijd voor mij hebt 
vrijgemaakt. Ik waardeer het bijzonder dat je nu deel wil uitmaken van de grote commissie. 
Natuurlijk mogen de mensen uit Den Haag die mij de mogelijkheid hebben geboden om 
dit onderzoek te doen hier niet ontbreken. 
Andre Broekmans, Elize Jansen en Arthur Meiners hebben in praktisch opzicht aan de basis 
van dit project gestaan. Dank voor jullie vertrouwen, het was toch een experiment. N ad at een 
project gestart is, moet het natuurlijk ook afgerond kunnen worden. Heel veel dank ben ik 
Aginus Kalis daarvoor verschuldigd! 
Frits Lekkerkerker ben ik dankbaar voor zijn interesse en betrokkenheid bij het onderzoek. 
Frits, je wist me (op je eigen charmante wijze) te overtuigen op het CBG lustrum te 
spreken, dank voor je vertrouwen. 
Pieter de Graeff dank ik voor zijn cardiologische hulp, zijn heldere inzichten, de gezellige 
en leerzame gesprekken en zijn vermogen QJ verlenging "simpel'' te maken. 
Mijn collega's geneesmiddelenbewaking ben ik dankbaar voor het feit dat ze er altijd voor me 
waren en nu ook weer zijn. Doordat ik twee dagen per week ging buitenspelen kwam er meer 
werk op hun schouders. Angela, Anja, Ineke, Maarten, Manuela, Maxime en Ursula: dank 
voor het geduld, de collegialiteit en de gezellige werksfeer. Pim van der Giesen heeft na de 
reorganisatie de coordinatie van geneesmiddelenbewaking op zich genomen. Pim, ondanks 
aile drukte die dat met zich mee bracht, informeerde je altijd even naar de laatste stand van 
zaken, vaak met een wijs advies of een bemoedigend woord, iets dat ik erg gewaardeerd he b. 
Heel veel dank ook aan Andre van Niel voor het verwerken van mijn eindeloze stroom van 
mailtjes en aile publica ties die je elke keer weer voor me wist op te sporen. 
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Mijn collega's van FT III in Den Haag wil ik graag bedanken voor aile interesse in de 
beslommeringen en activiteiten rond mijn onderzoek en boek, de steun, bemoedigende 
woorden en de prettige sfeer. Vooral dankzij jullie viel de overgang van buitenspelen naar 
werken heel wat minder zwaar. Ton, Cathy, Marianne en Nelleke zorgen dat ailes elke 
keer weer goed loopt. De eerste verdieping is met zoveelleuke en plezierige collega's geen 
slechte plek om te vertoeven! Ook, en vooral, door mijn 2 fantastische kamergenotenJoris 
en Robert. Ik waardeer jullie luisterend oor, interesse, adviezen en geduld als ik weer eens 
mijn verhaal kwijt moet, ik kan ook heel rustig zijn ... 
Veel andere collega's in het Haagse ben ik voor ailerlei andere dingen dankbaar, zoals Anne en 
Anne (voor de ex OR etentjes),Andre (voor het feit dat hij toch nog met rnij in de trein durft), 
Danielle (voor het regelen van aile personele beslommeringen), Hans (voor het fluiten van de 
Asterixen), Henk (voor de koffie en zijn heerlijke Haagse accent), de heren van de repro, de 
heren en dames van de postkamer (voor hun hulp) en Menno (voor zijn optirnisme). 
Rob van Mechelen ben ik dankbaar voor zijn enthousiaste telefoontjes, het organiseren van 
leerzame etentjes en proefdiscussies. 
Ik mag me ontzettend gelukkig prijzen twee geweldige mensen bereid te hebben gevonden 
om mijn paranimfen te zijn: Anja en Bettie. 
Anja, mijn eerste kamergenote bij het CBG (en uberhaupt), het klikte meteen, veel heb ik 
van jouw praktische en pragmatische instelling geleerd (ik bewaar nog altijd bonnetjes!). 
Dank voor je spontane en enthousiaste ja op mijn verzoek. 
Bettie, samen Den Haag, samen Rotterdam, samen Bordeaux (in een BMW past nou 
eenmaal niet zoveel als in een bestelbus, maar het is toch, samen met Miriam, gelukt) en 
samen promoveren! Hopelijk volgen er na dit avontuur nog veel meer. 
Heerlijk dat ik altijd even bij jullie mijn hart kan luchten. Dank voor jullie steun en voor 
aile gezelligheid. Met jullie naast me weet ik zeker dat het ailemaal goed komt! 
Ron Smeding wil ik bedanken voor aile organisatie rondom drukwerk, lay-out en 
voorpagina, maar meer nog dan voor al deze praktische zaken wil ik je bedanken voor aile 
geruststellende en opbeurende woorden, voor je onverwoestbare optimisme en aile steun 
als ik weer eens een auto in elkaar had gereden of 22 kids naar huis moest brengen. 
Heel veel dank ook aan Marc van Gijn. Voor ailebei de eerste keer, dat schept een band! 
Dan zijn er ook heel veel mensen die ik hier heel graag wil bedanken voor ailes wat weinig 
tot niets met het maken van dit proefschrift te maken heeft. 
Mijn eerste echte baas Wim van Bree. Wim, dank voor wat je me hebt geleerd. Veel, zo niet 
ailes, over de farmawereld, reclame en marketing, heb ik van jou geleerd. J e hebt me, toen ik 
nogjong en onbezonnen was, alle kansen en vrijheid gegeven. De liefde voor geneesmiddelen 
is met Tildiem en Lorex begonnen, wie weet wat de toekomst nog in petto heeft. 
Alle lieve vrienden en vriendinnen voor hun nooit aflatende steun en hun interesse. Altijd 
weer waren jullie bereid om te informeren hoe het ervoor stond en, nog belangrijker, om 
naar mijn verhaal te luisteren. Op het schoolplein, het hockeyveld of de Albert Heijn (life is 
pretty exciting!), of tijdens koffie, lunch, borrel, etentje, vakantie of feestje (it get's better!!). 
Ik ben jullie daar allemaal heel, heel erg dankbaar voor. 
Een speciaal 'dank jewel' aan de vakantiemoeders (voor alle leuke weken), de heksenclub 
(voor alle 'spirituele' belevenissen), mijn jaarclub (goed dat we nog steeds 'dingen' doen), 
Arjen ( voor alle pep mail), Marijke ( voor alle jaren vriendschap), David ( voor het meedenken 
metlokatie en hap), Erna (voor haar bemoedigende woorden en lunches), Marianne (voor 
Kiev en 'wattedoenalsjejebulkwijtbent'), Cees (voor het meedenken over stellingen), en de 
hofpleinlijndebatingclub (voor het veraangenamen van de treinreis) . 
Lia, bij jou weet ik mijn kinderen in vertrouwde handen en dat is onbetaalbaar. 
Lieve Pap en Mam,jullie liefde, steun, vertrouwen en wijze raad zijn heel belangrijk voor 
mij. Mijn broertjes Qa, ik blijf de oudste!) Harm en Olav, dank voor jullie belangstelling en 
steun op allerlei fronten. Harm en Norbert voor alle mode- en stylingadviezen (en is het 
wat?). 0 lav voor lees- en kookadvies en filosofische inslag. 
Maarten, Marijne, Maud en Lex, dank voor alles wat jullie voor me betekenen! Alle cliches 
over kinderen maken jullie waar, en nog veel meer. Jullie creeren chaos en geven structuur, zijn 
confronterend, soms frustrerend en egocentrisch, maar ook altijd weer optimistisch, betrokken 
en opbeurend, tijdrovend en zingevend, spontaan en ondernemend,jullie zijn mijn anker en 
mijn vleugels, kortom jullie zijn mijn alles! Jullie geven mijn leven zin, iedere dag weer! 
P, dank voor hardware, software en vooral voor alles wat niet in woorden te vangen is! I hope 
that I don't fall in love with you, you're the worst kind of guy for me to be around, but just 
the nearness of you makes this such a perfect day, I'm glad I spend it with you. And 
I think that I just fell in love with you!!* 
*(met dank aan Tom, Keith en Lou). 
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